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ABSTRACT
The Azinothricin family of compounds are based on a cyclodepsipeptide core and were 
first encountered in the late 1980s. Most of the members exhibit potent antitumour and antibiotic 
activities. In 1997, the Hale group synthesised A83586C through a chemoselective coupling 
strategy between an unprotected cyclohexadepsipeptide and a fully elaborated pyran activated 
ester. In this thesis, the asymmetric synthesis of two cyclodepsipeptides analogues are 
investigated, the L-proline analogue of GE3 cyclodepsipeptide and the (3S,5S)- 
5-hydroxypiperazic acid analogue of A83586C cyclodepsipeptide. The synthesis of analogues 
may be of value for elucidating the mode of action of these natural products. Furthermore, it 
might allow the identification of a considerably simplified structure for industrial purposes.
In a second project, a new approach to the synthesis of (+)-allopumiliotoxin 339A was 
studied. The pumiliotoxin and allopumiliotoxin class of amphibian alkaloids displays significant 
cardiotonic activity. Allopumiliotoxin 339A is one of the most potent compounds of the family; its 
activity is due to an interaction with a modulatory site on the voltage-dependent sodium 
channel. Our strategy to (+)-allopumiliotoxin 339A was based on the synthesis of two main 
fragments, an a-alkoxyaldehyde and a functionalised side chain fragment. Our initial research to 
the a-alkoxyaldehyde involved a Sharpless Asymmetric Aminohydroxylation reaction. However, 
this reaction proved not to be feasible on the trisubstituted alkene precursor. Eventually the a- 
alkoxyaldehyde was successfully prepared using a Trost's opening of an epoxide followed by an 
asymmetric induction of chiral sulfinimine to access the desired stereochemistry. The synthesis 
of the side chain segment was achieved via an O-directed hydrostannation strategy developed 
in the Hale group. This strategy allowed the stereoselective synthesis of the trisubstituted 
alkene moiety of the side chain.
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Ac acetyl
acac acetylacetonate
AIBN azobisisobutyronitrile
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3
DCM dichloromethane
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(DHQD)2PHAL 1,4-bis(9-0-dihydroquinidinyl)-phthalazine
(DHQ)2PHAL 1,4-bis(9-0-dihydroquininyl)-phthalazine
DIEA A/,A/-diisopropylethylamine (HOnig’s base)
DIBAL-H diisobutylaluminium hydride
DMAP 4-(dimethylamino)pyridine
DMF dimethylformamide
DMP Dess-Martin periodinane
DMPU 1,3-dimethyl-3-4-5-6-tetrahydro-2(1 H)-pyrimidinone
DMSO dimethylsulfoxide
DNP dinitrophenyl
dppf 1,1 '-bis(diphenylphosphino)ferrocene
dr diastereoisomeric ratio
E+ electrophile
ee enantiomeric excess
ESI electrospray ionisation
eq equivalent
Et ethyl
FAB fast atomic bombardment
Fmoc fluorenylmethyloxycarbonyl
h hour
HATU A/-[(dimethylamino)-1/-/-1l2,3-triazolo[4l5,b]pyridin-1-ylmethylene]-A/-
methylmethanaminium hexafluorophosphate 
HOBt 1-hydroxybenzotriazole
HMBC heteronuclear multiple bond connectivity
HMPA hexamethylphosphoramide
HMQC heteronuclear multiple quantum coherence
HRMS high resolution mass spectroscopy
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Hz Hertz
IR infra red
J coupling constant
KHMDS potassium hexamethyldisilazide
L ligand
LDA lithium diisopropylamide
LiDBB lithium di-ferf-butylbiphenyl
m meta
M molar
m/z mass to charge ratio
m-CPBA mefa-chloroperbenzoic acid
Me methyl
min minute
mM milimolar
MOM methoxymethyl
Ms methylsulfonyl
MS molecular sieves
MTPA methoxy(trifluoromethyl)phenylacetyl)
NBS A/-bromosuccinimide
NEM A/-ethylmorpholine
NMO A/-methylmorpholine-A/-oxide
NMR nuclear magnetic resonance
Nu' nucleophile
o ortho
ox. oxidation
p para
PCC pyridinium chlorochromate
PG protecting group
Ph phenyl
Piz piperazic
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PMB para-methoxybenzyl
PPTS pyridinium para-toluenesulfonate
i-Pr isopropyl
PTX pumiliotoxin
pyr pyridine
R alkyl
RedAI-H sodium bis(2-methoxyethoxy)aluminum hydride
rt room temperature
s singlet
SAA Sharpless Asymmetric Aminohydroxylation
SEM [2-(trimethylsilyl)ethoxy]methyl
SM starting material
t triplet
TBAF tetra r?-butylammonium fluoride
TBDMS ferf-butyldimethylsilyl
TBDPS fe/t-butyldiphenylsilyl
TEMPO 2,2,6,6-tetramethylpiperidine-1 -oxyl
Tf trifluoromethanesulfonyl
TFA trifluoroacetic acid
TFAA trifluoroacetamide
THF tetrahydrofuran
TIPS triisopropylsilyl
TLC thin layer chromatography
TMS trimethylsilyl
TPAP tetra-n-propylammonium perruthenate
Troc trichloroethoxycarbonyl
Ts p-toluenesulfonyl
Z benzyloxycarbonyl
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PART A: SYNTHETIC STUDIES ON MOLECULES RELATED TO 
THE AZINOTHRICIN FAMILY
In recent years, interest in phamacologically active natural products has occupied a 
central position in organic chemistry. Cyclodepsipeptides are cyclic peptides possessing at least 
one ester linkage and their chemical syntheses represent a considerable challenge. Indeed, 
their unusual architecture stimulated many synthetic chemists leading them to develop 
numerous new synthetic methodologies. These molecules also exhibit potent biological 
activities. Thus, the chemical synthesis of cyclodepsipeptides can provide leads for the 
development of novel pharmaceutical agents.
To understand the basis of cancer biology, it is necessary to understand the 
mechanisms that control cell growth and cell cycle. In fact, most eukaryotic cells reproduce
1. The Azinothricin family of antibiotics
1.1. Biological introduction
Figure 1. The cell cycle
9
through a sequence of four phases: 2 gap phases (G, and G2) where RNA and protein are 
synthesised, one synthesis phase (S) where DNA synthesis or replication occurs, and mitosis 
(M), in which the cell's chromosomes are divided between two daughter cells. The cell can also 
temporarily or reversibly exit cell cycle and enter a state of quiescence called G0 phase. A 
molecular surveillance system monitors the progress of cell cycle through various check points 
of which the two most important are between G-i and S and between G2 and M. 
Proto-oncogenes are genes which promote cell growth and mitosis, and tumor suppressor 
genes discourage cell growth, or temporarily halt cell division in order to carry out DNA repair. 
Typically, a series of several mutations to these genes are required before a normal cell 
transforms into a cancer cell. e 2F transcription factors1"4 regulate the expression of genes that 
control cell proliferation during the Gi/S transition. The mechanisms of action of E2Fs are very 
complex, and involve a network of interactions with various molecules. A pathway in which E2F 
is regulated by its interaction with the retinoblastoma protein (pRB), a tumor suppressor protein, 
had been identified.5 It is known that virtually all human cancers exhibit alterations in this 
pRb/E2F pathway.6 In this regard, targeting E2Fs could be a promising approach to treat cancer 
and molecules of the Azinothricin family that are known to inhibit, directly or indirectly, E2F 
transcription factors might serve as antiproliferative drugs.
1.2. Isolation and Biological Activity of Some Member of the Family
In 1986, Maehr and co-workers at Hoffman La-Roche isolated the first member of a 
growing family of antitumour antibiotics from Streptomyces sp. X14950. 7 They named the new 
molecule azinothricin 1 and found it to be one of the most potent antibiotics ever discovered in 
the Roche natural product screening assay. Its MIC values1 ranged from 0.008 to 0.063 pg/mL 
against a variety of Gram-positive strains of bacteria. The structure of azinothricin 1 is presented 
in Figure 2 along with other members of the family. It was determined by X-ray crystallography 
and chemical degradation.
f  Minimum Inhibitory Concentration: the lowest concentration of drugs that prevents visible bacterial growth
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Two years later, the second member of this family was discovered by Smitka et a !8 It 
was named A83586C 2 and was isolated from fermentation broths of the Guam soil 
microorganism Streptomyces Karnatakensis. A83586C was highly toxic to mice at doses of 9.3 
mg/kg and so its clinical development was never considered viable. However, it exhibited 
pronounced antitumour properties in vitro against a large number of cancer cells; it was 
particularly efficient at inhibiting growth of a CCRF-CEM human T-cell leukaemia line, its IC50* 
value being 0.0135 pg/ml. Recent work has shown that A83586C 2 exhibits activity against 
various other mouse and human tumour cell line HCT-116 human colon cancer cells (IC50 = 40 
± 10 nm), HT-29 cancer cells (IC50 = 60 ± 30 nm), MDA-MB-435 cancer cells (IC50 = 90 ± 10 
nm), MCF-7 human breast cancer cells (IC50 = 90 ± 30 nm), A549 human lung cancer cells 
(IC50 = 30 ± 10 nm), PC-3M human prostate cancer cells (IC50 =160 ± 30 nm) and U20S human 
ulterine cancer cells (IC50 = 80 ± 10 nm). A83586C 2 also possesses strong antibiotic properties 
against Gram-positive bacteria such as Staphylococcus aureus, Staphylococcus epidermis, 
Streptococcus pyogenes, and Streptococcus pneumoniae.
Other isolated molecules of this class include citropeptin9 3 in 1990, GE310,11 4 in 1997, 
and Kettapeptin12 5 in 2006 (Figure 2).
* Inhibitory Concentration: Concentration of a drug required to observe 50% inhibition of tumour growth
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Figure 2. Structure of the A83586C/Azinothricin Family of Antibiotics
Citropeptin 3 shows in vitro and in vivo activity against P388 leukaemia cells. Its IC50 
value is 0.02 pg/mL and it provides 120% life extension when given to mice with P388 
lymphocytic leukaemia at the non-toxic dose of 2 mg/kg/day.
The producing strain GE3 4 was isolated from a soil sample collected in Shimane 
prefecture, Japan. GE3 4 possesses antibacterial and antitumour activities against human 
pancreatic carcinoma, PSN-1 both in vitro and in vivo. It exhibits high in vitro cytoxicity against 
human tumour cell lines HeLa S3, A431 and Saos-2 with IC50 value of 6nM, 16 nM, and 3.6 nM
12
respectively. The in vivo activity was examined in the human xenograft mouse tumour model: a 
47% reduction in tumour size was observed when GE3 4 was given to mice at the non-toxic 
dose of 2 mg/kg/day. Contrary to A83586C 2, it showed only a weak activity against Gram- 
positive strains of bacteria. It is noteworthy that only two structural diffferences between GE3 4 
and A83586C 2 are responsible for divergent profiles against bacteria.
More recently, Kettapeptin 5 was isolated by Maskey and co-workers from the ethyl 
acetate extract of the Streptomyces sp. Isolate GW99/1572.12 It exhibits antibacterial activity 
against Bacillus subtilis with a MIC value of 3.75 pg/mL, and also against Streptomyces 
viridochromogenes, Staphylococcus aureus and Escherichia coli. Furthermore, Kettapeptin 5 
shows anticancer activity against human cell lines LXFA 629L, LXFL 529L, MAXF 401NL, 
MEXF 462NL, RXF944L and UXF 1138L with IC50 values of < 0.6 jg/mL.
Other cyclodepsipeptides that are considered to belong to the Azinothricin family 
include the molecules shown in Figure 3: Verucopeptin 6,13,14 Variapeptin 7,9 L-156,602 815 and 
Polyoxypeptins A, 9 and B 10,16IC101 11,17 and the recently discovered Pipalamycin 12.18
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Verucopeptin 6 was isolated in 1993 from the soil microorganism Actinomadura 
verrucospora, and exhibits specific in vitro toxicity against mouse B16-F10 cells with IC50 value 
of 0.004 pg/mL. Verucopeptin presents a weaker activity against P388 leukaemia and HCT-116 
Human Colon Cancer with IC50 value of 0.08 pg/mL and 0.04 pg/mL respectively. In vivo activity 
was tested in the experimental mouse tumor system; Verucopeptin 6 significantly prolongs the
14
life expectancy of mice with B16 melanoma, conferring a 162% life extension when given at the 
dosage of 2 mg/kg/day.
Variapeptin 7, was isolated from Streptomyces variabilis, that was taken from a soil 
sample collected in Bosque, Brazil. It showed a potent activity in vitro against Gram-positive 
strains of bacteria and demonstrated potent cytotoxicity against P388 leukaemia cells (IC50 = 
0.01 pg/mL).
L-156,602 8, isolated from cultures of Streptomyces spp. MA6348, was found to be a 
C5a antagonist. Such molecules might function as anti-inflammatory agents or be useful for 
treating allergic disease states. Its total synthesis was achieved in 1990 by Durette et a/.19
Polyoxypeptin A, 9 and polyoxypeptin B 10 were isolated in 1999 by Umezawa and 
coworkers16 from the culture broth of Streptomyces MK498-98F14 and are known to exhibit 
potent apoptosis against human pancreatic adenocarcinoma AsPC-1 cells, an apoptosis- 
resistant cell line. Polyoxypeptins A, 9 and B, 10 decreased the viability in AsPC-1 cells with 
ED50 values of 0.08 and 0.17 pg/mL.
IC101 1117,20 and Pipalamycin 1218were isolated from the same strain; the producing 
strain, MJ202-73F3, was extracted with EtOAc, concentrated to dryness and purified by 
chromatography with CHCIVMeOH (50:1). IC101 11 was eluted first as the major compound 
followed by Pipalamycin. IC101 inhibited MLCR (Mixed Lymphocyte Culture Response) with an 
IC50 value of 0.009 pg/mL and showed its strongest activity against P388D! cells (IC50 = 0.006 
pg/mL). Pipalamycin 12 induced apoptosis in human pancreatic adenocarcinoma AsPC-1 cells 
at 0.3 pg/mL in 24-48 hours.
Almost all molecules of the cyclic hexadepsipeptide class have been found to show 
potent cytotoxicity. However mechanisms for cytotoxicity have been little described. The 
synthesis of analogues following by the comparison of their biological activities should give a
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path to determine these mechanisms. Additionally, it might prove possible to find analogues that 
will possess interesting biological properties.
In this first part of my PhD, I worked on the synthesis of two modified cyclodepsipeptide 
analogues shown in Figure 4: the L-proline modified mimetic of GE3 cyclodepsipeptide 13 and 
the (3S, 5S)-5-hydroxypiperazic acid modified mimetic of A83586C cyclodepsipeptide 14.
Me . N - /  Y  : Me
I o °  / °
.Me 0=:f
A  OH
Me S V  O
13
L-proline modified mimetic 
of GE3 cycbdepsipeptide
,NHNH3+CI
(  O O 
.Me ° ;O N
HN : 
M« oh
hn y
OH
14
(3S, 5S)-5-hydroxypiperazic acid 
modified mimetic of A83586C 
cyclodepsipeptide
Figure 4. Two cyclodepsipeptide analogues
2. Previous work on the Azinothricin Family
Prior to our group’s research, only one group has achieved a total synthesis of a 
molecule of the Azinothricin family. In this part, the synthesis of L-152,602 by Durette and 
coworkers will be reviewed along with the work published by our group on the Azinothricin 
family. This work includes the total synthesis of A83586C and the synthesis of the verucopeptin 
and GE3 cyclodepsipeptides. Additionally, two cyclodepsipeptides analogues were also 
prepared.
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2.1. Past Syntheses of Some Related Natural Products
2.1.1. Total Synthesis of L-152,602
Durette and coworkers achieved the first total synthesis of L-152,602 8 in 199019. Their 
original plan was to complete the synthesis with a coupling between cyclodepsipeptide 15 and 
the HOBt activated ester 16 (Scheme 1). Activated ester 16 would be accessed via a Seebach 
enantioselective Claisen condensation reaction.21 Cyclodepsipeptide 15 would originate from 
the linear hexapeptide 19. The linkage selected to achieve the ring closure was the bond 
between the glycine and /V-benzyloxy-L-alanine residues. The assembly strategy for 
hexapeptide 19 employed a [2 + 2 + 2] fragment condensation of dipeptides 20, 21 and 22.
NZ NHTroc
AllocHN
AllocHN^Y^
17 18
22
Scheme 1. Retrosynthetic plan to L-156,602 8
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The synthesis of ester 16 started with a diastereoselective Frater-Seebach alkylation 
reaction of the enolate derived from methyl (ft)-3-hydroxybutanoate 23 with (S)-1-iodo-2- 
methylbutane 24 to afford alcohol 25 in 46% yield. Subsequent protection of the hydroxyl group 
and reduction of the methyl ester gave alcohol 26 in 52% yield. After Swern oxidation, the 
product aldehyde 27 was condensed with carboxymethylphosphorane to give (E)-olefin 28 in 
70% yield. Hydrogenation over Pd/C and O-desilylation led to concomitant ring closure affording 
lactone 18. After a diastereoselective Claisen condensation between lactone 18 and the lithium 
enolate derived from dioxolane 17, compound 29 was obtained as a single isomer in 75% yield. 
Compound 29 was then converted into the methyl pyranoside by treatment with methanolic HCI 
in 89% yield. Transesterification with excess sodium methoxide afforded methyl ester 30 which 
was converted into a potassium salt using potassium hydroxide. Finally, the N- 
hydroxybenzotriazole active ester 16 was prepared by reaction with the BOP reagent and NMO 
in DMF.
MeO 2C
X
/Pr2NLit THF, -50 X ;  
cool to -7 8 X  
then add 24
warm to rt (46%) M e 02C ^ ,o "
T Me
HO Me 
23
Me
Me
24
Me
HO Me
25
M e02C~
XX MeO O Me 
18
Me
(1) H2, Pd/C 
EtOAc (98%)
(2) n-Bu4NF, THF
(1) Et3SiOTf, CH2CI2. 
2,6-lutidine, -4 0 X  to rt
(2) DIBALH, PhMe 
-7 0 X  to -40°C 
(52%, 2 steps)
HO Me
Et3SiO Me 
26
Me
Me2SO, (COCI)2 
CH2CI2, -70°C, Et3N 
-20 X  (98%)
'M e Ph3P=CHC02Me
OHC.
Et3SiO Me 
28
Me
* ' Y ' ' M e  
THF, A ,70% Et3SiO MeM ®
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n-A'Me
f-Bu»»< I 
17 ° A C
17, i-Pr2NLi, THF, -70°C  
add 18 warm to -2 5 X  
(75%)
(1) HCI, MeOH
O'C to rt (89%) HQ M (1) aq. KOH, EtOH
(2) NaOMe L O
MeOH (78%) M e O ^ O
30
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Scheme 2. Synthetic route to activated ester 16
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The synthesis of fragments 21 and 22 required the preparation of Z-protected piperazic 
acids 34 (3R) and 39 (3S). It was achieved via a Diels-Alder cycloaddition between 2,4- 
pentadienoate 31 and di-te/t-butylazodicarboxylate 32 in hot CCI4 as shown in Scheme 3. After 
hydrogenation of the double bond and saponification, racemic acid 33 was obtained in 93% 
yield over 2 steps. The Boc groups were then cleaved with TFA and subsequent Z group 
protection of the N( 1) atom afforded racemic A/(1)-Z-piperazic acid that was resolved with (+) 
and (-) ephedrine. (3ft)-Z-piperazic acid 34 was obtained in 18% yield and (3S)-Z-piperazic acid 
39 in 15% yield. To complete the synthesis of dipeptide 21, (3R)-Z-piperazic acid 34 was 
protected with an Fmoc group and converted to acid chloride 36 with oxalyl chloride. A Carpino 
biphasic coupling with protected hydroxamic acid ester 37 yielded compound 38. Fmoc- 
deprotection furnished the desired dipeptide 21 in 62% yield over 3 steps.
M e 0 2c  
31
BocN
',NBoc
32
(1) CCI4, reflux 
36 h (65%)
(2) H2. Pd/C, MeOH
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Scheme 3. Synthesis of dipeptide 21
(3S)-Z-piperazic acid 39 was protected as a fert-butyl ester and the latter condensed 
with acid chloride 40 using the Carpino two phase aq. NaHCO^acid chloride coupling conditions 
(Scheme 4). Finally acid 22 was obtained in 98 % yield after deprotection with TFA.
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Scheme 4. Synthesis of fragment 22
To achieve the synthesis of fragment 20, Caldwell and Bondy developed a synthesis of 
(2S, 3S)-3-hydroxyleucine 46 (Scheme 5).22 It began with a Sharpless asymmetric epoxidation 
on allylic alcohol 42 to give epoxide 43. After oxidation of the hydroxyl group, the resulting acid 
44 was treated with benzylamine and sodium hydroxide. Regioselective opening of the epoxide 
occurred in 66% yield to give compound 45. Finally hydrogenolysis of the A/-benzyl group 
afforded (2S, 3S)-3-hydroxyleucine 46 in 89% yield.
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f-BuOOH, Ti(OPr-/)4 
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-20*C (82%)
O OH 
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MeOH, AcOH,25°C
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Me
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Scheme 5. Caldwell and Bondy’s route to (2S, 3S)-3-hydroxyleucine 46
The synthesis of fragment 20 was achieved as shown in Scheme 6. (2S, 3S)-3- 
hydroxyleucine 46 was protected in 2 steps to afford compound 47 in 68% yield. The latter was 
condensed with the A/-hydroxybenzyl-(R)-Ala residue 49 in presence of CDI to afford dipeptide 
20 in 67% yield.
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Scheme 6. Synthesis of fragment 20
After conversion of acid 22 to chloride 50, the peptide linkage between dipeptide acid 
chloride 50 and depsipeptide 20 was formed by AgCN-assisted amidation (Scheme 7). The 
resulting tetrapeptide 51 was then deprotected with TFA and converted into acid chloride 52 
using oxalyl chloride. Finally, linear hexapeptide 19 was obtained after coupling with dipeptide 
21 using 10% aq. NaHC03 in 69% over 3 steps.
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Scheme 7. Synthetic route to linear hexapeptide 19
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Removal of both the Alloc protecting group and the ally) ester from hexapeptide 19 was 
achieved in a single step by palladium-catalysed hydrostannolysis (Scheme 8). Cyclisation of 
the crude resulting hexapeptide was then performed by the mixed phosphonic anhydride 
method to give cyclodepsipeptide 53. The Troc group was then cleaved and the resulting free 
amine 15 coupled with the HOBt activated ester 16. Unfortunately, the amidation did not 
succeed, and Cadwell and co-workers isolated the cyclic peptide alcohol 54 resulting from 0,N- 
acyl shift.
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Scheme 8. Formation of cyclodepsipeptide 15 and attempted coupling with activated ester 16
The authors revised their retrosynthetic plan and decided to attach the side chain at the 
linear hexapeptide stage (Scheme 9). The Troc protecting group was cleaved from hexapeptide 
19 and the resuting crude amine was reacted with HOBt ester 16 to afford the desired 
hexapeptide 55 in 56% yield. Deprotection of the Alloc and allyl protective groups by palladium 
catalysed hydrostannolysis was accompanied by conversion of the methyl pyranoside to the 
hemiketal. Ring closure was achieved by means of the mixed phosphonic anhydride method to
22
afford cyclic hexapeptide 56 in 56% yield from linear hexapeptide 55. Finally, hydrogenolysis of 
the Z and Bn protective groups gave L-156,602 8 in 53% yield.
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Scheme 9. Completion of the synthesis of L-156,602 8
2.1.2. Total Synthesis of A83586C
A first retrosynthetic plan of A83586C 2 was elaborated; the C(1)-C(47) 57 sequence 
was synthesised (Scheme 10).23 Unfortunately difficulties occurred in the macrolactamisation 
and new ways of synthesis were considered. In 1997, our group achieved the first total 
synthesis of A83586C through an endgame that exploited a highly chemoselective coupling 
between the fully elaborated cyclodepsipeptide 59 and the activated pyran ester 60.24 The last 
two steps were the union of an activated ester 60 with a pre-assembled, unprotected 
cyclodepsipeptide 59 followed by a chemoselective hydration of the resulting glycal 58 under
23
very mild acidic conditions with wet deuterochloroform. A [2+2+2] condensation strategy was 
used to prepare cyclodepsipeptide 59 from peptides 64, 65 and 66. The synthesis required a 
total of 95 individual steps, but because it was highly convergent, the longest linear sequence 
was only of 28 steps.
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Scheme 10. Retrosynthetic analysis of A83586C
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Synthetic planning for the pyran sector was centred on the preparation of intermediates 
61, 62 and 63. Sulfone 63 was obtained from compound 67 as shown in Scheme 11. An Evans 
asymmetric aldol reaction between oxazolidinone 67 and aldehyde 68 afforded compound 69.25 
The chiral auxiliary was cleaved from compound 69 with sodium methoxide. The resulting 
methyl ester was reduced with DIBAL-H to afford diol 70. Selective thioesterification of the 
primary alcohol with tributylphosphine and phenyldisulfide provided 71 and after O-silylation and 
Trost-Curran oxidation with oxone, compound 63 was obtained in a 50% overall yield.
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Scheme 11. Synthesis of sulfone 63
Two key reactions were used to install the anti-relationship of the two adjacent 
stereocentres in compound 61 (Scheme 12). First, a Sharpless asymmetric epoxidation was 
used to prepare the chiral 2,3-epoxy alcohol 74. Then, a chelation-controlled epoxide ring- 
opening reaction with trimethylaluminium was performed. It proceeded with 20:1 selectivity in 
favour of the C(3)-ring opened product. Protection of the diol as p-methoxybenzylidene, 
cleavage of the obtained acetal and Swern oxidation of the resulting primary alcohol gave 
aldehyde 61.
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Scheme 12. Synthesis of aldehyde 61
Unification of sulfone 63 and aldehyde 61 was successfully performed with n-BuLi 
(Scheme 13). The resulting p-hydroxysulfone 76 was oxidised with trifluoroacetic anhydride and 
DMSO. The resulting p-ketosulfone was reduced with AIBN / tri-n-butylstannane to give ketone 
77. Alkene 78 was formed from compound 77 via a Grignard addition followed by POCI3- 
pyridine mediated dehydration. Compound 78 was obtained as the major isomer in a 2.6:1 
mixture with the 1,1-disubstituted alkene. Cleavage of the primary silyl group and sulfonation of 
the obtained alcohol provided compound 80.
P h$02 9SiPh2Bu-f 
‘Me
Me Me
n-BuLi, THF,-78*C  
then add 61
(64-75%)
f-BuPh^iO-
PMBO PhS02 9SiPh2 f-Bu 
"Me
Me OH Me Me
76
(1 )(C F 3C 0 2 )0, Me2 SO, 
CH2CI2, -78°C, Et3N 
warm to rt (92%)
(2)Bu 3SnH, AIBN, PhMe 
reflux (82%)
f-BuPh2SiOv ..Me OSiPh2f“Bu
PMBO
Me Me Me
78
HF-pyridine 
THF (8 6 %)
PMBO
Me Me Me
(1) MeMgBr, THF 
-78 °C to rt (98%)
(2) POCI3, Py 
55°C (97%)
f-BuPh2S iO v ^ / \ . .M e  
PMBO
SiPh2 f-Bu (1) Bu3 P, DMF, (PhS)2 (94%)
Me (2) oxone, THF, MeOH 
H20  (96%)
SiPh2/-Bu 
Me
O Me Me 
77
Ph02S ^ ^ \ . >Me 
PMBO
SiPhjf-Bu 
Me
Me Me Me 
80
Scheme 13. Synthesis of compound 80
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The synthesis of fragment 62 is shown in Scheme 14. The stereochemistry of the chiral 
diol 82 was obtained from alkene 81 by a Sharpless catalytic asymmetric dihydroxylation 
reaction. A strategy involving formation of a p-methoxybenzylidene followed by acetal reduction 
was used to position a PMB group preferentially on the more hindered hydroxyl. Alcohols 84 
and 85 were readily separated by flash chromatography. Alcohol 84 was oxidised and esterified 
to deliver the methyl ester 86. The last steps involved deprotection of the silyl group and 
oxidation of the resulting alcohol under Swern conditions.
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Scheme 14. Synthesis of p-aldehydo ester 62
The last steps of the preparation of activated ester 60 are illustrated in Scheme 15. The 
p-hydroxysulfone 87 formed by condensation of sulfone 80 and aldehyde 62 was subjected to 
Swern oxidation. Reduction of the resulting p-ketosulfone proceeded efficiently with aluminium 
amalgam in aqueous THF to give compound 88. A regioselective O-debenzylation was next 
attempted with DDQ in aqueous CH2CI2 at 0° C. It furnished a mixture of the p-hydroxyketone 
and the two a- and p-ring-closed hemiketals, which was treated with PPTS and methanol to give 
the glycal 89. Deprotection of the alcohol followed by conversion of the methyl ester to the acid 
afforded compound 90. Construction of the activated ester 60 was thereafter accomplished by 
treatment with Castro's BOP reagent, Swern oxidation, and deprotection of the tertiary PMB 
ether with DDQ in wet chloroform.
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Scheme 15. Synthesis of the pyran sector of A83586C
During the A83586C project, the Hale group had to find new methods for the synthesis 
of many of the key units of A83586C. Indeed the first short enantioselective synthesis of both 
(3R)- and (3S>piperazic acids was developed.26 The (3R)-piperazic acid and (3S,)-piperazic acid 
were synthesised via tandem electrophilic hydrazination-asymmetric nucleophilic cyclisation.26 
The synthesis of A/(1)-Z-(3R)-piperazic acid 34 is illustrated in Scheme 16. The route 
commenced with a regioselective deprotonation of (4R)-phenylmethyl-2-oxazolidinone 91 and 
subsequent A/-acylation with bromovaleryl chloride 92. The resulting bromide 93 was treated 
with LDA to produce an internally-coordinated enolate that underwent a stereoselective 
hydrazination with di-fe/t-butylazodicarboxylate (DBAD). Tandem cyclisation occured after 
addition of DMPU to afford compound 94. A/(1)-Z-(3R)-piperazic acid 34 was obtained after 
removal of the auxiliary using lithium hydroxide, cleavage of both Boc groups with TFA and Z 
group protection of the A/(1)-atom. Dipeptide 64 was obtained via a silver cyanide coupling 
between the acid chloride 36 derived from A/(1)-Z-/V(2)-Fmoc-(3R)-piperazic acid 35 with the 
glycine derivative 96. Deprotection of the acid with TFA yielded dipeptide 64.
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Scheme 16. Syntheses of A/(1)-Z-(3R)-piperazic acid 34 and dipeptide 64
The same silver cyanide assisted amidation methodology was used to couple the (3S)- 
piperazic acid derivative 99 to the acid chloride of Fmoc-A/(Me)-D-Ala 98 to yield compound 65 
(Scheme 17). For both these procedures, the amino-acid chloride was used in its Fmoc- 
protected form because first, these Fmoc amino-acid chorides are very stable and easy to 
prepare but also because they are highly reactive and able to couple to donors with low 
nucleophilicity with minimum epimerisation at the a-stereocentre. However, difficulties were later 
encountered upon removal the Fmoc protecting group from 65 leading to the formation of the 
diketopiperazine. Replacement of the diphenyl methyl ester group from compound 65 with a t- 
butylcarbazide function avoided that problem. Peptidic coupling of the resulting amine 100 with 
acid 64 activated with BOP-CI/Et3N afforded compound 101. The Boc group was removed with 
TFA and the resulting acyl hydrazine oxidised to the acid with NBS.27 Esterification with 
diphenyldiazomethane followed by cleavage of the Fmoc group with diethylamine gave 
compound 102.
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Scheme 17. Formation of compound 102
Dipeptide 66 contains the (2S,3S,)-3-hydroxyleucine moiety and is common to the five 
antibiotics described at the beginning of this section. A novel large scale synthesis of (2S.3SJ-3- 
hydroxyleucine 46 was developed by the Hale group for the synthesis of A83586C.28 This new 
method, depicted in Scheme 18, requires only 6 steps and begins with a Wittig condensation 
between isobutyraldehyde 103 and carboethoxymethylene triphenylphosphorane 104 to afford 
alkene 105. An efficient entry into the chiral anti-amino alcohol motif was achieved by use of the 
Sharpless asymmetric dihydroxylation reaction.29 The resulting diol 106 was converted with 
thionyl chloride to its 2,3-cyclic sulfite that was oxidised in situ into sulfate 107 with RuCh/NalO^ 
A ring opening strategy using NaN3 afforded azido ester 108 in 92% yield. Hydrolysis of the 
ester with aqueous sodium hydroxide followed by hydrogenation afforded (2S.3SJ-3- 
hydroxyleucine 46.
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Scheme 18. Synthesis of (2S,3S>3-hydroxyleucine 46
Compound 112 was then obtained via a DMAP-assisted DCC coupling of the protected 
derivative 109 with acid 111. O-Deallylation of 112 with Pd(0) and morpholine followed by 
treatment with oxalyl chloride provided the depsipeptide acid chloride 66 (Scheme 19).
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Scheme 19. Synthesis of depsipeptide 66
The final steps of the synthesis of A83586C are shown in Scheme 20. The coupling of 
chloride 66 to amine 102 was achieved efficiently (86% yield) with silver cyanide at 60 °C to 
afford peptide 113. The reaction needed to be conducted for 2 min otherwise decomposition 
quickly ensued. The Troc group was then detached with Zn dust and replaced with a Z group. A 
mild acidolysis with TFA and phenol was used to cleave the Boc and the diphenylmethyl groups 
and generate compound 114. The phenol trapped out the diphenylmethyl cation and prevented 
it from causing unwanted side reactions. After screening many activation reagents 
unsuccessfully, macrolactamisation of compound 114 was eventually accomplished with HATU 
and /V-ethylmorpholine in CH2CI2 under conditions of very high dilution30 in 25-40% yield. The
31
benzyl protecting groups were then cleanly deprotected by catalytic hydrogenation over a 10% 
Pd on carbon catalyst in methanol containing 1% eq of HCI. This acidic medium helped prevent 
O- to A/-acyl shift from occuring in the /3-hydroxyleucine residue. The last steps of the synthesis 
consisted in the union of the crude cyclodepsipeptide core 59 with the activated ester 60. Both 
were suspended in CH2CI2 and after cooling that mixture to -78 °C, Et3N was added and the 
reaction mixture warmed to room temperature and stirred for 10 minutes. Compound 58 was 
obtained in 31% yield after chromatography purification. Finally compound 58 was hydrated with 
wet deuterochloroform to deliver A83586C 2 in a quantitative yield.
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Scheme 20. Total synthesis of A83586C 2
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2.1.3. Synthesis of Verucopeptin Cyclodepsipeptide Core
In 2001, our group reported a synthesis of the cyclodepsipeptide core of verucopeptin 
6.31 This antitumour antibiotic incorporates a more functionalised pyran sector than other 
members of the azinothricin family but a greatly simplified cyclodepsipeptide core. Achieving its 
synthesis could pave the way for the synthesis of simplified analogues. The relative and 
absolute configurations of verucopeptin remain currently unknown. Hence it was decided to 
synthesise the diastereoisomer that was closest in structure to the other members of the family 
i.e. the isomer containing a (3Rj-piperazic acid unit linked to a (2S,3S>)-3-hydroxyleucine. With 
the experience gained during the A83586C synthesis, a [2+2+2] fragment condensation 
strategy was planned to link the linear hexapeptide domain. This strategy would also involved a 
union between fragments 116 and 117. Fragment 117 could be obtained by successive 
coupling between compounds 118 and 120, removal of the Fmoc group from the resulting 
tetrapeptide and union with fragment 119 using acid chloride coupling technology (Scheme 21).
Verucopeptin 6
o
NZ
NFmoc
BocN
118 Me
NHNHBoc
O
120
Scheme 21. Retrosynthetic plan of verucopeptin 6
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The synthesis of peptide 118 commenced from the protected hydroxamic acid 121, the 
synthesis of which was reported by Kolasa and Chimiak.32 Compound 121 was esterified with 
diphenyldiazomethane 122 to afford compound 123. Silver cyanide assisted coupling with acid 
chloride 36, followed by removal of the diphenylmethyl ester group of 124 gave acid 118 
(Scheme 22).
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Scheme 22. Synthesis of peptide 116
The peptide linkage of tetrapeptide 127 was built by a DMAP-assisted DCC coupling 
between compounds 125 and 126 (Scheme 23). Removal of the Z group followed by coupling of 
the resulting amine 120 with compound 118 using BOP-CI and Et3N afforded compound 128. 
Subsequent cleavage of the Fmoc group gave tetrapeptide 129 in 87% yield.
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Scheme 23. Synthesis of tetrapeptide 129
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To complete the preparation of cyclodepsipeptide 117, the synthesis of acid chloride 
119 still had to be accomplished (Scheme 24). A DCC-DMAP mediated O-esterification 
between alcohol 109 and acid 130 provided ester 131, which was submitted to deallylation with 
Pd(0)/morpholine and chlorination with oxalyl chloride to give acid chloride 119. The coupling 
between compounds 119 and 129 took place efficiently (80% yield) when silver cyanide was 
used as the promoter and the mixture was heated at 80 °C for 2-3 min. Hexapeptide 132 was 
then converted to the amino acid 133 by TFA treatment followed by chemoselective oxidation of 
the Gly acyl hydrazide group with NBS.27 Contrary to the A83586C synthesis, the 
macrolactamisation had to be carried out before A/-Troc to N-Z group interconversion otherwise 
degradation occurred under the basic Z-protection conditions. The cyclisation was performed 
using Carpino’s HATU protocol30 and cyclodepsipetide 134 was obtained in 67% yield over 3 
steps. The Troc-urethane was then detached with Zn dust and successfully replaced with a Z 
group using benzylchloroformate and 10% aqueous NaHC03. Catalytic hydrogenation in 
methanol in the presence of one equivalent of HCI afforded cyclodepsipeptide 117.
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Scheme 24. Synthesis of Verucopeptin cyclodepsipeptide core 117
2.1.4. Synthesis of GE3 Cyclodepsipeptide Core
In 2002, our group achieved the synthesis of the GE3 cyclodepsipeptide. The 
retrosynthetic plan which was based on the synthesis of A83586C, is shown in scheme 25. It 
also involved a [2+2+2] fragment condensation strategy and utilised two of the three dipeptide 
components that were used for the synthesis of A83586C.
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Scheme 25. Retrosynthetic analysis of the GE3 cyclodepsipeptide
The synthesis of tetrapeptide 137 is depicted in Scheme 26. It started from the (3S)- 
A/(1)-Z-A/(2)-Fmoc-piperazic acid 138 which was protected with a f-butylcarbazide function using 
DCC as the condensing agent. The Fmoc group was then detached to allow 139 to be coupled 
with acid chloride 140 in presence of silver cyanide. Tetrapeptide 137 was obtained after 
cleavage of the Fmoc group. All efforts to couple tetrapeptide 137 to acid 64 using the BOP- 
CI/NEt3 system which was so efficient in the A83586C synthesis, failed. After having tried a wide 
range of conditions, it was discovered that the combination of BOP-CI and collidine could yield 
the desired tetrapeptide 141 in 66% yield. The Fmoc group was then cleaved from 141, and the 
third fragment, 66, was attached using silver cyanide to give peptide 142. After the cleavage of 
the two Boc group, the A/-acyl hydrazine was oxidised with NBS/water to give the acid. The 
macrolactamisation was achieved using the same conditions as for A83586C, i.e. with HATU in 
very high dilution in CH2CI2, as developed by Carpino. It proceeded in a 40% yield over three 
steps from compound 142. The last steps involved replacing the Troc group with a Z group and
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deprotecting the three Z-groups by hydrogenolysis under mildly acidic conditions to give the
cyclodepsipeptide 136.
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Scheme 26. Preparation of the GE3 cyclodepsipeptide 136
2.2. Previous Syntheses of Analogues of the Azinothricin Family of 
Antibiotics
The synthesis of analogues of A83586C is of interest as these may be of value for 
elucidating the mode of antitumour action of these natural products. In fact, by testing 
analogues, it should be possible to determine which part of the molecule is essential for potent 
antitumour activity. Analogue work might also allow a considerably simplified structure to be 
identified that has good antitumour properties and which can be more readily synthesised 
industrially. Some cyclodepsipeptides analogues have already been synthesised: the A-epi- 
analogue33 144 is one such compound, as is the L-proline modified A83586C 145.
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The 4-ep/'-analogue 144 has a (3ft)-piperazic acid component replacing the (3S)- 
piperazic acid unit (Figure 5). Making this change improved the yield of the macrolactamisation 
from 25% to 70% but the 4-ep/'-analogue 144 was much less active as an antitumour drug. It is 
believed that in that analogue, the C(8)-carbonyl adopts a conformation cis to the C(7), whereas 
the relationship between these two bonds is trans in A83586C.
For this reason, it was decided to synthesise an analogue that had similar 
conformational properties than A83586C. The L-proline analogue was selected, because, first, 
the (3S)-piperazic acid has previously functioned as a very effective mimic of L-proline in ACE- 
inhibitor such as cilazaprill34 and secondly, cyclisation at an activated proline residue is usually 
free of racemisation risk. The synthesis of the L-proline modified mimetic of the A83586C 
cyclodepsipeptide 145 was thus performed in our laboratory in 2002.35 The strategy involved 
coupling of fragments 146, 64, and 66 as shown in Scheme 27.
Figure 5. 4-ep/-A83586C 144
NHTroc
NFmoc
NHNHBoc BocHN
cr
146 146 64 66
Scheme 27. Retrosynthetic plan to the L-proline modified mimetic of the A83586C
cyclodepsipeptide 145
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Units 64 and 66 of A83586C were used for the synthesis of cyclodepsipeptide 145. 
Dipeptide 146 was prepared from /V-Z-L-proline 147 as shown in Scheme 28. The latter was 
converted to the acyl hydrazide 148 by treatment with BocNHNH2/DCC followed by catalytic 
hydrogenation to cleave the Z group. A peptide bond was formed by silver cyanide assisted 
coupling between Fmoc-A/-methyl-D-alanyl-chloride 149 and compound 148 to afford compound 
150. Fmoc cleavage afforded amine 146 which was purified and readily coupled to acid 64 by 
treatment with BOPCI and Et3N at low temperature. Fmoc deprotection followed by 
condensation of tetrapeptide 152 with acid chloride 66, using silver cyanide as a promoter, gave 
hexapeptide 153 in 73% yield. The last stages of the synthesis were performed in the same 
order as for verucopeptin and GE3 cyclodepsipeptides: the two Boc groups were cleaved with 
TFA, the liberated A/-acylhydrazine was converted to the acid with NBS, and the 
macrolactamisation was carried out at very high dilution utilising HATU as the carboxyl 
activating reagent. Macrolactam 154 was obtained in 48% yield over 3 steps. Acquisition of 
cyclodepsipeptide 147 was accomplished after Z replacement of the Troc group and 
hydrogenation over Pd/C in the presence of one equivalent of HCI in MeOH.
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Scheme 28. Synthesis of the L-proline modified mimetic of the A83586C cyclodepsipeptide 145
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3. Synthetic Studies Towards Analogues of the Azinothricin 
Family
As outlined in the introduction, our group had developed a large knowledge concerning 
the synthesis of molecules of the Azinothricin family at the outset of this project and so was now 
in a very good position to exploit this knowledge for constructing more analogues. As a member 
of this research program, I worked on the synthesis of two modified cyclodepsipeptides. The l- 
proline modified mimetic of GE3 cyclodepsipeptide 13 was chosen because: (a) GE3 was the 
most potent E2F inhibitor to have been discovered so far and we considered that its proline 
congener is likely to have promising properties, (b) comparing its biological activity with the 
already synthesised L-proline modified mimetic of A83586C would help to uncover which 
features of these molecules were essential for activity and; (c) the structure being simpler, the 
synthesis could potentially be more readily achieved on a large scale as was required for 
possible industrial applications.
We also selected the (3S, 5S)-5-hydroxypiperazic acid modified mimetic of A83586C, 
14, in order to analyse how the biological and pharmacokinetic properties of a more hydrophilic 
molecule would vary; a key problem with molecules of the A83586C class is their poor water 
solubility. Adding an extra hydroxyl might improve this situation and give a more readily 
administered drug. The retrosynthetic analyses of these two cyclodepsipeptides are depicted in 
Scheme 29.
43
NHTroc
Me
Me
NFmoc
64
OH Me
BocHN
OBn
Me
Me
NHNHBoc
MeMe
Me
HN
Me
Me' A  oH
L-proline modified mimetic 
of GE3 cyclodepsipeptide
/JHNH3 Me
I 0 °
. Me  0 ;=f^
0H 
V
HO 14
(3S, 5S)-5-hydroxypiperazic acid modified 
mimetic of A83586C cyclodepsipeptide
NFmoc
Fmoc
NHTroc
Cl
BocHN
NHNHBoc
Me
Me
0
Me 
OBn 
66
Scheme 29. Retrosynthetic plan to two cyclodepsipeptides
Again, a [2+2+2]-fragment condensation strategy would be adopted. Two of the three 
fragments are common to both cyclodepsipeptides and their syntheses had already be 
developed for the A83586C synthesis. Thus, a large part of this project is dedicated to large 
scale synthesis. To access dipeptide 66, the 6 step synthesis of hydroxyleucine 46 was 
performed on a multigram scale without purification by chromatography (Scheme 30). 
Hydroxyleucine 46 was obtained in 45% yield from isobutyraldehyde 107. The detail of each 
step was described earlier in the introduction. Then, the DMAP-assisted DCC coupling yielded 
dipeptide 60, which was deprotected using Pd(0) and morpholine to afford acid 157 in 89% 
yield. Acid 157 would be converted into chloride 66 just before use. The spectral data obtained 
for acid 157 corresponded to that published by our group during the GE3 cyclodepsipeptide 
synthesis.36 40 g of the protected hydroxyleucine 109 was synthesised.
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Scheme 30. Synthesis of acid 157
Compound 64 was prepared using the route developed in the A83586C synthesis 
(Scheme 31). Compounds 34 and 96 were already prepared by L. Lazarides of this group.36 
Protection of 34 was achieved in a good yield using FmocCI in presence of 
diisopropylethylamine and trimethylsilyl chloride. The acid was converted to its chloride and 
combined with 96 in a silver cyanide mediated coupling. The acid group of compound 97 was 
then deprotected with TFA to afford acid 64.
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Scheme 31. Synthetic route to compound 64
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3.1.Synthesis of an L-proline analogue ofGE3 cyclodepsipeptide
The synthetic route to dipeptide 155 is depicted in Scheme 32. It started from 
commercially available D-leucine 158.37 An Fmoc group was attached to amine 158 with Fmoc­
CI and sodium carbonate in dioxane. Addition of water and ether to the reaction mixture, 
acidification of aqueous layers and extraction with diethyl ether allowed isolation of acid 159. 
The latter was cyclised using paraformaldehyde in presence of phenol in toluene at 120°C using 
a Dean-Stark apparatus. Treatment of crude oxazolidinone 160 with TFA / Et3SiH in chloroform 
liberated the Fmoc protected A/-methylamine 161 which was obtained in 74% yield over 2 steps 
after crystallisation. The 500 MHz 1H NMR spectrum of compound 161 in CDCI3 indicated the 
presence of two rotamers. The formation of the peptide linkage between amine 148 and the 
acid chloride of 161 was carried out using silver cyanide at 80 °C in benzene for 30 min to 
provide dipeptide 155 in 90% yield over 2 steps.
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Scheme 32. Synthesis of fragment 155
Fmoc deprotection of dipeptide 155 was achieved with diethylamine (35 eq) in MeCN at 
room temperature for 35 minutes. After purification of the crude residue by silica gel 
chromatography, deprotected dipeptide 162 could not be isolated pure. TLC analysis showed 
that a faster moving product had formed during the purification. The presence of 10% of
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diketopiperazine 163 was detected by 1H NMR analysis of the mixture obtained after flash 
chromatography (Scheme 33).
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155 162 163
Scheme 33. Removal of the Fmoc group from compound 155
A second purification by S i02 flash chromatography of the mixture allowed isolation of 
pure diketopiperazine 163. However, dipeptide 162 could never been separated from some 
diketopiperazine 163. 500 MHz 1H NMR spectrum of the mixture of 162 and 163 in CDCI3 is 
shown in Figure 6 and 500 MHz 1H NMR spectrum of diketopiperazine 163 in CDCI3 is shown in 
Figure 7. In the 1H NMR spectrum of diketopiperazine 163 in CDCI3l the lack of singlet around 5 
1.40 ppm indicated the absence of the tert-butyl group. Additionally, the signal corresponding to 
the N-Me group in diketopiperazine 163 is shifted downfield compared to 162 due to the 
proximity of the carbonyl group.
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Figure 6 .1H NMR spectrum of the mixture containing dipeptide 162 with 10% of 
diketopiperazine 163 in CDCI3 at 298K
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Figure 7 .1H NMR spectrum of 163 in CDCI3 at 298K
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It is believed that the formation of diketopiperazine 163 is triggered by the acidity of the 
silica as shown in Scheme 34.
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Scheme 34. Mechanism of formation of diketopiperazine 163
A diketopiperazine formation was observed at the same stage of the synthesis of 
A83586C24 (Scheme 35). However, the acid was protected with the more labile Ph2CH ester 
group and the diketopiperazine formation was avoided by replacement of the Ph2CH ester 
group with a BocNHNH group.
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Scheme 35. Formation of diketopiperazine 164 observed in the A83586C synthesis
Attempts to couple the purified dipeptide 162 (with 10% of diketopiperazine 163) to acid 
64 remained unsuccessful. This difficulty was overcome by coupling crude dipeptide 162 and 
acid 64 with BOPCI and NEt3 at -10°C in dichloromethane (Scheme 36). Tetrapeptide 165 was 
obtained in 73% yield over 2 steps; its formation was easily followed on the TLC plate with the 
appearance of a yellow spot with anisaldehyde. The formation of tetrapeptide 165 was 
confirmed by FAB HRMS analysis which contained an (M+Na)+ peak at m/e 1024.48548 (Calcd 
(M+Na)+ for CssHeyNyNaOn 1024.47960). Tetrapeptide 165 was then deprotected using
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diethylamine (40 eq) in MeCN at room temperature for 25 minutes to afford 166 in quantitative 
yield.
FmoCs .Me
N (1) Et2NH (40 eq)
M e . X / j O  MeCN. rt. 25 min
Me' I ft (2)
   {  NZo)B n \— fsjFO "  NHNHB0C 9 V -N F m o e
161 M° Y  0
. 64
NHNFmoc
MeMe
(3) Et2NH (40 eq) 
MeCN, rt, 15 min .Me.Me
( 100%) MeMe
Me'Me
NHNHBocNHNHBoc
165O OH
BOP-CI, Et3N, CH2CI2 
-10*C, 3 h (73%. 2 steps)
Scheme 36. Synthesis of tetrapeptide 166
The final steps of the synthesis of cyclodepsipeptide 13 are shown in Scheme 37. Acid 
157 was first converted to chloride 66. The [4+2] condensation was achieved by heating 
chloride 66 with tetrapeptide 166 in the presence of AgCN in C6H6 at 80°C. It is important to 
stop heating this reaction after 5 min, otherwise decomposition might ensue. The structure of 
the resulting compound 167 was confirmed by FAB HRMS analysis which contained an 
(M+Na)+ peak at m/e 1396.54502 (Calcd (M+Na)+ for CesHgoNgNaO^ 1396.54176). In fact, the 
1H NMR and 13C NMR spectra of 167 were complex due to the presence of rotamers. The 
conversion of hexapeptide 167 to cyclodepsipeptide 168 was performed in 70% yield using the 
3-step protocol developed in this research program. The Boc groups were cleaved by treatment 
with excess trifluoroacetic acid, the acyl hydrazine was oxidised with NBS in THF/H20  to give 
the acid and high dilution macrolatamisation with HATU/NEM provided compound 168. In this 
macrolactamisation, a solution of hexapeptide 167 (1 eq) and NEM (13.5 eq) in dry CH2CI2 
(0.0008 M) was added dropwise to an ice-cold solution of HATU in dry CH2CI2 (0.0008 M). After 
the addition, the reaction mixture was warmed to rt, stirred for 48 h and concentrated in vacuo. 
Cyclodepsipeptide 168 was obtained after an acid/base work-up and purification by S i02 flash 
chromatography. The product appeared as 2 inseparable spots. The only way to confirm the 
structure of the cyclodepsipeptide was to use mass spectroscopy. The FAB HRMS spectrum of 
168 contained the appropriate (M+Na)+ peak at m/e 1164.39772 (Calcd for CssCbHyoN/NaOn 
(M+Na)+ 1164.39946). The Troc group was then detached with Zn dust in aqueous acetic acid,
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and the crude amine immediately capped with a Z-group using benzylchloroformate and 10% 
aqueous NaHC03. The product appeared again as 2 inseparable spots after purification by 
silica gel flash chromatography and the structure was confirmed by mass spectroscopy 
analysis. Cyclodepsipeptide 169 shows the appropriate (M+Na)+ peak at m/e 1124.52750 
(Calcd for C6oH75N7Na013 (M+Na)+ 1124.53203). Hydrogenation over Pd/C in the presence of 
one equivalent of HCI in MeOH provided the final cyclodepsipeptide 13 as a yellow powder.
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Scheme 37. Synthesis of an L-proline analogue of GE3 cyclodepsipeptide 13
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1H and 13C NMR spectra of cyclodepsipeptide 13 in MeOD are shown in Figure 8 and 9.
6 . 5 6 . 0 5.5 3.5 3.05 . 0 4 . 5 4 . 0 2.5 2 . 0 1 .5 1.0 0.5 ppm
Figure 8 .1H NMR spectrum of cyclodepsipeptide 13 in MeOD
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Figure 9 .13C NMR spectrum of cyclodepsipeptide 13 in MeOD
These NMR spectra hinted that the formation of the desired cyclodepsipeptide occured. 
However 13C NMR spectrum shows that the product 13 is not pure. As it is very difficult to purify
52
a salt, a more careful purification will have to be carried out at an earlier stage. Indeed all effort 
to purify the mixture obtained for compound 169 by S i02 flash chromatography and preparative 
chromatography failed.
3.2. Toward the synthesis of an (3S, 5S)-5-hydroxypiperazic acid 
modified mimetic ofA83586C
The retrosynthetic plan of the cyclodepsipetide analogue of A83586C incorporating a 
(3S, 5S)-5-hydroxypiperazic acid 14 was described earlier in this section (Scheme 29). Since 
dipeptides 64 and 66 has already been synthesised, our attention focused on the formation of 
compound 156 which contains the (3S, 5S)-5-hydroxypiperazic acid moiety. The desired 
protected form of hydroxypiperazic acid was synthesised following a procedure developed in 
our lab38 (Scheme 38 and 39). The synthesis commenced with a regioselective protection of d - 
mannitol 170 as shown in Scheme 38.39 First, protection of 1,3-diols occurred with 
benzaldehyde and conc. H2S04 in dry DMF for 4 days. The reaction had to be quenched very 
slowly with saturated aqueous NaHC03 because of liberation of gas. The resulting diol was 
protected with benzylbromide and sodium hydride in dry DMF to give 171. Compound 171 was 
then hydrolysed with conc. HCI in MeOH and water. After neutralisation of the reaction mixture 
with 20% aq. NaHC03 and extractive work-up with EtOAc, the resulting tetrol 172 was 
selectively protected with TBDPSCI and imidazole. Diol 172 was obtained as the single product 
and was cleaved with Pb(OAc)4 in CH2CI2 to give aldehyde 173.
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Scheme 38. Formation of aldehyde 173
Aldehyde 173 was condensed with known phosphonate 17440 in a Wittig-Horner 
olefination to furnish alkene 175. This reaction took place under Roush-Masamune conditions41, 
i.e. in the presence of lithium chloride and diisopropylamine; Li+ form a complex with the 
carbanion derived from the phosphonate. Desilylation was next performed with 40% aq. HF to 
afford alcohol 173 in 93% yield. A carefully monitored hydrogenation allowed chemoselective 
reduction of the the olefin. The hydrogenated product 177 move slightly slower than alkene 176 
on TLC. The more polar product visible on TLC is the debenzylated product. The resulting 
alcohol 177 was converted to bromide 178 using PPh3 and CBr4. The piperazic unit was then 
elaborated by delivery of di-ferf-butylazodicarboxylate to the lithium enolate of compound 178. 
This highly stereoselective hydrazination took place only when DMPU was added to the 
reaction mixture and proceeded in 58% yield. The chiral auxiliary was cleaved with sodium 
methoxide in 93% yield to give methyl ester 180. The Boc protective group was removed with 
TFA in CH2CI2, and the crude TFA salt was selectively protected using benzylchloroformate in 
aq. NaHC03. Hydrolysis of ester 181 with Li0H-H20  produced hydroxy-piperazic acid derivative 
182 in 98% yield. It is noteworthy that using this procedure, we were able to produce 20 g of 
intermediate 182.
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Scheme 39. Synthetic route to hydroxypiperazic derivative 182
Acid 182 was converted to compound 183 using f-butylcarbazate in the presence of 
DCC and HOBt (Scheme 40). Subsequent coupling of acyl hydrazine 183 with Fmoc-A/-methyl- 
D-alanoyl chloride 184 in benzene at 80 °C using silver cyanide as a promoter proceeded in 
92% yield. After cleavage of the Fmoc group under standard conditions, the [2+2] coupling was 
conducted at -20 °C using BOPCI as a coupling reagent and collidine as a base. Tetrapeptide 
185 was obtained as a white foam in 68% yield over 2 steps. The structure of compound 185 
was confirmed by FAB HRMS analysis which showed a (M+Na)+ peak at m/e 1237.52395 
(Calcd for C67H74N8NaOi4 (M+Na)+ 1237.52219). The 1H NMR and 13C NMR spectra displayed 
very broad peaks due to the presence of rotamers. Eventually cleavage of the Fmoc group 
provided compound 186 in 99% yield.
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Scheme 40. Formation of tetrapeptide 186
Coupling of the deprotected tetrapeptide 186 with acid chloride 66 was performed using 
silver cyanide as shown in Scheme 41.
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Scheme 41. Formation of hexapeptide 187 and attempt of macrolactamisation
TLC analysis of the crude mixture showed the formation of 2 compounds. After 
separation by silica gel flash chromatography, two compounds were isolated in 43% and 48% 
yield respectively. FAB HRMS analysis showed a (M+Na)+ peak at m/e 1609.59520 and a 
(M+Na)+ peak at m/e 1609.59929. These two compounds showed a (M+Na)+ peak that matched 
the theoretical mass of hexapeptide 186 (Calcd (M+Na)+for CyyClaHgyN^NaC^o : 1609.58436).
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It can be speculated that the [4 + 2] condensation gave rise to diastereoisomers; some 
epimerisation had occured. Nevertheless, we decided to carry out the 3 steps 
macrolactamisation procedure on both compounds separately. For both reactions, TLC analysis 
showed the formation of at least five compounds, and no pure product could be isolated from 
the reaction mixtures. Unfortunately hexapeptide 186 was all used up in this last reaction. 
Therefore, the macrolactamisation could not be repeated.
4. Conclusion
Our initial aim of this work was to achieve the total synthesis of two new 
cyclodepsipeptide rings; the proline analogue cyclodepsipeptide of GE3 13 and the 
(3S,5S)-5-hydroxypiperazic acid analogue cyclodepsipeptide of A83586C 14. These syntheses 
were based on a [2+2+2] coupling of three dipeptides (Scheme 42). Dipeptide 64 and 
depsipeptide 66 were synthesised using procedures previously developed in our lab and large 
amount (40g) of protected (2S,3S)-3-hydroxyleucine 109, precursor of 66 were prepared. 
Furthermore, intermediates 155 and 156 were successly prepared. Intermediate 155 was 
prepared in 8 steps and 36% overall yield from L-proline and D-leucine. Intermediate 156 was 
synthesised in 24 steps and <0.04% yield from commercially available starting materials. 20 g of 
protected (3S,5S)-5-hydroxypiperazic acid 182 were prepared.
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Scheme 42.
Cyclodepsipeptide 13 was prepared but it could not be purified. Further investigation 
would have been needed to confirm the formation of 13 and develop a procedure to access the 
pure form of 13. Furthermore, degradation occured at the macrolactamisation step of the 
synthesis of cyclodepsipeptide 14. Again further work would have been required to find a way to 
close the cyclodepsipeptide ring.
However, we learnt at that time that Novartis no longer wished to test the proposed 
analogues. We thus decided that it was not worth starting again the multistep synthesis of some 
precursors that were missing to pursue the investigation. We therefore changed programme 
and decided to start investigating the total synthesis of (+)-allopumiliotoxin 339A.
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PART B: SYNTHETIC STUDIES TOWARDS THE SYNTHESIS OF 
(+)-ALLOPUMILIOTOXIN 339A
5. Introduction
5.1. Isolation of the Pumiliotoxin A and the Allopumiliotoxin 
alkaloids
A wide range of lipophilic alkaloids are present in the skin of amphibians.42 The 
pumiliotoxin A and allopumiliotoxin classes of alkaloids are a major group of alkaloids of general 
structure 187 (Figure 10). The pumiliotoxin A alkaloids have R, = R2 = H whereas the 
allopumiliotoxins have a 7-hydroxy substituent on the indolizidine ring (R! or R2 = OH). The 
allopumiliotoxins are the most complex members of this class of alkaloids and are present in 
Dendrobatid frogs in a small quantity.
Me OH
pumiliotoxin A alkaloids : = R2  = H
allopumiliotoxin alkaloids : R1 = H, R2 = OH 
or R, = O H ,R 2  = H
Figure 10. General structure of the pumiliotoxin family of alkaloids
The pumiliotoxin alkaloids were originally believed to be unique to Dendrobatid frogs, 
however they are now known to be present in virtually all anurans that are chemically defended 
by the presence of lipophilic alkaloids.43'44 The pumiliotoxins appear to be derived from dietary 
sources45, such as ants and arthropods. Recently the pumiliotoxins 307A and 323A were 
detected in extracts of formicine ants46, other pumiliotoxins (237A and 251D) were found in 
oribatid mites.47 Furthermore, it has been recently shown that dendrobatid frogs have an
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enzyme, pumiliotoxin 7-hydroxylase that can convert a dietary pumiliotoxin to a more toxic 
allopumiliotoxin.48
In 1967, pumilotoxin A (327A) and pumiliotoxin B (323A) were the first molecules of the 
family to be isolated by Daly and co-workers, from the brightly colored Panamanian poison frog 
Dendrobates pumilio49 The structures of these pumiliotoxins remained unknown until 1980 
when X-ray analysis of the crystalline hydrochloride salt of pumiliotoxin 251D established the 
structure and absolute configuration of this alkaloid.50 Analysis by mass spectroscopy and NMR 
allowed the elucidation of the structures of other members of the family.50,51 Figure 11 shows 
the structure of some pumiliotoxin alkaloids.
Allopumiliotoxin 339A 191 was isolated, along with its isomer, allopumiliotoxin 339B, in 
skin extracts of Dendrobates auratus in 1984.51 Allopumiliotoxin 339A differs from 339B in the 
stereochemistry of the hydroxyl group at C(7). Allopumiliotoxin 339A and 339B had been first 
detected in 1978 and had been incorrectly classified as the alkaloid 395, due to the fact that 
they were converted to a dimethylsilanate during gas chromatography analysis.52 They 
represent minor alkaloids in these Dendrobatid frogs. The allopumiliotoxins 339 are the hydroxyl 
congeners of pumiliotoxin B.
Me OH 
Pumiliotoxin A 188
Me q h
Me OH
Pumiliotoxin B 189
Me OH 
Pumiliotoxin 251D 190
Me q h
Me OH
Allopumiliotoxin 339A 191
Figure 11 : Structure of some pumiliotoxin alkaloids
5.2. Biological Properties of the Pumiliotoxins
The dendrobatids frogs are notoriously toxic; the native people of Western Columbia use 
skin secretions from three species of these frogs to poison the darts used in hunting. The 
pumiliotoxin family of alkaloids exhibit potent cardiotonic and myotonic activities.
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5.2.1. Ion Channels and the Electrical Properties of Membranes
Ion channels are proteins that form hydrophilic pores across plasma membranes of cells 
(Figure 12). Most of the ion channels exist in either an open or a closed conformation, and are 
said to be gated. The main types of stimuli that are known to cause ion channels to open are 
the binding of a ligand (ligand-gated channels) or a change of the voltage across the membrane 
(voltage-gated channels).
Na+
outside
Cell
membrane
inside
Figure 12. Voltage gated sodium channels
A voltage gradient, also called an electric potential exists across the plasma membrane of 
all cells, the inside of the cell is negative relative to the outside. This potential across the 
membrane at rest is called the resting potential and is between -30mV and -70 mV. When the 
cell is at rest, anions give it a negative charge, with sodium ions outside and potassium ions 
inside the cell. In most animal cells, this potential does not vary with time. However, neurons 
and muscles cells, which are electrically active cells, undergo changes in their membrane 
potential.
When changes occur in the membranes, the voltage-gated sodium channels respond to 
allow sodium ions to enter thereby, balancing the charge. When this occurs the membrane 
potential becomes less negative and more sodium channels open, causing an even greater 
influx of sodium ions. When the membrane potential reaches around +30 mV, the gates of the 
sodium channels close and the voltage-gated potassium channels begin to open. The sodium 
channel remains unactivated for a few milliseconds, such that no further sodium ions can enter 
the cell from that gate.
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This occurs at one little segment of the axon at a time: sodium ions go in at section one; 
which triggers the efflux of potassium ions to start at section one and the influx of sodium ions at 
section two. That, in turn, triggers potassium ions to exit at section two and sodium ions to enter 
at section three; and so on along the membrane (Figure 13).
More Sodium Channels 
Open
Sodium Channels 
Close
Sodium Channels 
Open
♦30 mV
0 mV
-70 mV
Potassium Channels 
Open
Potassium Channels
Close
Time (ms) 1 ms
Figure 13. An action potential
An action potential results from the sequential opening and closing of voltage-gated 
cation channels and propagates along the cell. In conclusion, voltage-gated sodium channels 
are responsible for the generation and conduction of action potentials along the membrane and 
a transmission of a signal from one end of the cell to the other.
5.2.2. Phosphoinositide Breakdown
A variety of natural products that can affect voltage-dependent sodium channels were 
found to stimulate the phosphoinositide breakdown in brain synaptoneurosomes. Daly et al. 
have shown that modulation of sodium ion or sodium channel causes phosphatidylinositol 
turnover. However, the mechanism involved in this process is still unclear.53 Phosphatidylinositol 
is a class of phospholipid, made up of glycerol, fatty acids and a hexahydric alcohol, inositol 
(Figure 14).
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o
Phosphatidylinositol
Figure 14. Phosphatidylinositol (PI)
Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10% 
of the phospholipids, but it is present in all tissues and cell types. Phosphatidylinositol is 
phosphorylated by a number of different kinases that place the phosphate moiety mainly on 
positions 4 and 5 of the inositol ring (PIP2). Cleavage of phosphatidylinositol phosphates leads 
to generation of secondary messengers, 1,2-diacylglycerol (DAG), a lipophilic molecule that 
remains linked to the membrane, and free phosphorylated inositols (IP3), which can diffuse into 
the cytosol (Scheme 43). Diacyglycerols regulate the activity of a group of at least a dozen 
related phosphorylating enzymes known as protein kinase C which, in turn, control many key 
cellular functions, including differentiation, proliferation, metabolism and apoptosis. The various 
inositol phosphates appear to be involved in the control of cellular events in very specific ways; 
for example, inositol 1,4,5-trisphosphate is an important cellular messenger stimulating calcium 
ion release from the endoplasmic reticulum.
o
Phosphatidylinositol 4,5-bisphosphate (PIP2)
O
O
1,2-diacylglycerol (DAG) Inositol 1,4,5-triphosphate (IP3)
Scheme 43. Phosphoinositide breakdown
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5.2.3. Biological Activity of Pumiliotoxin Family of Alkaloids
Pumiliotoxin B (PTX-B) and some of its congeners have marked myotonic and cardiotonic 
activities. In nerve-striated muscle preparations, PTX-B increases direct and indirect elicited 
twitch. In guinea pig ileum segments, PTX-B caused rhythmic contractures which were 
suppressed by tetrodotoxin, a specific antagonist of the sodium potential channel.54 This activity 
is due to interaction of PTX-B with a site on the voltage dependant sodium channel in 
synaptoneurosomes.55 It results in a delay in inactivation of the sodium channel and repetitive 
firing in nerve and muscle. The resultant influx of sodium will cause activation of 
phosphatidylinositols thereby generating two second messengers, the inositols phosphates 
(which can mobilize calcium ions) and the diacylglycerols (which activate protein kinase C).53 In 
neuroblastoma cells, PTX-B and active congeners had no effect on sodium flux unless 
synergized by a scorpion venom.56 The pumiliotoxin binding site on voltage-dependant sodium 
channel appears to be allosterically coupled to the scorpion venom site.55 Biological activity of 
various pumiliotoxins was initially evaluated by measuring the force and the rate of spontaneous 
contractions in guinea pig atrial preparations,57 and later, the phosphoinositide breakdown and 
the sodium influx in synaptoneurosomes.58,59
5.2.4. Structure-Activity Relationship
The structures of the pumiliotoxin alkaloids discussed are drawn in Figure 15
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Pumiliotoxin A 188 Pumiliotoxin B 189 Pumiliotoxin 251D 190
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Allopumiliotoxin 339A 191 Allopumiliotoxin 339B 192 Allopumiliotoxin 323B' 193 Alopumilbtoxin 267A 194
Figure 15. Members of the pumiliotoxin family of alkaloids
Pumiliotoxin B 189 is the most potent and efficacious of the compounds tested with 
respect to its chronotropic (rate) and inotropic (force) effects in guinea pig atrial preparations. It 
causes at 6 pM a 3 fold increase in force and a 2-fold increase in the rate of contractions. The 
nature of the side chain is critical for the biological activities of pumiliotoxins. In pumiliotoxin A 
188, the lack of the side chain C16-hydroxy group results in a reduction in activity. The absence 
of both C15 and C16 hydroxy groups yields cardiodepressant compounds. However, in 
allopumiliotoxins, the number of hydroxy groups on the side chain does not change the activity. 
Allopumiliotoxin 323B’ 193, the allo(C-7-hydroxy)pumiliotoxin of pumiliotoxin A, is as active as 
allopumiliotoxin 339A 191. In conclusion, at least three hydroxyl groups appear to be required 
for high cardiotonic activity. The 7-hydroxy group on the indolizidine ring must also be axial for 
high cardiotonic activity; allopumiliotoxin 339B 192 is significantly less active than 
allopumiliotoxin 339A 191 and pumiliotoxin B 189. Allopumiliotoxin 339A is as potent as PTX-B, 
with respect to rate of contractions (150% of control at 6 pM) but less efficacious with respect to 
the force (160% of control at 6 pM).57,58
The structure-activity profile for stimulation of sodium flux and phosphoinositide 
breakdown by pumiliotoxins is very similar to the cardiotonic activity.56 Allopumiliotoxin 339A is 
the only alkaloid of the pumiliotoxin family to be more effective than pumiliotoxin B in stimulating
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sodium influx (120% of response to PTX-B) and phosphoinositide breakdown (110% of 
response to PTX-B). Indeed, in guinea pig cerebral cortical synaptoneurosomes, the percent of 
control of phosphoinositide breakdown is 280% for PTX-B at 10 pM compared to 304% for Allo- 
PTX 339A at the same concentration.58
5.3. Past syntheses of Some Members of the Pumiliotoxin Family of 
Alkaloids
5.3.1. First Synthesis of a Pumiliotoxin A Alkaloid
The first total synthesis of a pumiliotoxin A alkaloid was reported by Overman and Bell in 
1981.60 They achieved an enantiospecific synthesis of pumiliotoxin 251D 190 using an iminium 
ion-vinylsilane cyclisation to stereospecifically assemble the (Z)-6-alkylideneindolizidine ring 
system (Scheme 44). The cyclisation precursor 195 would be obtained from the L-proline- 
derived epoxide 196 and the vinyl nucleophile 197.
Me OH
Me
(+)-pumiliotoxin 251D 190 195
N C02Bn
H ' "O 
Me
196
\ y
L-proline
MesSi-
m'
/ — n-Bu
197
( I
Me3S r
198
n-Bu
Scheme 44. Overman’s first retrosynthetic plan to pumiliotoxin 251D
A non-stereoselective route was developed to access epoxide 196 from L-proline. 
Reaction of A/-carbobenzyloxy-L-proline methyl ester 199 with MeMgl, followed by dehydration 
of the resulting tertiary alcohol with thionyl chloride afforded the propenyl derivative 200 in 54% 
yield. Epoxidation with m-CPBA gave in quantitative yield a 1:1 mixture of epoxides 196 and 
201 that could be easily separated on a large scale (Scheme 45).
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Scheme 45. Preparation of epoxides 196 and 201
Elaboration of the side chain of (+)-pumiliotoxin 251D started with the reduction of 1- 
heptyne-3-one with B-3-pinanyl-9-borabicyclo[3.3.1]nonane into (S)-1-heptyn-3-ol 202. 
Conversion into silyl carbonate 203 followed by organocuprate coupling provided 
stereospecifically the (R)-silyl akyne 198 in 56% yield from alcohol 202. After treatment of 
alkyne 198 with DIBAL-H, the resulting vinylalanate 204 was heated at reflux with epoxide 196 
to afford bicyclic carbonate 205 in 38% yield. Compound 205 was hydrolysed into the 
aminoalcohol, which was directly converted to the cyclopentaoxazolidine 206 with 
paraformaldehyde. The cyclisation was achieved by heating 206 in ethanol in the presence of 
camphorsulfonic acid (Scheme 46).
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SiMe3
198
Me Me.
SiMe: 77-Bu(60% from 205)
Me OH
Me
207(+)-pumiliotoxin 251D 190
DIBAL-H
MeLi
M e-,,^n-Bu
M e3Si-
AI/-Bu2Me
204
EtOH
reflux
(38%)
C 0 2Bn
H ) ' ''O 196
CSA, EtOH
reflux
205 X = O
206 X
,0 SiMe3  Me 
H ~  n-Bu
(1) 3M KOH, reflux
(2) (CH2 0)„, EtOH
(80%)
Scheme 46. Overman’s route to (+)-pumiliotoxin 251D 190
This first total synthesis of a pumiliotoxin A alkaloid proceeded in 13% yield from 
(S)-1-heptyn-3-ol and 4.7% yield from A/-carbobenzyloxy-L-proline methyl ester. Iminium ion-
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vinylsilane cyclisation was developed in this synthesis. This methodology was used in the total 
syntheses of pumiliotoxin B 189 in 198461 and pumiliotoxin A 188 in 1985.62
The synthesis of pumiliotoxin B 189 is summarised in Scheme 47. At the time this 
retrosynthetic plan was designed, the stereochemistry of the allylic diol of (+)-pumiliotoxin B 189 
was still unknown. The strategy adopted allowed access to any of the four possible 
diastereoisomers. Iminium ion-vinylsilane cyclisation was used to obtain alkylideneindolizidine 
aldehyde 209 which was condensed with stabilised ylide 210 to provide (+)-pumiliotoxin B 189.
e QSiPh2 f-Bu
C 0 2Bn
(+)-Pumiliotoxin B 189
Scheme 47. Preparation of (+)-pumiliotoxin B 189 using iminium ion-vinylsilane cyclisation
Using the same methodology, (+)-pumiliotoxin A was synthesised from epoxide 196 and 
vinylalanate of 211 (Scheme 48).
C 0 2Bn Me3Si
H 1 'O Me
196 Me OH
(+)-pumiliotoxin A 188
Scheme 48. Preparation of (+)-pumiliotoxin A 188 using iminium ion-vinylsilane cyclisation
In theses 3 syntheses, low yields were obtained in the epoxide-alanate coupling step 
requiring optimisation for each side chain nucleophile. A more efficient strategy had to be 
designed in order to synthesise larger amounts of the compounds necessary for investigation of 
the biological activities of the pumiliotoxin family of alkaloids.
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5.3.2. Overman Aldol Attachment of the Alkylidene Side Chain: First Entry 
to an Allopumiliotoxin Alkaloid
The first synthesis of an allopumiliotoxin A alkaloid was reported in 1984 by Overman and 
Goldstein.63,64 Their method was based on an aldol attachment of the alkylidene side chain 214 
to indolizidinone 213 as illustrated in Scheme 49 and was used in the synthesis of 
allopumiliotoxin 267A and allopumiliotoxin 339B.
Me-,,
Me OH 
Allopumiliotoxins
Me OH H .Me OH
213 214
Scheme 49. Overman Aldol Attachment of the Alkylidene Side Chain
The synthesis of indolizidinone 213 started from A/-Boc-L-proline 215 which was first 
converted to ketone 216 in 2 steps (Scheme 50). After deprotection with TFA, the labile 
2-acetopyrrolidine salt 217 was treated with 5 equivalent of 1-lithio-1-methoxyallene 218 in THF 
at -78 °C to afford the allenyl pyrrolidine 219 as a single diastereoisomer. Crude 219 was 
reacted with slightly less than one equivalent of p-toluenesulfonic acid in acetonitrile to provide 
the bicyclic enol ether 220 in 25-45% yield from compound 216. Conversion of enol ether 220 to 
the 7-indolizidinone 213 was then achieved in 76% yield by hydrolysis with 5% aqueous HCI.
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Scheme 50. Synthesis of intermediate 213
The final steps of the synthesis of (+)-allopumiliotoxin 267A 194 are shown in Scheme 51. 
The best result for the aldol condensation was obtained with 2 equivalent of trityllithium in ether 
0°C. The aldol adduct 222 was directly dehydrated with trifluoroacetic anhydride and DBU to 
yield compound 223, which was selectively reduced with Me4NBH(OAc)3 to afford 
(+)-allopumiliotoxin 267A 194 in 73% yield.
n-Pr (CF3 C 0 )20  
DBU
Me4 NBH(OAc) 3 
Acetone-HOAc 
(73%), ds> 25 : 1
Me\ / Y Y ' Me
_
Me OH
(+)-allopumiSotoxin 267A 194
Scheme 51. Synthesis of (+)-allopumiliotoxin 267A 194
Similar chemistry was utilised for the preparation of (+)-allopumiliotoxin 339B 192 as 
illustrated in Scheme 52. Reduction of compound 226 under Luche conditions furnished only 
the equatorial alcohol 227 in 58% yield. Silylation of alcohol 227 followed by debenzylation with
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sodium in ammonia and Swern oxidation afforded aldehyde 228. Wittig olefination of aldehyde 
228 with enantiomerically pure ylide 210 provided the a’-silyloxy (£)-enone 229 in 54% yield. 
Threo-selective reduction with LiAIH4 was accompanied by desilylation to afford 
(+)-allopumiliotoxin 339B 192 in 44% yield.
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Scheme 52. Overman’s route to (+)-allopumiliotoxin 339B 192
The overall yields of these syntheses are quite low; (+)-allopumiliotoxin 267A was 
prepared in 9 steps and 5.6% overall yield from A/-Boc-L-proline and (+)-allopumiliotoxin 339B 
was prepared in 14 steps and an overall yield <1% from A/-Boc-L-proline. However, these 
syntheses allowed confirmation of the absolute configurations of these alkaloids. Moreover, this 
aldol dehydration strategy was also employed by Gallagher and coworkers in their synthesis of 
pumiliotoxin 251D.65
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5.3.3. Total Syntheses Using Iodide-Promoted Iminium lon-Alkyne 
Cyclizations
Overman et al. reported that alkynes can react intramolecularly with iminium ions in the 
presence of a nucleophile.66 This strategy, illustrated in scheme 53, was first utilized to prepare 
pumiliotoxin A in 198867 and has later been successful for the preparation of pumiliotoxin B68 
and allopumiliotoxins alkaloids59,69 as well as many structural analogues.70
Scheme 53. Preparation of pumiliotoxins using iodide-promoted ion-alkyne cyclisation
5.3.3.1. Total synthesis o f Pumiliotoxin B
(+)-Pumiliotoxin B 189 was prepared using iodide-promoted iminium ion-alkyne 
cyclisation from epoxide 196 and alkyne 233 (Scheme 54).
Me
Scheme 54. Retrosynthetic analysis of (+)-pumiliotoxin B
(+)-pumiliotoxin B 189
The synthesis of alkyne 233 is depicted in Scheme 55 and began with Evans allylation of 
propionyl oxazolidinone 234. Removal of the auxiliary with hydrogen peroxide and LiAIH4 
reduction afforded (ft)-2-methyl-4-pentenol 236. Dibromide 237 was obtained after Swern 
oxidation of alcohol 236 followed by dibromomethylenation with PPh3 and CBr4. Wittig
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olefination of aldehyde 238 with phosphorane 210 provided a-siloxyenone 239 which was 
selectively reduced with triisobutylaluminium. Deprotection of the silyl group afforded the syn 
diol 240 which was converted to the acetonide with 2,2-dimethoxypropane. Conversion of the 
dibromoalkene to the terminal alkyne 233 was achieved under standard conditions. The 
synthesis of alkyne 233 was achieved in 8 steps from pentanol 236 and 42% overall yield.
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Scheme 55. Synthesis of the side chain segment of pumiliotoxin B
Coupling of pyrrolidine epoxide 196 with 2 equivalents of the diethylaluminium derivative 
of alkyne 233 proceeded efficiently to afford intermediate 241 in 95% yield (Scheme 56). In 
contrast to the vinylsilane route, the unreacted alkyne 233 was easily recovered allowing this 
key coupling step to proceed in excellent yield with net use of stoichiometric amounts of the 
coupling partners. The same conditions were used in the synthesis of pumiliotoxin A and 
analogues. Hydrolytic removal of the carbamate group with Ba(OH)2 provided alkynylamine 242 
in 73% yield. After optimisation, the iodide-promoted cyclisation was performed with 1.5 equiv of 
PPTS which resulted in both cyclisation and isopropylidene cleavage to afford compound 243 
as a single isomer in 65% yield. Deiodination of 243 followed by protonolysis provided (+)- 
pumiliotoxin B 189 in 89% yield.
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Scheme 56. Preparation of (+)-pumiliotoxin B using iodide-promoted ion-alkyne cyclisation
This synthesis allowed preparation of 500 mg of pumiliotoxin B for biological and 
structural investigations. The overall yield was 8% from /V-carbobenzyloxy-L-proline and 10% 
from (4S, 5S)-4-methyl-5-phenyl-2-oxazolidinone, the commercially available precursor of 
acyloxazolidinone 234.
5.3.3.2. First Enantioselective Total Synthesis of (+)-Allopumiliotoxin 339A
The first total synthesis of (+)-allopumiliotoxin 339A was reported in 1992 by Overman et 
al. The general approach is outlined in retrosynthetic format in Scheme 57 and involves the 
coupling of the proline-derived aldehyde 245 with the terminal alkyne 233.69 The key issue of 
the synthesis was the viability of the pivotal nucleophile-promoted iminium ion-alkyne cyclisation 
step with a substrate that contained a potentially labile and inductively deactivating C(7) allylic 
hydroxyl group. This was achieved using the electron-withdrawing cyanomethyl protecting group 
which would disfavour competitive chelation with the pyrrolidine nitrogen during the carbonyl 
addition step.
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Scheme 57. First retrosynthetic plan to (+)-allopumiliotoxin 339A 191
Aldehyde 245 was obtained from propenyl derivative 246 through an efficient 9 step- 
sequence which is depicted in Scheme 58.71 lodocyclisation of 246 afforded a bicyclic iodo 
carbamate 247 which was converted to alcohol 248 after conversion into a nitrate ester and 
reduction. After protection of the alcohol, the cyclic carbamate was hydrolysed with KOH and 
the secondary amine was protected with a cyanomethyl group to give compound 249. Following 
protection of the tertiary alcohol with benzyl bromide, the primary alcohol was deprotected and 
oxidised under Swern conditions to afford aldehyde 245 in 45% overall yield from 246.
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Scheme 58. Synthesis of aldehyde 245
Addition of compound 250, the alkynyl lithium derivative of 233, to aldehyde 245 occured 
in 68% yield with 4:1 diastereoselectivity in favour of 251. A first iminium ion cyclisation by 
internal attack of oxygen nucleophile yielded cyclopentaoxazine 252. Then iodide-promoted 
cyclisation occured cleanly at 100 °C with loss of isopropylidene group to afford
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alkylideneindolizidine 253 in 76% overall yield from 251. Deiodination followed by removal of the 
benzyl ether provided (+)-allopumiolliotoxin 339A 191 in 62% yield (Scheme 59).
Li
Me
Me AgOTf
THFMe250
CN (94%)(68%)
^ e  OBn
Me Me
MeMe
251 252
Nal, (CH2 0)n, CSA 
H2 0-acetone, 100°C 
(81%)
OH OH
(1) n-BuLi, MeOH
(2) Li, NH3, -78°C
Me Me
OH OH
(62%)
H A  0H  
Me OH
(+)-allopumiiotoxin 339A 191
OH
Me OBn
253
Scheme 59. First total synthesis of (+)-allopumiliotoxin 339A
This first synthesis of (+)-allopumiolliotoxin 339A proceeded in 17 steps and 7.5% overall 
yield from A/-(benzyloxycarbonyl)-L-proline and 16 steps and 6% overall yield from the 
commercially available precursor of acyloxazolidinone 234.
5.3.4. Alternative Strategies for (+)-Allopumioliotoxin 339A Synthesis
5.3.4.1. Nozaki-Kishi cyclisation
In 1992, Kibayashi and co-workers utilised an intramolecular Cr(ll)-mediated coupling 
reaction72,73 to build the indolizine framework of the allopumiliotoxin alkaloids.74,75 The strategy 
employed is summarized in Scheme 60, the cyclisation proceeded via an alkenylchromium (III) 
species 254. The cyclisation precursor 255 came from the combination of the protected 
pyrrolidine fragment 256 and allylic bromide 257.
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Scheme 60. Kibayashi’s retrosynthetic analysis of allopumiliotoxins
The synthesis of pyrrolidine 256 commenced with the preparation of ketone 259 with a 
thiol esterification-Grignard reaction of A/-Boc-L-proline 215 (Scheme 61). Deprotection of 259 
with trifluoroacetic acid afforded the pyrrolidine trifluoroacetate salt, which was immediately 
treated with 3-lithio-1,3-dithiane to produce the tertiary alcohol 260 as a single diastereoisomer 
consistent with a Cram chelation-controlled transition state. The cyclic dithioacetal group of 260 
was converted to the dimethyl acetal with methanol and Hg(CI04)2. Protection the amino group 
with a cyanomethyl group afforded compound 261. O-benzylation of the tertiary alcohol was 
then achieved using benzyl bromide and potassium hydride. Removal of the cyanomethyl group 
with AgN03 and subsequent A/-protection by the Z group afforded carbamate 262. Acetal 
hydrolysis and NaBH4 reduction of the resulting aldehyde proceeded in very good yield to 
provide alcohol 263. Silylation of alcohol 263 and hydrogenolytic removal of the Z group 
resulted in 256. Pyrrolidine 256 was prepared in 13 steps and 14 % yield from A/-Boc-L-proline.
258 a  j o
N S -S  N
215
/  NBoc
v 4 „ ,
(1) PPh3) MeCN 
reflux (98%)
(2) MeMgBr, 
THF, 0°C, (85%)
/-"N B o c
v f r Me 
H o
C 0 2H 259
»/'0HMe
OTBDMS
(1)TBDMSCI, imidazole 
DMAP, CH2 CI2, rt (94%)
(2) H2, 10% Pd-C 
MeOH (85%)
(1 )C F 3C 0 2H 
CH2 CI2, rt
(2) 1,3-dithiane 
o-BuLi, hexane/THF 
-78°C (54%)
256
. OH 
H 1 OBn 
Me
263
(97%)
(1)H g(C I0 4 )2 3 H20  
MeOH, rt (6 8 %)
(2) ICH2 CN, Et3N 
THF, rt (89%)
T
/" " N  OMe
• i ■
H Me0H
261
OMe
(1) 3N HCI, THF 
(2) NaBH4, MeOH, rt / ^ N Z  OMe
(1) BnBr, KH 
THF, reflux
(2) AgN03, EtOH, rt
(3) ZCI, Et3 N, CH2CI2
0°C to rt 
(6 8 %)
■ V\Q.
H Me' 
262
OMe 
OBn
Scheme 61. Synthesis of 256
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The side chain segment was elaborated from the known D-4-deoxythreose derivative 
(Scheme 62). Aldehyde 264 was first subjected to Grignard reaction with MeMgBr followed by 
PCC oxidation to afford the methyl ketone 265 which was converted to the (E)-olefin 266 by 
Horner-Emmons condensation. The ester group was reduced to the alcohol that was 
transformed to the bromide 267 under standard conditions. Evans alkylation with propionyl 
oxazolidinone 268 was used to install the R stereogenic center of compound 269. The Evans 
auxiliary was cleaved with LiAIH4 and the resulting alcohol oxidised under Swern conditions to 
give aldehyde 270. Treatment of aldehyde 270 with CBr4 and PPh3 provided a dibromide, which 
was converted to the propargylic alcohol 271 by reaction with butyllithium and 
paraformaldehyde. Synthesis of 271 was performed in 10 steps and 30% overall yield from 
aldehyde 264. Palladium-catalysed hydrostannation of 266 furnished the 
(E)-2-(tributylstannyl)alkene 272 in 93% yield along with a minor amount (3.8%) of its 
regioisomer. lododestannylation gave the (E)-iodoalkene, which was then transformed to the 
desired allylic bromide 257 in 96% yield.
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Scheme 62. Preparation of allylic bromide 257
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The final route that led to (+)-allopumiliotoxin 339A is shown in scheme 63. Coupling of 
bromide 257 and amine 256 in the presence of the Hunig’s base provided compound 273 in 
70% yield. Desilylation of 273 followed by Swern oxidation afforded aldehyde 274. Cyclisation 
was performed smoothly in 79% yield by treatment with nickel(ll)/chromium(ll) and with 
complete stereoselectivity to afford compound 275. Cleavage of the isopropylidene group 
followed by debenzylation gave (+)-allopumiliotoxin 339A 191 in 71% yield. This synthesis of 
(+)-allopumiliotoxin 339A was achieved in 19 steps and 4.5% yield from 
/V-(te/?-butoxycarbonyl)-L-proline and 24 steps and <4% yield from L-threonine.
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Scheme 63. Preparation of (+)-allopumiliotoxin 339A by Kibayashi et al.
5.3.4.2. Nickel Catalysed Synthesis
In 1999, Montgomery and Tang reported a nickel catalyzed synthesis of (+)- 
allopumiliotoxin 339A as summarised in Scheme 64.76 Their synthesis involved a triethylsilane- 
promoted cyclisation of ynal 276.
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Scheme 64. Montgomery and Tang’s retrosynthetic plan to (+)-allopumiliotoxin 339A
Synthesis of the alkylideneindolizidine ring began with the coupling of compound 277 with 
bromide 278 in the presence of Hunig’s base in 92% yield (Scheme 65). Oxazolidinone 277 was 
prepared from L-proline methyl ester following Overman’s procedure71 as illustrated in Scheme 
58 and propargyl bromide 278 by bromination of the corresponding alcohol 271 used in 
Kibayashi total synthesis of allopumiliotoxin 339A.75 Benzylation of the tertiary alcohol and 
desilylation of the primary alcohol led to alcohol 280 in 75% yield. Alcohol 280 was then 
oxidised under Swern conditions to yield the cyclisation substrate 281. Aldehyde 281 was then 
treated with triethylsilane (5 eq), Ni(COD)2 (0.2 eq) and tributylphosphine (0.8 equ) in THF at 
0°C for 18 h to afford bicycle 282 as a single diastereoisomer in 93% yield. After removal of all 
the protecting groups, (+)-allopumiliotoxin 339A 191 was obtained in 64% yield.
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Scheme 65. Synthesis of (+)-allopumiliotoxin 339A by Montgomery et al.
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It is noteworthy that this route also led to (+)-allopumiliotoxin 339B: after removal of the 
silyl group from compound 282, the alcohol was oxidised under Swern conditions. The resulting 
ketone 283 was stereoselectively reduced with CeCI3/NaBH4 in methanol in 95% yield. 
Deprotection with 3N HCI and then Li/NH3 afforded (+)-allopumiliotoxin 339B 192 (Scheme 66).
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Scheme 66. Synthesis of (+)-allopumiliotoxin 339B by Montgomery et al.
5.4. Others Approaches to Pumiliotoxins and Allopumiliotoxins 
Indolizines Core
5.4.1. Trost’s Total Synthesis of Allopumiliotoxin 339B
Trost and Scanlan reported a synthesis of allopumiliotoxin 339B using Pd(0) chemistry.77 
A Pd(0)-mediated allylic alkylation of epoxide 284 was used to transfer the chirality from the 
indolizine ring to the side chain and a Pd(0)-mediated cyclisation of vinyl epoxide 286 was 
employed to forge the piperidine ring (Scheme 67).
HA "'OH
MeOH
(+)-allopumiliotoxin 339B 192
Scheme 67. Trost’s retrosynthetic plan to (+)-allopumiliotoxin 339B
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Once again, A/-Boc-L-proline was the starting material of choice as shown in Scheme 68. 
Cyclisation precursor 286 was generated by chelation-controlled addition of allyltitanium 
intermediate 287 to the unprotected 2-acetylpyrrolidine generated from ketone 216. S- 
Methylation and subsequent base treatment yielded epoxide 286. The best result for the 
cyclisation step was obtained using Rd2(dba)3.CHCI3 as the catalyst and compound 289 as the 
chiral ligand. Formation of epoxide 284 was achieved using CF3C 03H. Palladium(0)-catalysed 
condensation of vinyl epoxide 284 and allyl sulfone 290 proceeded with a perfect chirality 
transfer from C(6) to C(11) using Pd2(dba)3.CHCI3 and dppf in the presence of water. Direct 
reductive desulfonylation of the crude product provided ketone 291 in 24% yield from epoxide 
284. Reduction-desilylation of compound 291 yielded (+)-allopumiliotoxin 339B 192. The total 
synthesis was accomplished in 11 steps and <3% yield from A/-(terf-butoxycarbonyl)-L-proline.
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Scheme 68. Trost’s total synthesis of (+)-allopumiliotoxin 339B
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5.4.2. Holmes’ Total Synthesis of Allopumiliotoxin 323B’
Holmes and Tan reported the first synthesis of an allopumiliotoxin alkaloid that did not 
use a proline derivative as a starting material.78,79 Their strategy was based on an aldol 
condensation of aldehyde 292 with the potassium enolate of the indolizine core 213 (Scheme 
69). The indolizine core 213 was synthesised from the isoxazolidine 293, which can be derived 
from an intramolecular [3 + 2] cycloaddition reaction of the (Z)-A/-alkenylnitrone 294.
Me
OH
OH
Me OH
Allopumiliotoxin 323B' 193
H
Me OH
213
OBOM
BzO
TBDMS OBz
0 . + -.N QTBDMS
293 294
Scheme 69. Retrosynthetic analysis to (+)-allopumiliotoxin 323B’ by Holmes et al.
The synthesis began with (ft)-te/t-butyl-3-hydroxy-pent-4-enoate 295 which was obtained 
by enzymatic resolution with Amino PS lipase (Scheme 70). After silylation of the alcohol, the 
ester group was reduced with DIBAL-H into the aldehyde 296. Treatment with hydroxylamine 
gave oxime 297 which was subsequently subjected to a 2 steps reduction-condensation 
procedure to provide the (Z)-/V-alkenylnitrone 294. The intramolecular [3 + 2] cycloaddition 
reaction was carried out by heating a dilute solution of the crude nitrone 294 in toluene for 18 h 
at 70°C to give four oxazolidine cycloadducts. Isoxazolidine 293 was obtained in 32% yield and 
was separated by flash chromatography.
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Scheme 70. Synthesis of oxazolidine 293
Hydrogenolysis of isoxazolidine 293 followed by Z protection of the resulting free amino 
group provided the hydoxymethyl Z-protected piperidine 304 in 90% yield (Scheme 71). The 
dehydration the primary alcohol to form exocyclic alkene 305 was achieved by formation of a 
selenide followed by oxidation with one equivalent of m-chloroperoxybenzoic acid. Ozonolysis of 
alkene 305 gave a ketone that was subjected to a diastereofacial selective nucleophilic addition 
with an excess MeMgBr. Concomitant removal of the benzoyl group occured at this stage of the 
synthesis and provided alcohol 306. Selective tosylation of the primary alcohol and removal of 
the benzyloxycarbonyl group triggered an intramolecular ring closure that yielded the 
indolizidine 307. Desilylation and Swern oxidation gave the desired indolizidone core 213 in 
50% yield.
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Scheme 71. Holmes’s route to Overman intermediate 213
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The synthesis of the side chain aldehyde 292 was achieved in 8 steps and 30% overall 
yield.79 The aldol condensation between aldehyde 292 and the indolizidone core 213 was 
carried out using KHMDS and a mixed solvent (HMPA/THF)(Scheme 72). Direct dehydration 
afforded 308 in 42% yield. Reduction using tetramethylammonium triacetoxyborohydride and a 
catalytic amount of acetic acid in acetone gave the anf/'-diol as the only observable product. 
Finally, removal of the BOM protecting group using lithium di-fert-butylbiphenyl provided 
(+)-allopumiliotoxin 323B’ 193. This synthesis was achieved in 20 steps and 1.7% overall yield 
from the /3-hydroxyester 295 and was significantly different from other previous syntheses by 
contructing the chiral azabicyclic core in avoidance of using L-proline or its derivative.
(1) KHMDS, THF/HMPA
Me
MeMe
OBOMMe 292 OBOM
(2) DBU, TFAA. DMAP 
-50*C, CH2CI2Me OH Me OH
213
(42%)
(1) Me4NHH(OAc)3  
acetone, AcOH
(2) LiDBB, THF, -78°C 
(78%)
308
Me OH 
(+)-allopumiliotoxin 323B' 193
Scheme 72. Total synthesis of (+)-allopumiliotoxin 323B’ by Holmes et al.
5.4.3. Comins’ Total Synthesis of Allopumilotoxin 267A
More recently, Comins and co-workers devised a route to (+)-allopumiliotoxin 267A using 
an enantiopure dihydropyridone building block.80 Once again, an aldol condensation strategy 
was chosen and the synthesis of Overman’s intermediate 213 was the key issue of the 
synthesis (Scheme 73). The synthesis commenced by lithiation of pyridine 309 with mesityl 
lithium81 followed by treatment with methyl iodide to give pyridine 310. To a 1-acylpyridium salt, 
prepared in situ from pyridine 310, and (+)-TCC chloroformate, was added lithiated ethyl 
propiolate. An acidic work-up provided dihydropyridone 311 in 70% yield and 96% de. Catalytic 
hydrogenation of the triple bond afforded compound 312 and did not affect the enone system 
protected with the TIPS group. Removal of the chiral auxiliary with lithium methoxide resulted in 
cyclisation and provided indolizidinone 313 as an 8:1 mixture of diastereoisomers. This mixture
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was subjected to an acetoxylation in a stereocontrolled manner using lead acetate in refluxing 
AcOH/m-hexafluoroxylene to give compound 314. Protodesilylation of 314 using formic acid 
afforded compound 315, which was reduced using K-Selectride followed by lithium aluminium 
hydride to afford diol 316 in 83% yield. Finally, oxidation under Swern conditions provided 
Overman’s intermediate 213.
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Scheme 73. Comins’ route to Overman intermediate 213
Overman’s intermediate 213 was converted to (+)-allopumiliotoxin 267A in 48% yield
using a modified literature procedure (Scheme 74). 64
213 (3) TFAA, DBU, DMAP
one pot (51%)
Me<„
(1) Ph3CLi, THF, -78°C
2 Me
Me OH
Me OH
317
‘Me Me4NBH(OAc)3 
Acetone-HOAc
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M e % / \
^ M e
,_
/ ^ n
Me OH
(+)-allopumJiotoxin 267A 194
Scheme 74. Final steps to (+)-allopumiliotoxin 267A 194
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5.4.4. Lin’s Approach to the Indolizidine Core of Pumiliotoxins and
Allopumiliotoxins
In 2003, Lin and co-workers developed a method to construct the chiral azabicyclic core 
without using proline and its homologue.82 As shown in retrosynthetic analysis depicted in 
Scheme 75, a common key intermediate was used to access both pumiliotoxins and 
allopumiliotoxins. Their strategy was based on an intramolecular aminolysis of epoxide.
The synthesis started from a Sharpless asymmetric dihydroxylation of the trisubstituted 
olefin 320 that afforded diol 321 in 98% yield and 95% ee (Scheme 76). A monomesylation of 
the secondary alcohol followed by treatment with K2C 03 yielded epoxide 322. After 
hydrogenolytic cleavage of the benzyl group, the alcohol was activated into mesylate 323. A 
stepwise substitution-ring-opening sequence took place gently after treatment of benzylamine in 
refluxing MeCN to provide the pyrrolidine derivative 324 as a single isomer. Protection of the 
tertiary alcohol, followed by selective removal of A/-benzyl and acetylation afforded acetamide 
325 in 75% yield. A Claisen condensation was then successfully achieved using potassium 
hydride and gave the desired intermediate 319.
Pumiliotoxins
Me OH 
213
Allopumiliotoxins
Scheme 75. Lin’s retrosynthetic analysis of pumiliotoxin alkaloids from 319
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Scheme 76. Preparation of intermediate 319
Sodium borohydride reduction of ketone 319 furnished alcohol 326 that was converted to 
its mesylate and subjected to elimination under basic conditions to provide compound 327 in 
90% yield (Scheme 77). The pumiliotoxin intermediate 318 was obtained after saturation of the 
double bond and debenzylation in quantitative yield.
The allopumiliotoxin intermediate 213 was obtained after reduction with LiAIH4 of lactam 
319, followed by benzyl deprotection and Swern oxidation.
H2, 10% Pd/C 
EtOHNaBH4, MeOH
0°C, (100%) (2) DBU.tol, reflux 
(90%)
(100%)
LiAIH4, THF
reflux, (75%) (2) Swern ox. 
(75%)
Scheme 77. Preparation of the indolizidine core of pumiliotoxins and allopumiliotoxins from 319
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5.4.5. Stevenson’s Rapid Synthesis of the Indolizidine Core of 
Pumiliotoxins and Allopumiliotoxins
More recently, Stevenson et al. reported a rapid synthesis of the two key intermediates 
318 and 213 in the synthesis of pumiliotoxins and allopumiliotoxins.83 Their retrosynthesis 
analysis is summarised in Scheme 78.
Pumiliotoxins
Allopumiliotoxins
Scheme 78. Stevenson’s retrosynthetic analysis of pumiliotoxin alkaloids from alkene 329
These 2 key indolizidines were prepared from a common alkene precursor 329 whose 
synthesis is depicted in Scheme 79. The synthesis commenced from the known 
carbamate61 330 that was deprotected and coupled in situ with 3-butenoic acid 331 to afford 
alkene 332. A ring closing metathesis using second generation Grubbs’ catalyst provided 
alkene 329 in 88% yield.
2nd gen Grubbs'NBoc
catalyst
(88%)
Scheme 79. Preparation of key intermediate 329
The synthesis of the pumiliotoxin intermediate 318 started with epoxidation of alkene 329 
with m-CPBA. An in situ ring opening reaction using strongly basic ion-exchange resin Amberlite
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IRA-400-(OH) afforded alkene 333 in 85% yield. Hydrogenation over a palladium catalyst 
provided the desired intermediate 318.
To obtain the allopumiliotoxin intermediate 213, osmium tetroxide catalysed 
dihydroxylation was achieved on alkene 329. An acetylation was performed to isolate the polar 
water-soluble product 334. After reduction of amide 334 and Swern oxidation of alcohol 335, the 
key allopumiliotoxin intermediate was isolated in 34% yield from alkene 329. An X-ray structure 
of diol 335 confirmed the stereochemistry of the intermediate.
(1) m-CPBA
(2) Amberlite
IRA-40O(OH) resin 
(85%)
(100%)
Me OH 
333
Me
329
Swern ox.
OH (44%)(84%) OAc (78%)
Me OHMe OHMe
329 334 335
Me OH 
213
Me OH 
318
Scheme 80. Synthesis of Overman’s intermediate by Stevenson et al.
6. Synthetic efforts towards (+)-Allopumiliotoxin 339A
6.1. Retrosynthetic Analysis of (+)-Allopumiliotoxin 339A
There were two main aims guiding our retrosynthetic planning for (+)-allopumiliotoxin 
339A. First, we wished to demonstrate the utility of the recently developed O-directed free 
radical hydrostannation of disubstituted acetylenes with Ph3SnH/Et3B/air in total synthesis. 
Secondly, we wished to develop a very flexible route capable of being readily modified to create 
novel analogues for future biological testing.
90
(+)-Allopumiliotoxin 339A would be synthesised from its protected form 275 as shows in 
Scheme 81. The last steps of the synthesis would involve acidic deprotection of the 
isopropylidene, and O-debenzylation with Li/ammonia as previously described.74 Indolizidine 
275 would be prepared from ketone 336 via a hydroxyl directed reduction using Me4NBH(OAc)3 
analogously to that used in the synthesis of (+)-allopumiliotoxin 267A (Scheme 74).64 Enone
336 would be constructed by an aldol condensation of ketone 213 with aldehyde 270 followed 
by dehydration; the geometry would arise from the desire to minimise steric repulsions in the 
product. Although, this aldol methodology has been widely used in the total synthesis of various 
pumiliotoxins and allopumiliotoxins, it has never been applied in the synthesis of (+)- 
allopumiliotoxin 339A. Intermediate 213 appeared derivable from enone 338 by a base-inducted 
intramolecular conjugate addition. Enone 338 would itself be prepared from a vinyl stannane 
addition to a-alkoxyaldehyde 339 followed by oxidation of the resulting alcohol and deprotection 
of the Boc-group. Aldehyde 270 would be made by removal of the auxiliary from intermediate
337 followed by reduction.
Deprotection
M6 QH \
Selective reduction
Me OBn Me OBn
(+)-allopumiliotoxin 339A 191 336276 e irio l condensation
V inyl stannane 
addition
r\ar\ rn tan f inn
Intram olecular corrugate 
addition
NTFAf^
339 338 213 270
337
Scheme 81. Retrosynthetic plan for (+)-Allopumiliotoxin 339A 191
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6.2. Synthetic Studies Towards a-Alkoxyaldehyde 339
6.2.1. First Generation Strategy for a-Alkoxyaldehyde 339
6.2.1.1. Retrosynthetic analysis
Sharp!oss asymmetric Stabilised Wlttlg
amlnohydroxylatlon Oleflnatlon
339 340 341 342 343
Scheme 82. Initial retrosynthetic plan for a-alkoxyaldehyde 339
Our approach to a-alkoxyaldehyde 339 would avoid the use of L-proline as a starting 
material, to allow for flexibility in ring substitution patterns and different ring sizes in analogues. 
a-Alkoxyaldehyde 339 appeared derivable from compound 340 via intramolecular SN2 
cyclisation. According to Baldwin’s Rules, a 5-exo-tet ring closure of this sort should be 
favourable. Reduction of the ester to the aldehyde would complete the synthesis. The key step 
to introduce the 2,3-syr?-aminoalcohol motif would be a regioselective Sharpless asymmetric 
aminohydroxylation (SAA) performed on alkene 341. The trisubstituted alkene would be 
prepared by a Wittig condensation between aldehyde 242 and the Marshall phosphorane 343, 
an ylide well known to favour this stereochemical outcome.
6.2.1.2. Attempted Implementation o f the Sharpless Asymmetric Aminohydroxylation  
Strategy fo r a-Alkoxyaldehyde 339
The synthesis of a suitable precursor for the Sharpless asymmetric aminohydroxylation 
was first investigated; we explored a variety of procedures to form the monoprotected alcohol 
345 from 1,4-butanediol 344. The use of silver oxide and potassium iodide described by 
Bouzide and Sauve was too expensive to be applied for the first step of our total synthesis.84 
Choudary et al. have reported a monotosylation of 1,4-butanediol mediated by metal-exchanged
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Montmorillonite clay catalyst.85 The preparation of the catalyst was not straightforward and thus 
we decided to use Ahlberg and Wu’s method.86 The tosylation was achieved in absence of 
solvent employing p-toluenesulfonyl chloride as tosylating agent in presence of DMAP (0.04 eq) 
and triethylamine (1.05 eq) in 1,4-butanediol (7.7 eq). The original authors found that the use of 
solvent favoured the formation of the ditosylate and recommended that the extractive work-up 
with dichloromethane be conducted as quickly as possible. Two spots appeared on TLC with 
anisaldehyde, the more polar one was the mono-protected alcohol 345 and the faster moving 
the diprotected alcohol. The product 345 could not be stored as it decomposed into the 
diprotected alcohol. Furthermore, the mono-protected alcohol 345 could not be isolated as it 
decomposed into the diprotected alcohol during purification by Si02 flash chromatography. As a 
consequence, the PCC oxidation was performed on the crude mixture in dichloromethane at 
room temperature. After a quick purification on a pad of silica gel, the unstable aldehyde 342 
was reacted with carbethoxyethylidene triphenylphosphorane 343 in dichloromethane at room 
temperature overnight. In this Wittig olefination, the use of phosphorane 343 gave rise to the 
E-alkene selectively. Evaporation and purification by S i02 chromatography led to alkene 341 in 
21% yield over 3 steps (Scheme 83).
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1,4-butanediol 344 345 342 3 4 1
Scheme 83. Synthesis of alkene 341
Evidence for the formation of this alkene was given by the presence of a tq at 5 6.54 ppm 
on the 500 MHz spectrum of 341 in CDCI3. The chemical shift of an alkene proton is influenced 
by other alkene substituents and can be predicted using the formula 5 = 5.2 + Zgem + Zeis + 
Ztrans.87 In our case, we should have 6 6.6 ppm for the E-alkene and 6 6.3 ppm for the Z- 
alkene. Our chemical shift of 5 6.54 ppm is in favour of the E-isomer.
The low yield obtained for the synthesis of alkene 341 led us to develop a new 
intermediate for the Sharpless asymmetric aminohydroxylation. It was thought that the 
p-toluenesulfonyl leaving group might be beneficially replaced by a bromide, and the synthesis
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of bromide 348 was therefore investigated. The developed route, depicted in Scheme 84, 
commenced with the reduction of bromobutyronitrile 346 with DIBAL-H in ether at 0°C.88 This 
furnished aldehyde 347 after hydrolysis of the intermediary imine. Aldehyde 347 was volatile, 
and so the crude product was reacted directly with carboethoxyethylidene triphenylphosphorane 
343 to afford olefin 348 as a yellow oil in 61% yield over 2 steps. Analysis by 500 MHz 1H NMR 
confirmed the formation of the E-alkene with the presence of a tq at 6.68 ppm. Again, the 
olefinic proton is deshielded because of the presence of the cis-carbonyl, the geometry is thus 
confirmed.
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O r u n .  rt onh OEtEther, O'C to rt w CH 2CI2, rt, 2 0 h
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Scheme 84. Synthesis of alkene 348
With precursors 341 and 348 in hand, we investigated the Sharpless asymmetric 
aminohydroxylation, which provides protected vicinal aminoalcohols enantioselectively in a 
single step from alkenes as illustrated in Scheme 85.
ROCONH2 N iwrnnR om(DHQ)2PHAL NHCOOR o h
K20 s 0 2(Q H )4   ^ R i^ \ ^ R 2
NaOH, /-BuOCI OH NHCOOR
349 R '0H /H 20  3 5 0  3 5 1
Scheme 85. The Sharpless Asymmetric Aminohydroxylation
The SAA was first reported in 1996 as a process in which the nitrogen source was the 
chloramine salt of a sulphonamide 352.89 Since then, various alternative nitrogen sources have 
been investigated and the sulfonamides can be replaced by alkyl carbamates 353 or by amides 
354 (Figure 16). Therefore, a large number of aminoalcohol products can be obtained 
depending on which protecting group is desired. In each case, the reactive species is the alkali 
metal salt made in situ from the /V-halogenated compound derived from the sulfonamides, 
carbamates and amides.
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Figure 16. The nitrogen sources used in the SAA
The enantioselectivity of the reaction results from the presence of chiral ligands that 
favour addition to one enantiopic face of the alkene. The asymmetric induction follows the rules 
described for the Sharpless Asymmetric Dihydroxylation (AD);29 (DHQD)2PHAL directs addition 
to the /3-face and (DHQ)2PHAL to the cr-face (Figure 17).
(DHQD)2PHAL
(DHQ)2PHAL
Figure 17. The Sharpless model for the asymmetric hydroxylation
One of the new challenges of the SAA is the control of the regioselectivity which can be 
influenced by many factors. However, it has been found that, generally, the nitrogen prefers to 
add on the less substituted end of the alkene. In the case of a trisubstituted alkene, the steric 
hindrance at one end is so high compared to the other that the SAA usually only gives the less 
hindered amine product. Finally, K2Os02(OH)4 is generally used as a catalyst.
Returning to our particular case, (DHQ)2PHAL would give rise to the desired 
enantioselectivity according to the AD mnemonic proposed by Sharpless depicted in Figure 17.
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90A carbamate-based nitrogen source was the more attractive nitrogen source in our 
system 341 or 348 as it would allow to fix directly the Boc group onto the nitrogen. The sodium 
salt of the A/-chlorocarbamate was made in situ from tert-butylcarbamate, tert- 
butylhypochlorite,91 and aqueous NaOH following Sharpless’ procedure.92 A quantitative 
investigation of the solvent revealed that a mixture of acetonitrile/water was the solvent of 
choice leading to a partial consumption of the starting material. No reaction occurred with 
alkenes 341 and 348 according to TLC analysis when r?-PrOH/water 2:1 was used, and the use 
of n-PrOH/water 1:1 led to degradation products. Difficulties were also encountered in removing 
unreacted tert-butylcarbamate and we did not manage to isolate any of the products that were 
formed. Nevertheless, we could see on TLC with anisaldehyde that at least 5 products had 
formed. Therefore, we decided to use benzylcarbamate as the nitrogen source in 1:1 
MeCN/H20  in the hope that its separation from the desired compound might be easier. Again 
five new spots appeared on the TLC along with the starting material that was not consumed 
completely. An extractive work-up with sodium sulfite and EtOAc afforded a complex mixture of 
products which was purified using S i02 flash chromatography. Unfortunately, it was not possible 
to completely purify the main product from the excess benzylcarbamate. TLC analysis showed 
that the aminohydroxylation of alkenes 341 and 348 led to the same main compound, hinting 
that a cyclisation might have occurred in situ. In fact, four different compounds can arise from 
the Sharpless Asymmetric Aminohydroxylation step depending on the regioselectivity of both 
the aminohydroxylation and the ring closure. The formation of these four compounds is shown 
in Scheme 86.
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Scheme 86. Formation of the four possible products after the SAA
To establish the structure of the major product, hoped to be 357, the Z group was 
hydrogenated with Pd(OH)2 in ethanol and the resulting free amine was protected with a 
dinitrophenyl group as shown in Scheme 87.
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5% (DHQ)2PHAL 
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361
N 0 2
OH OEt
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Scheme 87. Formation of the DNP-derivative 362
The four different compounds that could be obtained after the 2 step sequence 
described in Scheme 87 are depicted in Figure 18.
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362 363 364 365
Figure 18.
The peaks of the proton and carbon spectra of the 2,4-dinitrophenylated product were 
first assigned using 500 MHz 1H NMR, 13C NMR, COSY, HMQC and DEPT experiments in 
CDCI3. In fact, the CH close to the nitrogen was found much deshielded at 5 4.60 ppm. The use 
of COSY and HMQC experiments allowed attribution of the different CH2 peaks. The protons on 
C3 are obviously the more deshielded at 5 3.58 and 2.73 ppm. Furthermore, a 1H-1H coupling 
was visible on the 500 MHz cosy spectrum between the protons on C3 and the one on C2. The 
protons of C2 were thus detected at 5 2.05 and 1.71 ppm and the one on C1 at 6 2.20 ppm.
Finally, analysis of the HMBC spectrum demonstrated that the cyclisation had given rise 
to a nitrogen-containing 5-membered ring (Figure 19). In the HMBC spectrum, a long-range 
1H-13C coupling between the protons on C3 and the quaternary carbon of the DNP at 6 147.4 
ppm was observed; hence compounds 363 and 364 could be ruled out. Additionally, there was 
a 1H-13C coupling between the hydrogen of the only CH of the ring with C3 at 6 62.3 ppm. A 
reciprocal 1H-13C coupling between the protons on C3 and the carbon of CH at 6 68.1 ppm was 
also observed. Thus structure 365 could be discarded. NMR studies confirmed the desired 
structure of 362 and as a consequence, the structure of compound 357.
oh OEt
Figure 19. The long-range 1H-13C coupling in 362
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We were thus pleased to find that the formation of 357 occurred in one step. We now had 
to optimize the reaction using bromide 345 in order to increase the yield and solve the 
purification issues. The amount of catalyst K2Os02(OH)4 was increased from 5 to 8 mol% and 
the amount of ligand (DHQ)2PHAL from 6 to 10%. We were pleased to observe complete 
disappearance of the starting material according to TLC analysis. Again, a complex mixture of 
compounds was obtained and it was not possible to isolate all of them. Unfortunately, after 
purification on silica gel, the main blue spot visible on the TLC with anisaldehyde was found to 
be the tetrahydrofuran 366 arising from the cyclisation of the dihydroxylated product (Scheme 
88).
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Scheme 88. The Sharpless Asymmetric Aminohydroxylation of alkene 366
Tetrahydrofuran 366 was contaminated with the excess benzylcarbamate and extensive 
purification by Si02 flash chromatography allowed isolation of a small amount of nearly pure 
tetrahydrofuran 366 in order to carry out analyses. Its structure was confirmed by its FAB HRMS 
which contained an (M+H)+ peak at m/e 189.11286 (Calcd (M+H)+ 189.11268 for C9H170 4). 
Significantly, we increased the amounts of K20 s 0 2(0H)4 and ligand in order to drive the 
reaction to completion, we instead favoured the formation of the dihydroxylated product which 
cyclised into tetrahydrofuran 366.
The formation of the diol by-products during SAA reactions is a common issue. The 
main recommendations to avoid its formation are to decrease both the amount of water and of 
the osmium catalyst in the reaction mixture. The proportion of water was thus reduced to a 3:2 
MeCN/water ratio. We could not reduce the proportion of water any further as the starting 
material remained untouched when a 2:1 MeCN/water mixture was used. To understand the 
role of water in the SAA, it is instructive to examine the proposed mechanism for the 
aminohydroxylation (Scheme 89).
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Scheme 89. A proposed mechanism for the SAA
This mechanism involves two catalytic cycles, each giving different selectivity pattern. In 
the primary cycle the alkene addition to the imidotrioosmium (VIII) species 367 is mediated by 
the ligand to give the osmium azaglycolate 368. Species 370 is then formed after re-oxidation of 
368 by the nitrogen source 369. Azaglycolate 370 can then either be hydrolysed by water to 
afford the product with high selectivity or be attacked by the alkene and enter the secondary 
cycle. The limiting step in each cycle is the hydrolysis of the azaglycolate complexes by water. 
High water concentration is thus needed for the reaction to occur.93 Moreover, if the 
concentration of the osmium catalyst is too high, the alkene can react directly with the catalyst 
and undergo a ligand-mediated asymmetric dihydroxylation reaction, to form an osmium (VI) 
glycolate complex 372, analogous to the azaglycolate complex 368. Formation of the diol 373 
will ensue.
After much effort at optimizing the process, bromide 345 was used as the substrate and 
only 5% mol of the osmium catalyst was used. Furthermore, K20 s 0 2(0H)4 was added at 0 °C, 
by small portions over 20 min. A quick purification by Si02 flash chromatography was achieved
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to remove most by-products, and hydrogenation of the partially purified mixture in presence of 
Boc-anhydride94 led to a-alkoxyester 375. Decomposition of the excess benzylcarbamate 374 
occurred under these reductive conditions and a-alkoxyester 375 could be purified successfully 
after Si02 flash chromatography and was obtained as a white foam in 15% yield from olefin 345 
(Scheme 90).
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(DHQ)2PHAL ( 6  mol %)
K2 0 s 0 2 (0 H ) 4 (5mol %) 9BnOCONH2 (3.1 eq) '
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MeCN / H20  (3:2) 357
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H2, 5% Pd/C 
B o c20
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Me OH
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Scheme 90. Improved conditions for the Sharpless Asymmetric Aminohydroxylation of 345
We finally developed a reproducible procedure for the synthesis of the a-alkoxyester 375. 
Even though the yield was quite low, this method did allow us to install 2 stereocenters, to carry 
out the cyclisation and to protect the nitrogen in just 2 steps. The difficulties we met are 
probably due to the fact that the substrate is a trisubstituted alkene. In fact, there are very few 
examples in the literature in which trisubstituted alkenes have been used as substrates for the 
SAA. Barboni et al. could not apply the SAA in their synthesis of Paclitaxel, and used a SAD 
instead.95 Clark et al. succeeded in 2001 using Chloramine-T as the nitrogen source.96 Wang et 
al. did not try to use the aminohydroxylation in their work towards the Pumiliotoxin synthesis and 
prepared a-alkoxyester 324 from alkene 320 in five steps (Scheme 76).82
We next investigated the protection of alcohol 375. Most of the conditions we tried left the 
alcohol untouched (Table 1, entry 2,4,5,6).
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Table 1. Protection of alcohol 304
Entry Conditions Yield
1 NaH (1 eq), BnBr (1 eq), DMF, rt, 3 h Mixture
2 Benzyltrichloroacetimidate (1.2 eq), PPTS (0.1 eq), Et20, 50 °C,18 h No reaction
3 NaH (1 eq), BnBr (1 eq), n-Bu4NI, CH2CI2, rt By-products
4 MOMCI (2 eq), /-Pr2NEt (2 eq), THF, 80°C, 3 days No reaction
5 TBDPSCI (2 eq), imidazole (1.1 eq), DMF, rt, 24 h No reaction
6 TBDMSCI (2 eq), imidazole (1.1 eq), DMF, rt, 24 h No reaction
Treatment of alcohol 375 with NaH and BnBr (entry 1) led to a complex mixture of 
unidentified compounds. However when n-Bu4NI was added to the reaction mixture (entry 3), 
we isolated an inseparable mixture of carbamates 376 and 377 as shown in Scheme 91.
I  l
NaH, BnBr / N O
NBoc
Me OH n-(Bu)4 NI, CH2 CI2 ^  ^  C 0 2Et ^  = C 0 2Bnn Me H Me
375 376 377
Scheme 91. Protection of alcohol 375
The carbamate formation could be easily explained by nucleophilic addition of the 
alkoxide to the carbonyl group of the Boc as illustrated in Scheme 92.
NaH
C 0 2Et 
Me OH 
375
k~\0  ^
-o-
Me C 0 2Et 
378
O
A
CH.
H t ie 0 0 * '
376
Scheme 92. Formation of carbamate 376
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Formation of the transesterification product was much more surprising as we are under 
basic conditions. Saponification of the ester might occur if the medium is not completely dry, the 
resulting carboxylate would then attack BnBr to form 377.
I I
^  ^  'O H  
O - H
1
0 o
375 379 380 377
Scheme 93. Formation of carbamate 377
In light of the collective problems we experienced in this route, we eventually decided to 
investigate an alternative method for securing the a-alkoxyaldehyde.
6.2.2. New route for the synthesis of the a-alkoxyaldehyde
In light of these difficulties, we then explored a completely new strategy to synthesise the 
targeted a-alkoxyaldehyde, and again, our goal was to avoid the use of L-proline. This strategy 
would install one stereocenter at a time as depicted in Scheme 94. Aldehyde 381 would 
originate from linear alkene 382 via a 3-step sequence. We would utilise the chiral induction of 
tert-butyl sulfinimine 383 to introduce the (C8a) stereocenter of 382 through an addition of an 
allyl magnesium halide. The sulfinyl group not only would play the role of a chiral auxiliary, but 
would then be used as a protecting group for the nitrogen. In fact, the sulfinyl group can be 
removed with TFA like a Boc protecting group. The C(8) stereocenter would be delivered at the 
first step of the synthesis using a Trost opening of epoxide 385. With due modification, these 
disconnections would potentially give us the flexibility to synthesise the a-alkoxyaldehyde with 
different substituents on the 5 membered-ring.
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Scheme 94. New retrosynthetic plan to a-alkoxyaldehyde
The synthesis started with a chemo-, regio- and enantioselective addition of 
p-methoxybenzylalcohol to the commercially available racemic isoprene oxide 385. This 
deracemization reaction, originally described by Trost and co-workers, was achieved using 0.01 
equiv of Pd2(dba)3.CHCl3, 0.01 equiv of triethyl borate, 0.01 equiv of chiral ligand 386 and 1 
equiv of PMB-OH97 (Scheme 95).
385
Pd2(dba)3 CHCI3 
Et3B, PMBOH
CH2 CI2, rt, 1 2 h 
6 8 %, 82%ee
384
d
Q ,
HN I*
(\ ph2p_\ = /  
386 
Ligand (R,R)-L1
Scheme 95. The Trost opening of epoxide 385
Many factors come into play for the addition to be chemo-, regio- and enantioselective 
as summarised in Scheme 96. In the absence of Et3B, attack of a nucleophile would occur at 
the less hindered end of the TT-allylpalladium intermediate. The first role of the triethylborane is 
to control the regioselectivity. Secondly, Et3B enhances the nucleophilicity of the alcohol, which 
is normally a poor nucleophile, and finally, Et3B controls the chemoselectivity of the reaction. In 
fact, the product primary alcohol does not react after its formation. Finally, for the reaction to be 
enantioselective, the diastereomeric interconversion of the TT-allylpalladium intermediates must 
be faster than the alkoxide attack. This issue is controlled by the palladium catalyst and its 
ligand.
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Scheme 96. Mechanism of Trost’s reaction
In our case, the addition of p-methoxybenzylalcohol proceeded in 68% yield and 82% ee. 
The enantiomeric excess was determined from the 300 MHz 19F NMR analysis of the Mosher’s 
ester 391. Alcohol 384 was reacted with the Mosher acid (R)-(+)-MTPA in presence of DCC and 
DMAP in dichloromethane to afford ester 391 (Scheme 97). The diastereoisomeric excess was 
then easily calculated by integrating the signals from the trifluoromethyl group in the 19F NMR 
spectrum.98
Alcohol 384 was next oxidised under Swern conditions into the unstable aldehyde 392 
(Scheme 98). After rapid purification by Si02 flash chromatography, the structure of aldehyde 
392 was confirmed by its 500 MHz 1H NMR spectrum that showed a singlet at 6 9.49 ppm due 
to the aldehyde proton. On normal runs, aldehyde 392 was used crude and converted to the 
carboxylic acid 393 by Pinnick addition using sodium chlorite in the presence of NaH2P04 and 
2-methyl-2-butene to act as a chlorine scavenger.99 Again, acid 393 was purified only for 
analytical purpose as it could be used crude for the next step. Evidence for the success of this 
reaction was given by the presence of a very broad OH band that overlapped with the CH band 
around 3250 cm'1 in the infra-red spectrum of acid 393. Furthermore, 500 MHz 1H NMR analysis
(,Kj-<+)-MTPA
DCC, DMAP
384 391
Scheme 97. Synthesis of the Mosher’s ester 391
in CDCb showed the disappearance of the aldehyde hydrogen previously at 5 9.49 ppm. 
Treatment of the crude acid with Mel and K20O3 in DMF afforded ester 394 which was purified 
by S i02 flash chromatography. The combined three-step sequence was easily implemented on 
a large scale since it only required purification at the last step, ester 394 being obtained pure in 
a very good yield (80%) over the 3 steps.
Ozonolysis of the double bond led to aldehyde 395 in 92% yield, as evidenced by the 
presence of a singlet at 5 9.64 ppm in the 500 MHz 1H NMR spectrum of the isolated product. 
Aldehyde 395 was condensed in dichloromethane with chiral fR^-fe/t-butylsulfinamide 396 in 
presence of anhydrous copper sulfate to afford (7?J-terf-butanesulfinyl imine 383 in a very good 
yield.100 Copper sulfate is an excellent promoter of this reaction; it acts both as a Lewis acid and 
as a drying agent. Importantly, the work-up of this reaction was very easy; the reaction mixture 
was filtered through a pad of silica, the filtrate was concentrated in vacuo to afford the pure 
sulfinyl imine 383. The success of this conversion was apparent from the presence of the imine 
proton at 6 8.17 ppm in the 500 MHz 1H NMR spectrum of 383 in CDCI3.
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Scheme 98. Synthesis of sulfinylimine 383
Chiral (RJ-terf-butanesulfinamide 396 is commercially available. However, it is very 
expensive and can be prepared easily on a large scale following Ellman’s procedure101(Scheme 
99). First, chiral ligand 399 is made by mixing 1 equivalent of (1S,2R)-(-)-cis-1-amino-2- indanol 
397 with 1 equivalent of 3,5-di-tert-butyl salicylaldehyde 398 in EtOH. The ligand is obtained as 
a yellow solid after evaporation of EtOH. (RJ-fe/t-butanesulfinamide is then prepared in two 
steps from tert-butyl disulfide 400. A catalytic asymmetric oxidation of the tert-butyl disulfide
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using hydrogen peroxide and catalytic amount of vanadium(IV) acetylacetonate in the presence 
of chiral ligand 399 affords the (S)-f-butyl-f-butanethiosulfinate 401. Hydrogen peroxide must be 
added in a very slow, steady stream at 0 °C. The course of the reaction was conveniently 
followed by 500 MHz 1H NMR. Following extraction with dichloromethane, crude 401 is added to 
a solution of lithium amide in liquid ammonia to afford ('RJ-terf-butanesulfinamide 396. We were 
able to conduct this procedure on 20 g scale.
EtOH
X n  0 LiNHo, NH3, THF nVO(acac)2, acetone v /  Fe(N 0 3 )3 9 H20  W
/ x  0°C, 30% H20 2 (aq) / \  ii) ice, CICH2C 0 2H / \
3 9 9  (70% from 400)
400 401 396
Scheme 99. Synthesis of (7^-terf-butanesulfinamide 396
With imine 383 in hand, our initial plan was to synthesise the homoallylic sulfinamide 382 
using the addition of an allylmagnesium halide. Despite this reaction being widely described in 
the literature,102 when we added allylmagnesium bromide to fe/t-butanesulfinylimine 383, a very 
low yield of 382 was obtained. After some literature searching, we found a very interesting 
paper from Foubelo and Yus who reported the indium-mediated addition of allyl bromides to 
fe/f-butanesulfinylimine.103 Their conditions were applied to our substrate and to our delight the 
indium-mediated addition of allyl bromide to sulfinyl imime 383 took place smoothly at 60°C, 
using 1.3 equiv of In and 1.3 equiv of AIIBr in THF. The homoallylic sulfinamide 382 was 
obtained in 85% after purification by S i02 flash chromatography. The diastereomeric ratio of the 
reaction was found to be 80:20, as determined by 500 MHz 1H NMR spectroscopy in CDCI3. It 
can be explained by a chair like transition state. The reactivity of the electrophilic centre of the 
imine is increased by coordination of the indium to nitrogen while coordination to the oxygen of 
the sulfinyl group is responsible for the face selectivity (Scheme 100).
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Scheme 100. Indium-mediated addition of allyl bromide
The diastereoisomers could not be separated at this stage and the hydroboration reaction 
was next investigated on the mixture enriched in olefin 382. The use of pinacol borane, catechol 
borane and 9 BBN was unsuccessful. We believe that this lack of reactivity is attributable to the 
steric hindrance of the (R)-A/-tert-butanesulfinamide group. Therefore, the reaction was 
achieved using the less hindered BH3-THF complex (Scheme 101). A complex mixture of 
compounds was formed, from which alcohol 403 was isolated in 40% yield for the two steps 
from sulfinyl imine 383. Evidence for the success of this reaction was provided by the 
appearance of an OH stretching band at 3333 cm'1 in the infra-red spectrum of alcohol 403. 
Moreover, 500 MHz 1H NMR analysis in CDCI3 showed disappearance of the olefinic protons at 
5 5.71 and 4.97 ppm. O-Mesylation was then accomplished in a nearly quantitative yield using 
MsCI and NEt3. The structure of mesylate 404 was confirmed by the appearance of a singlet at 
5 2.93 ppm in the 500 MHz 1H NMR spectrum of 404 in CDCI3.
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Scheme 101. Synthesis of a-alkoxyaldehyde 381
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Cyclisation did occur in the presence of NaH/imidazole which permitted internal 
nucleophilic displacement in 72% yield. Proof of the cyclisation was provided by the 125 MHz 
2D NMR-HMBC experiment in CDCI3 that showed the long range 1H-13C couplings (Figure 20). 
Specifically, a coupling was observed between carbon 3 and the proton a to the nitrogen.
t-B ik / °
HMBC
OMe
OPMB
405
Figure 20. The long range 1H-13C couplings in 405
Finally, ester 405 was reduced with DIBAL-H to alcohol 406. Success was confirmed by 
the OH stretching band at 3391 cm'1 in its infra-red spectrum. Attempts to oxidise alcohol 405 
into the desired aldehyde failed using PCC; TPAP/NMO gave an incomplete reaction according 
to TLC. Eventually, the oxidation was achieved using [bis(acetoxy)iodo]benzene (BAIB) in 
presence of catalytic amount of TEMPO;104 it provided the desired a-alkoxyaldehyde 381 in 50% 
yield. The oxidising agent is the oxaammonium salt 407 resulting from the dismutation of 
TEMPO 411 in the presence of acetic acid (Scheme 102). The catalytic amount of acetic acid 
needed for the dismutation to occur arises from a ligand exchange around the iodide atom. 
TEMPO 411 is regenerated from hydroxylamine 410 by action of BAIB.
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Scheme 102. Mechanism of alcohol oxidation using TEMPO/BAIB
The structure of aldehyde 381 was confirmed by its 500 MHz 1H NMR spectrum in CDCI3 
that showed a singlet at 6 9.68 ppm.
6.3. Synthetic Studies Towards The Side Chain Segment
6.3.1. The O-Directed Free-Radical Hydrostannation of Propargyl Ethers, 
Acetals and Alcohols
Our synthesis of the side chain aldehyde segment 270 would utilise the recently 
developed O-directed free-radical hydrostannation of disubstituted alkynes for stereodefined 
alkene construction105,106 (Scheme 103). In this methodology, vinyl triphenylstannanes 413 are 
obtained in a regio- and stereoselective manner from disubstituted propargylic allyl oxygenated 
alkylacetylenes 412. The vinyl triphenylstannanes 413 are usually readily manipulated into 
trisubstituted alkenes with complete retention of olefin geometry following a tin-iodide exchange 
and transition metal catalysed cross-coupling.107
110
R3 Coupling R2'
SnPh;
Scheme 103. The O-directed hydrostanation and the subsequent elaboration of trisubstituted
alkenes
The procedure utilises 1.5 eq of Ph3SnH and 0.1 eq of Et3B in toluene at 0.1 M 
concentration with respect to the starting alkene. Coordination of Ph3SnH to the O-atom of the 
acetylene and subsequent H-atom abstraction and radical attack of the alkyne lead to two 
possible transition invertomers 416 and 417. Scheme 104 shows that great steric hindrance 
would operate in the transition state 417 in the vinyl radical H-atom abstraction step. In the 
transition state 416, however, the minimized steric repulsions preferentially lead to the formation 
of 413.
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ph3S n ^ ^ R 2
3 H-SnPh3 
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Scheme 104. Transition states of the O-directed free radical hydrostannation
The previously reported O-directed free-radical hydrostannation employing Bu3SnH is 
much less effective. This can be explained by two reasons. First, the electron-withdrawing 
phenyl group enhances the Lewis acidity of the tin atom, and secondly, greater steric effects 
favour the 416 transition state.
Our group has demonstrated that the vinyltriphenylstannane products 413 can readily 
undergo tin-halogen exchange with retention of configuration.107 The reaction outcome was not 
as predictable as it might at first sight appear. In fact, past literature shows many examples
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where the iododemetallation of p-vinyltriphenylstannanes with an allylic O-substituent (that could 
coordinate) could lead to replacement of one the phenyl groups by the iodide atom. However, 
X-ray crystallography of many vinyltriphenylstannanes of structure 414 later showed that O- 
coordination does not occur in these systems; hence the “normal” outcome.
Finally, the resulting vinyl iodides can readily be converted into trisubstituted alkenes 
through a range of Pd (0) catalyzed cross-coupling techniques.
6.3.2. Retrosynthetic plan
Returning to our allopumiliotoxin 339A synthesis, aldehyde 270 would be prepared from 
oxazolidinone 419. Trisubstituted alkene 419 appeared derivable from alkyne 337 using the 
previously described methodology. This would give us great flexibility regarding the substituent 
on the trisubstituted alkene. The C(11) stereocenter would be installed in an asymmetric 
alkylation with bromide 420 using the induction of a chiral auxiliary. Bromide 420 would itself be 
prepared from ester 421 through reduction into the aldehyde followed by a modified Corey- 
Fuchs alkynylation (Scheme 105).
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Scheme 105. Our retrosynthetic analysis of the side chain segment of (+)-allopumiliotoxin 339A
6.3.2. Implementation of the Retrosynthetic Strategy for the Side Chain 
Segment of (+)-Allopumiliotoxin 339A
Despite ester 421 being commercially available, it is very expensive. It was thus prepared
10fion a large scale from L-threonine in 41% yield according to Servi procedure. Kirschning and 
coworkers published a synthesis of dibromide 422 from ester 421.109 Unfortunately, very low 
yields were obtained when we followed this protocol. This is probably because reduction of 
ester 421 led to a mixture of aldehyde 264 and its hydrate.110 We modified their procedure by 
adding a dehydration step. The crude mixture obtained from the DIBAL-H reduction of ester 421 
was dehydrated in CH2CI2 at reflux using a Sohxlet extractor containing 4A activated molecular 
sieves for water removal. The resulting solution was then added to a mixture of CBr4 (2 eq), 
PPh3 (2 eq) and Zn (2 eq) in dichloromethane. After removal of the triphenylphosphine oxide, 
dibromide 422 was obtained in 41% yield from ester 421 after purification by Si02 flash 
chromatography. Analysis by IR and NMR spectroscopy was in accordance with the data 
published by Kirschning. Dibromide 422 was then converted to the propargyl alcohol 423 using 
n-butyllithium and paraformaldehyde in THF at -78 °C. TLC analysis showed complete 
disappearance of starting material and the appearance of a single spot. As the alcohol was very 
unstable, it was not possible to carry out all the characterisation. It was usually used straight
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after purification. Nevertheless, evidence for its formation was given by the disappearance of 
the ethylenic proton at 6 6.49 ppm in the 500 MHz 1H NMR spectrum in CDCI3. Subsequent 
treatment with CBr4 and PPh3 in THF at 0°C provided bromide 424 in 63% yield. Again, 
because of the instability of the bromide, a full characterisation could not be achieved. It is 
noteworthy that dibromide 422, propargylic alcohol 423 and bromide 424 are all very sensitive 
and can not be stored without appreciable losses. Their immediate use is therefore 
recommended.
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Scheme 106. Synthesis of bromide 420
We next explored a variety of conditions to achieve the Evans alkylation between bromide 
420 and oxazolidinone 424 (Table 2).
Table 2.
Entry Conditions Yield
1 KHMDS (1.3 eq), THF, -78 °C, 1 h 45%
2 KHMDS (1.3 eq), HMPA (5 eq), THF, -78 °C to 0 °C, 2 h degradation
3 LDA (1.1 eq), THF, -78 °C overnight 15%
4 n-BuLi (1.1 eq), THF, -78 °C overnight No reaction
Use of lithium hexamethyldisilazide as a base (entry 1) gave the best result providing 
alkyne 337 in a very moderate 45% yield (Scheme 107). When HMPA was added to the
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reaction mixture, degradation occurred (entry 2). Using LDA as a base (entry 3) afforded 337 in 
a very poor yield (15%), and n-BuLi left the starting material untouched (entry 4).
KHMDS, THF 
I^ Iq -78° C to 0°C
Me
O' then Me Ph
0 ^ 0
Me
Ph
424 337
Scheme 107. Evans alkylation of oxazolidinone 424 with bromide 420
We next investigated the feasibility of stereoselectively transforming acetylene 337 into 
trisubstituted olefin 41 9.105,107 The O-directed free-radical hydrostannation was achieved 
successfully in 75% yield using Ph3SnH and Et3B in toluene (Scheme 108). 500 MHz NMR 
analysis of the product in CDCI3 showed that a mixture of isomers in ratio 95:5 was obtained. 
The structure of the major isomer 425 was confirmed by an apparent triplet at 6 6.60 ppm, 
showing that stannation had occurred at the carbon a to the oxygen. The minor isomer was 
believed to be 426 even though no characterisation was possible.
The iododestannation proceeded with complete preservation of olefin geometry in 80% 
yield. Finally, a Stille coupling with Me4Sn afforded the trisubstituted alkene 419 in 72% yield. 
Evidence for the success of this reaction was given by the appearance of a singlet at 6 1.63 
ppm, integrating for 3 protons in the 500 MHz 1H NMR spectrum in CDCI3. Moreover, the 
olefinic proton was deshielded from 6 6.14 ppm for the vinyl iodide to 6 5.53 ppm for the 
trisubstituted alkene.
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Scheme 108. Synthesis of trisubstituted alkene 419
These last 3 steps showed us the feasibility of this methodology on this kind of substrates 
but the low yield for the alkylation reaction led us to abandon the use of the Evans auxiliary. 
Instead we investigated the alkylation reaction using Oppolzer's camphorsultam auxiliary. This 
strategy turned out to be successful as treatment of A/-propionylsultam 428 with n-butyllithium 
followed by bromide 420 in HMPA proceeded in 90% yield.111 The camphor sultam auxiliary was 
then removed under very mild conditions by means of a titanium-mediated 
transesterification.112,113 Exposure of adduct 429 to 10 equiv of Ti(OEt)4 in ethanol at reflux led 
to ester 430 in a quantitative yield along with 96% of the recovered sultam. This reaction was 
extremely convenient as it led directly to the ester. Indeed the other methods to remove the 
sultam auxiliary led either to the carboxylic acid (LiOH, H20 2) or to the secondary alcohol 
(LiAIH4). Moreover, it was very easy to separate the auxiliary from the ester because of the 
difference of polarity of these two molecules. In fact, on TLC, the ester was the fast moving 
product and the auxiliary stayed close to the baseline. When comparing the infra-red spectra of 
the starting material and of the product ester, it was clear that the stretching band of the C=0 
moved from 1697 cm'1 for the amide to 1736 cm'1 for the ester (Scheme 109).
116
in HMPA /  Me Me/  'm0
Me 429
Scheme 109. Synthesis of propargyl acetal 430
We next addressed the O-directed free-radical hydrostannation of propargyl acetal 430. 
We were very pleased to find out that the reaction proceeded in a very good yield using 2 eq of 
Ph3SnH and 3 eq of Et3B in toluene (Scheme 110). Vinylstannane 431 was obtained as a single 
diastereoisomer in 92% yield. Confirmation that the stannation occurred at the carbon a to the 
oxygen was assessed by 500 MHz 1H NMR analysis of 431 in CDCI3, which showed the olefinic 
proton as a ddd at 5 6.55 ppm. Furthermore, the vinylic proton (H13) showed a 1H-117Sn 
coupling constant of 150 Hz which is the expected value for this geometry.
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Scheme 110. Synthesis of aldehyde 270
Subsequent tin-halogen exchange furnished iodide 432 in 77% yield. The success of this 
conversion was apparent from the absence of any aromatic protons in the 500 MHz NMR 
spectrum of 432 in CDCI3. Once again, the formation of the iodo(diphenyl)stannylidene was not 
detected. A Pd(0)-mediated Stille coupling was successfully performed in the presence of 
copper(l) iodide and triphenylarsine in DMF at 140°C and trisubstituted alkene 433 was
obtained in 72% yield. Evidence for the success of this reaction was given by the appearance of 
a singlet at 5 1.63 ppm integrating for 3 protons in the 500 NHz 1H NMR spectrum of 433 in 
CDCI3. Moreover, the olefinic proton was deshielded from 6 6.07 ppm for the vinyl iodide to 5 
5.45 ppm for the trisubstituted alkene.
DIBAL-H reduction afforded alcohol 434 in 75% yield as evidenced by the appearance 
of a broad OH stretching band at 3433 cm'1 in the infra-red spectrum of 434. Oxidation of the 
alcohol into aldehyde 370 was achieved in 50% yield using Phl(OAc)2/TEMPO oxidation.104 The 
success of the oxidation was apparent from the presence of a singlet at 6 9.64 ppm in the 500 
MHz 1H NMR spectrum in CDCI3.
7. Conclusion and future work
The initial goal of this work was to achieve the total synthesis of (+)-allopumiliotoxin 
339A. The latter shows marked cardiotonic and myotonic activity. Our retrosynthetic plan was 
based on the synthesis of a-alkoxyaldehyde 339 and a side chain aldehyde 270 containing a 
trisubsituted alkene as summarised in Scheme 111.
(+)-allopumiliotoxin 339A 191
\ ✓V
,Boc
H
Me OBn 
339
Scheme 111. Retrosynthetic analysis of (+)-allopumiliotoxin 339A
Our initial efforts focused on the synthesis of a-alkoxyaldehyde 339 using a Sharpless 
Asymmetric Aminohydroxylation (SAA). A four-step route was developed to a-alkoxyester 375
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from bromobutyronitrile 346 (Scheme 112). The key reaction was the SAA which allowed to 
install two stereocenters and to close the nitrogen 5 membered ring in only one step. However a 
very low yield was obtained and difficulties were encountered to protect alcohol 375.
Bromobutyronitrile 346
(1) DIBAL-H in Hex 
<2 )  p h 3 p ^ p
Me OEt
CH2CI2i rt, 20h 
(61%, 2 steps)
OEt
(1) SAA 
(2 ) H2  5% Pd/C 
Boc20
(15%)
345
NBoc O
Me OH
OEt
Scheme 112. Synthesis of a-alkoxyester 375
The second approach to a-alkoxyaldehyde 381 was based on two key steps (Scheme 
113). First a Trost's opening of racemic aldehyde 385 afforded alcohol 384 which was converted 
in 4 steps to aldehyde 395. Secondly, attachment of chiral (R)-tert-butanesulfinamide 396 to 
aldehyde 395 using copper sulfate afforded chiral sulfinylimine 382. It allowed to install the 
second stereocenter via an asymmetric indium-mediated addition of allylbromide. Compound 
382 was converted to ester 405 after hydroboration, activation of the resulting alcohol and base 
mediated cyclisation. Eventually ester 405 was converted to aldehyde 381. a-Alkoxyaldehyde 
381 was synthesised in 6% overall yield over 12 steps.
385
Pd2(dba)3CHCl3 
Et3B, PMBOH 
(R,R)-Li 386
CH2a 2, rt, 1 2 h 
(6 8 %, 82% ee)
396
Me OPMB
f-Bux /
Me OPMB
O '  X  OMe 
Me OPMB
395
/- Bu + NH2
C uS 04, THF 
4 days (97%)
f-Bu v /
Me OPMB
0
1
f-Bu" + 'N OMe 
Me OPMB 
383
In, AIIBr 
THF, 55°C 
(85%, 60%ee)
/-Bu
405
OMe 
Me OPMB
382
Scheme 113.. Synthesis of a-alkoxyaldehyde 381
The synthesis of the side chain aldehyde 270 is summarised in Scheme 114 and started 
from methyl ester 421 which was converted into bromide 420 in 4 steps. An asymmetric
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alkylation of bromide 420 with compound 428 afforded alkyne 429. After removal of the sultam 
auxiliary, alkyne 430 underwent the O-directed free-radical hydrostannation reaction in very 
good yield to afford stannane 431 as a single isomer. Conversion to trisubstituted alkene 434 
was achieved via tin halogen exchange followed by Stille coupling. Finally ester 434 was 
converted to aldehyde 270 in 2 steps. The side chain aldehyde 270 was prepared in 4.2% 
overall yield over 12 steps from ester 421.
J U
Me
421
4 steps
420
( 1 ) l2, c h 2 ci2
(2) Me4 Sn, Cul 
/ M e  Ph3 As, NEt3 EtO
434 PdCI2 (MeCN ) 2
Me. .Me
Me
428 0 2S - /
/ M e
Me
Me.
MeMe
429
Ti(OEt)4, EtOH 
150°C, 3 days 
(100%)
Ph3Sn Ph3SnH 
Et3 B, PhMe
rt, 2 0  h 
(92%)
431 430
Scheme 114. Synthesis of side chain aldehyde 270
We have developed syntheses of two precursors needed in our designed route to 
(+)-allopumiliotoxin 339A. The strength of these routes is their flexibility. In fact, the avoidance 
of L-proline in the a-alkoxyaldehyde 381 synthesis would allow us to anchor substituents on the 
5 membered-ring or even to build a 6 membered-ring. Furthermore, we proved the great utility 
of the O-directed free-radical hydrostannation reaction of disubstituted alkynes with Ph3SnH and 
Et3B; using this method, we could easily modify the substituent on the trisubstituted alkene.
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PART C: EXPERIMENTAL
All starting materials were obtained commercially from Aldrich, Acros, Avocado, 
Lancaster or BDH. Reactions were carried out under a nitrogen atmosphere with freshly distilled 
solvents unless otherwise stated. All solvents were reagent grade. Dichloromethane, benzene 
and acetonitrile were distilled from calcium hydride under nitrogen. Diethyl ether and THF were 
distilled from sodium under nitrogen. Where petrol is specified this refers to the fraction that 
boils in the range 40-60 °C. 4-Toluensulfonyl chloride was recrystallised from chloroform/petrol 
prior to use. All other reagents were used as supplied from the manufacturer.
Reactions carried out at - 78 °C were cooled by means of an acetone/dry ice bath, those 
at -10 °C by means of an ice/salt/water bath and those at 0 °C by means of an ice/water bath.
Flash column column chromatography was carried out on Kieselgel 60 40/60A (220-240 
mesh) silica gel. TLC was carried out on pre-coated glass-backed plates (Merck Kieselgel 60 
F254), visualised at 254 nm and stained with either of anisaldehyde, iodine, or PMA.
Infrared spectra (IR) were recorded on a SHIMADZU FT-IR 8700 using potassium 
bromide (neat) disc. The wave number is given in cm'1 with intensity strong = s, medium = m, 
weak = w. Optical rotations were measured on an Optical Activity, Polaar 2000 automatic 
polarimeter. Mass measurements were recorded by Mr John Hill or Dr Lisa Harris of the 
Christopher Ingold Laboratories on a VG70-SE (Cl+, El+, FAB+).
Proton Nuclear Magnetic Resonance spectra (1H NMR) were recorded on a Bruker AMX- 
500 NMR Spectrometer at 500 MHz or on a Bruker AMX-400 NMR Spectrometer at 400 MHz. 
13C NMR were recorded at 125 MHz. The NMR spectra were recorded with reference to the 
solvent peak (CHCI3 in CDCI3 at 7.24 ppm for 1H NMR and 77.0 ppm for 13C NMR). 13C DEPT 
(CH and CH3 positive and CH2 negative) was also used to assign 13C NMR. HMQC (proton- 
carbon coupling) and HMBC (proton-carbon long range coupling) were used to determined 
structures. The signals are noted as s = singlet, d = doublet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets, t = triplet,q = quadruplet, dt = doublet of triplet, tt = triplet of 
triplet, tq = triplet of quadruplet, m = multiplet and br = broad. Coupling constants J are reported 
in Hz
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8. Synthetic studies on Molecules Related to the 
Azinothricin Family
Acid 64
NFmoc9 ® ° / — NFmoc TFA, PhOH
Me.Me
OHOCHPh2
64
To ester 97114 (11.43 g, 0.0138 mol) in dry CH2CI2 (150 mL) at 0 °C under N2 was added 
PhOH (1.85 g, 0.197 mol) and TFA (38 mL, 0.496 mol). The reaction mixture was stirred at 0 °C 
for 3 h and then concentrated in vacuo. The residue was co-evaporated from toluene (50 mL x 
3). The crude residue was purified by Si02 flash chromatography (gradient elution 5:1 to 2:1 
petrol:EtOAc) to give acid 64 as a white foam (8.34 g, 91%).
IR (neat) 3160 (br), 3065 (w), 2951 (m), 1715 (s, br), 1450 (s), 1412 (s), 1358 (m), 1296 (s), 
1257 (s), 1196 (s), 1124 (m), 1090 (m), 1051 (w), 970 (w), 912 (w), 883 (w), 741 (s), 700 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.74-7.13 (m, br, Ar), 6.0 (s, br), 5.47 (m, br), 5.22-4.77 (m, 
br), 4.73-4.46 (m, br), 4.31 (s, br), 4.21-3.96 (m, br), 2.86 (m, br), 2.33 (s, br), 2.20 (s, br), 1.84-
1.61 (m, br), 1.50-1.38 (m, br), 1.25 (s, br).
13C-NMR (125 MHz, CDCI3, 298K) 6 174.0, 172.6, 155.4, 143.8, 143.1, 141.3, 136.2, 134.0,
129.6-126.4 (Ar), 125.1, 120.0, 68.7, 68.3, 67.8, 50.5, 49.9, 47.0, 46.9, 45.6, 44.0, 29.7, 23.9,
23.1, 19.3, 18.6, 14.2.
FAB (+) HRMS: Calcd. for C38H38N20 8: (M+H)+: m/e 664.26588; Found: mle 664.26409.
The spectral data for this molecule corresponded with that in literature.36
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Acid 157
Trocv
NH Me NH
AIIO- HOMe Me(Ph3 P)4Pd
morpholine
THF (89%)Me MeBocHN BocHN
OBn OBn
112 157
To a solution of ester 11224 (7.64 g, 11.7 mmol) in THF (46 mL) at rt, under N2, was 
added morpholine (8.0 mL, 93.5 mmol) and tetrakis(triphenylphosphine) palladium (1.35 g, 1.17 
mmol). The reaction mixture was stirred at rt for 30 min, diluted with ether (40 mL) and washed 
with 1 M aq. KHS04 (2 x 60 mL) and brine (40 mL). The organic layer was dried (MgS04), 
filtered and concentrated in vacuo. The product was purified by Si02 flash chromatography 
(gradient elution 4:1 to 1:2 petrol:EtOAc) affording the title compound 157 as a yellow foam 
(6.37 g, 89%).
IR (neat) 3327 (br), 2979 (m), 1728 (s), 1508 (m), 1163 (m), 1095 (w), 816 (w), 737 (w), 698 (w)
1H-NMR (500 MHz, CDCI3, 298K) 5 7.34-7.22 (m, 5 H, Ar), 6.53 (d, J = 8.7 Hz, 1 H), 5.41 (d, J =
9.4 Hz, 1 H), 4.99 (dd, J = 8.5, 3.9 Hz, 1 H), 4.71 (d, J = 12.2 Hz, 1 H, CH20), 4.69 (m, 1 H)
4.62 (d, J=  12.2 Hz, 1 H, CH20), 4.56 (d, J = 11.5 Hz, 1 H, CH20), 4.42 (dd, J = 9.5, 2.4 Hz, 1 
H), 4.37 (d, J =  11.5 Hz, 1 H, CH20), 4.13 (m, 1 H), 2.21 (m, 1 H), 1.44 (s, 9 H, (CH3)3), 1-25 (d, 
J = 6.2 Hz, 3 H, CH(CH3)), 1.05 (d, J = 6.9 Hz, 3 H, CH(CH3)2) , 0.87 (d, J = 6.9 Hz, 3 H, 
CH(CH3)2).
13C-NMR (125 MHz, CDCI3, 298K) 5 171.0, 170.5, 156.9, 154.1, 137.5, 128.3, 127.7, 127.4,
95.3, 81.0, 80.9, 74.7, 74.2, 70.4, 58.6, 55.1, 29.3, 28.3, 19.1, 18.7, 16.2.
FAB (+) HRMS: Calcd. for C25CI3H35N2Na09: (M+Na)+: mle 635.13057; Found: m/e 635.12828.
The spectral data for this molecule corresponded with that in the literature.36
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Acid 159
Me NH2 FmocCI, Dioxane Me NHFmoc
10% aq.Na2C 0 3 M e ^ ' ^ C C ^ H  
D-leudne 158 159
To D-leucine 158 (10 g, 0.076 mol) in dioxane (75 mL) at 0° C was added 10 % aq. 
Na2C 03 (162 mL, 0.152 mol). A solution of Fmoc-CI (21.4 g, 0.083 mol) in dioxane (115 mL) 
was added dropwise over 30 min. The reaction mixture was stirred at 0 °C for 30 min and at rt 
for 2 h. H20  (200 mL) was added to the reaction mixture that was extracted with ether (3 x 250 
mL). The aqueous layer was acidified to pH 2 with conc. HCI and extracted with EtOAc (3 x 250 
mL). The combined organic layers were washed with brine (200 mL), dried (MgS04) and 
filtered. The solvent was then removed in vacuo. The resulting oil was used for the next step 
and was not purified any further.
Acid 110
Fmoc TFA, Et3SiH
Me NHFmoc (CH2 0 )n , Me N \  C H C I3 r Me NFmoc
i/ ^ ^ C 0 2H TsOH, PhMe (74%, 3 steps)Me ^  C Mf}'   Me X ' ^ C 0 2H
159 160 0  161
To the crude /V-Fmoc-D-Leucine 159 (0.076 mol) in dry toluene (330 mL) under N2 at rt 
was added paraformaldehyde (2.28 g, 0.076 mol) and TsOH (1.16 g, 6.1 mmol). The mixture 
was heated at reflux for 1 h and water was removed with a dean-stark apparatus. The reaction 
mixture was cooled to rt, washed with 10% aq. NaHC03 (200 mL), dried (MgS04) and filtered. 
The solvent was then removed in vacuo and compound 160, which was not characterised any 
further, was used immediately for the next step as described below.
To crude 160 (25.4 g, 0.0696 mol) in CHCI3 (140 mL) at rt under N2 was added TFA 
(134 mL, 1.809 mol) and Et3SiH (33 mL, 0.209 mol). The reaction mixture was stirred at rt for 2 
days and then concentrated in vacuo. The residue was co-evaporated from toluene (3 x 100 
mL). The crude product crystallised following trituration of the bulk syrup with EtOAc and petrol. 
Acid 161 was obtained as a white solid (19 g, 74% over 3 steps).
[a]D + 24.7° (c 1.03, CH2CI2).
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IR (Neat) 2941 (m), 1753 (s), 1653 (s), 1448 (w), 1327 (w), 1167 (m), 1113 (m), 1038 (w), 806 
(w), 762 (m), 739 (m), 650 (w), 606 (w), 542 (w).
1H-NMR (500 MHz, C6D6, 298K) Major rotamer 6 7.50 (m, Ph.), 7.40 (m, Ph.), 7.19 (m, Ph.),
5.14 (dd, 1 H, J = 11.2, 4.6 Hz, CHC02H ), 4.42 (m, 2 H, COOChh), 3.90 (t, J = 6.6 Hz, 
C02CH2CH), 2.63 (s, 3 H, NCH3 ), 1.66 (m, 1 H, ChbCHCOzH), 1.56 (m, 1 H, ChhCHCC^H),
1.36 (m, 1 H, CH(CH3)2), 0.84 (d, J = 6.5 Hz, 3 H, (CH3)2), 0.77 (d, J = 6.5 Hz, 3 H, (CH3)2); 
Minor rotamer 6 7.50 (m, Ph.), 7.40 (m, Ph.), 7.19 (m, Ph.), 4. 59 (dd, 2 H, J = 10.5, 5.3 Hz, 
COOCh^), 4.42 (m, 1 H, CHC02H), 4.03 (t, J = 6.6 Hz, C 02CH2CH), 2.76 (s, 3 H, NCH3), 1.47 
(m, 1 H, ChkCHCOzH), 1.36 (m, 1 H, CH(CH3)2), 1.26 (m, 1 H, ChbCHCOzH), 0.66 (d, J = 6.5 
Hz, 3 H, (CH3)2), 0.59 (d, J = 6.5 Hz, 3 H, (CH3)2).
13C-NMR (125 MHz, C6D6, 298K) Major rotamer : 5 177.5 (NCOO), 157.3 (C02H), 144.6 
(Ar), 144.3 (Ar),141.8 (Ar),128.5 (Ar),125.3 (Ar),125.2 (Ar),120.1 (Ar), 67.7 (COOCH2), 57.1 
(CHC02H), 47.7 (C02CH2CH), 37.4 (CH2CHC02H), 30.2 (NCH3), 25.0 (CH(CH3)2), 23.2 
((CH3)2), 21.2 ((CH3)2). Minor rotamer: 6 177.7 (NCOO), 157.3 (C02H), 144.5 (Ar), 144.4 (Ar),
141.8 (Ar),127.3 (Ar),125.0 (Ar), 124.9 (Ar),120.1 (Ar), 67.4 (COOCH2), 56.8 (CHC02H), 47.6 
(C02CH2CH), 37.7 (CH2CHC02H, m), 30.7 (NCH3), 24.8 (CH(CH3)2), 23.0 ((CH3)2), 21.0 
((CH3)2).
FAB (+) HRMS: Calcd. for C22H25NaN04: (M+Na)+: mle 390.16812; Found: m/e 390.16842.
The spectral data for this molecule corresponded with that in the literature.36
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Amine 94
H2, MeOH H 
.N  0CONHNHBoc Pd(OH)2/C^ N s -'C O  NH NH Boc
V J  435 08%) "  { - J  148
To compound 43535 (16.7 g, 46 mmol) in dry MeOH (90 mL) at rt was added 10% 
Pd(OH)2 on carbon (0.490 g, 4.65 mmol). The reaction vessel was sequentially purged with H2 
gas (3 times) before being allowed to stir vigorously under H2 at rt overnight. The suspension 
was then filtered through a pad of Celite® and the solvent concentrated in vacuo. The resulting 
white foam (10.28 g) was sufficiently pure for use in the next step and was not purified any 
further. Therefore, the yield was assumed to be ca. 98%.
IR (neat) 3250 (s), 3051 (w), 2974 (s), 2933 (w), 2870 (w), 1743 (s), 1670 (s), 1545 (m), 1394 
(w), 1365 (m), 1302 (w), 1248 (s), 1161 (s), 1090 (w), 1045 (w), 874 (w), 762 (w), 627 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 3.82 (dd, J = 9.2, 5.2 Hz, 1 H, CHCO), 2.98 (m, 1 H, 
NCHz), 2.91 (m, 1 H, NCH2), 2.11 (m, 1 H, CFhCHCO), 1.95 (m, 1 H, CI^CHCO), 1.75 (m, 1 H, 
CHbCHzCHCO), 1.68 (m, 1 H, ChbCHzCHCO), 1.44 (s, 9 H, C(CH3)3).
13C-NMR (125 MHz, CDCI3, 298K) 5 174.0 (NCOOf-Bu), 155.1 (CHC=ONH), 81.5 (OC(CH3)3),
59.8 (CH), 47.2 (CH2N), 30.5 (CH2CHCO), 28.1 (C(CH3)3), 26.0 (CH2CH2CHCO).
FAB (+) HRMS: Calcd. for C10H10NaN3O3: (M+H)+: m/e 230.15046; Found: m/e 230.15177.
The spectral data for this molecule corresponded with that in the literature.35
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Dipeptide 111
.N . ^CONHNHBoc Me\ ir-M < y  NFmoc
Me NFmoc (COCI)2  ^ M© 'NFmoc 1 4 8  Mey _ y ^ V ° g
Me'^C02H CH^  m/^COC. AflCN'C6He ^  J. X^NHBoc
161 140 '  H
155
To acid 161 (13.4 g, 0.0366 mol) at rt under N2 was added dry CH2CI2(100 mL) followed 
by (COCI)2 (61 mL, 7.32 mol). The mixture was stirred at rt for 2 h, it was concentrated in vacuo 
and evaporated from C6H6 (2 x 50 mL). To the residue was added a solution of the amine 148 
(8.4 g, 0.0366 mol) in dry C6H6 (120 mL) over 10 min under N2 at rt. Then AgCN (7.36 g, 0.549 
mmol) was added and the reaction mixture was heated at reflux for 30 min. The reaction 
mixture was cooled to rt and EtOAc (200 mL) was added. The suspension was then filtered 
through a pad of Celite®, the solvent concentrated in vacuo, and the crude residue purified by 
Si02 flash chromatography (gradient elution 2:1 to 1:2 petrol:EtOAc) to give dipeptide 155 as a 
white foam (19.1 g, 90%).
[a]D + 3.78° (c 0.56, CH2CI2).
IR (neat) 3288 (br), 2958 (m), 1707 (s), 1697 (s), 1639 (m), 1448 (m), 1396 (w), 1309 (w), 1250 
(w), 1159 (m), 1041 (w), 744 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 8.63 (br), 8.44 (br), 7.72 (m), 7.66 (m), 7.37 (m), 7.28 (m), 
6.52 (m, br), 4.85 (m 1 H), 4.77 (dd, J=  11.1, 3.7 Hz, 1 H), 3.51 (m, br), 4.42 (m), 4.31, 4.22 (t), 
4.15 (m, br), 4.05 (t) 3.51 (m, br), 2.83 (s, 3 H, NCH3), 2.67 (br), 2.45 (m, br), 2.26-1.73 (m, br), 
1.59 (m, br), 1.42 (m, br), 1.39 (s, 9 H, C(CH3)3), 0.91 (dd, J = 6.6, 2.3 Hz), 0.51 (dd, 3 H, CH- 
CH3), 0.49 (d, 3 H, CH-CH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 170.9, 170.0, 156.7, 155.5, 154.9, 143.7, 141.2, 127.6,
127.0, 124.9, 124.1, 119.9, 81.1, 67.5, 65.6, 58.7, 58.4, 55.1, 54.4, 47.2, 47.0, 46.0, 37.2, 29.6,
29.4, 28.0, 25.3, 25.0, 24.4, 24.3, 23.1, 22.3.
FAB (+) HRMS: Calcd. for C32H42N4Na06: (M+Na)+: m/e 601.30019; Found: m/e 601.29959.
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Dipeptide 162
NFmoc NH
Et2NH, MeCN MeMe.
5 NMe(87%)Me NHBoc Me NHBoc
’O " 1
2 3 
162
2 3156 163
To dipeptide 155 (19.1 g, 33 mmol) in dry MeCN (240 mL) at rt and under N2 was added 
Et2NH (120 mL, 1.15 mol). The reaction mixture was stirred at rt for 30 min before it was diluted 
with EtOAc (150 mL) and concentrated in vacuo. The crude residue was purified by Si02 flash 
chromatography (gradient elution 1:1 to 0:10 petrol:EtOAc and 1:5 EtOAc:MeOH) to afford a 
mixture of free amine 162 and diketopiperazine 163 as a white foam (10.22 g, 87%).
Data for 162
1H-NMR (500 MHz, CDCI3, 298K) 6 4.58 (d, J = 6.1 Hz, 1 H, H4 ), 3.77 (td, J = 8.9, 6.1 Hz, 1 
H, H5 ), 3.44 (m, 1 H, H1), 3.30 (dd, J = 8.8, 4.9 Hz, 1 H, CHNMe), 2.42 (m, 1 H, H1 ), 2.32 (s, 
3 H, NCH3), 2.15 (m, 1 H, H3), 1.98 (m, 2 H, H3, H2), 1.91 (m, 1 H, H2), 1.79 (m, 1 H, H7), 1.42 
(s, 9 H, C(CH3)3), 0.91 (dd, J = 6.7 Hz, 3 H, CH-CH3), 0.90 (d, J = 6.64 Hz, 3 H, CH-CH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 175.6 (C=0), 166.0 (C=0), 154.0 (C=0), 81.3 (OC(CH3)3),
60.0 (CHNMe), 58.4 (CHCONHNHBoc), 46.9 (CH2), 42.1 (CH2), 34.8 (NCH3), 28.1 ((CH3)3),
27.1 (C7), 24.8 (CH2CH2N), 24.9 (CH(CH3)2), 23.8 (CH-CH3), 22.0 (CH-CH3).
FAB (+) HRMS: Calcd. for C17H33N40 4: (M+H)+: mle 225.16029; Found: m/e 225.16071.
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After purification by S i02 flash chromatography diketopiperazine 163 (0.95 g) was isolated:
Me
5  NMe
113
[a]D- 124.7° (c 0.59, CH2CI2)
IR (neat film) 2952 (m), 2879 (w), 1872 (s), 1443 (m), 1404 (w), 1304 (w), 1240 (w), 1169 (w).
1H-NMR (500 MHz, CDCI3, 298K) 6 4.03 (dd, J = 9.4, 6.9 Hz, 1 H, H4 ), 3.77 (dd, J = 8.6, 6.3 
Hz, 1 H, H5 ), 3.54 (m, 1 H, H1), 3.46 (m, 1 H, H1), 2.92 (s, 3 H, NCH3), 2.35 (m, 1 H, H3), 1.96 
(m, 2 H, H3, H2), 1.83 (m, 1 H, H2), 1.75 (m, 1 H, H7), 1.59 (m, 2 H, H6), 1.55 (m, 2 H, H6), 
0.91 (d, J = 6.6 Hz, 3 H, CH-CH3), 0.87 (d, J = 6.6 Hz, 3 H, CH-CH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 167.5 (C=0), 165.9 (C=0), 63.4 (C5), 58.2 (C4), 45.5 (C1),
40.4 (C6), 32.9 (NCH3), 29.2 (C3), 24.5 (C7), 22.8 (CH-CH3), 22.5 (C2), 22.1 (CH-CH3).
FAB (+) HRMS: Calcd. for C12H21N20 2: (M+H)+: mle 225.16029; Found: m/e 225.16071.
Tetrapeptide 165
OBn NFmoc
(1) Et2NH (40 eq), M eCN, rt 25 min
Me.
Me
\  ,N Z  
9 Bn> — NFmoc
NHNHBoc Me
Me'in CH 2C I2 at -10°C  
add BOP-CI and Et3N 
stir for 3 h 
(73% , 2 steps)
155 NHNHBoc
OH 64 165
To dipeptide 155 (2.0 g, 3.46 mmol) in dry MeCN (20 mL) was added at rt under N2, 
Et2NH (10.8 mL, 10.4 mmol). The reaction mixture was stirred at rt under N2 for 30 min and 
concentrated in vacuo. The crude residue was co-evaporated from benzene (3 x 20 mL) and a
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solution of dipeptide 8 (2.3 g, 3.46 mmol) in dry CH2CI2 (18.6 mL) was added at rt under N2 over 
15 min. The reaction mixture was cooled to -10 °C and dry Et3N (1.06 mL, 7.60 mmol) was 
added dropwise followed by BOP-CI (1.06 g, 4.14 mmol). The reactants were allowed to stir at - 
10 °C for 20 min and at 0 °C for 2.5 h. The reaction mixture was diluted with EtOAc (100 mL) 
and washed with 0.5 M aq. HCI (2 x 60 mL), 5% aq. NaHC03 (2 x 60 mL) and brine (60 mL). 
The organic layer was dried (MgS04), filtered and concentrated in vacuo. The product was 
purified by Si02 flash chromatography (gradient elution 2:1 to 1:2 petrol:EtOAc) to afford 
tetrapeptide 165 as a white foam (2.55 g, 74%).
[a]D - 45.0° (c 0.74, CH2CI2).
IR (neat) 3304 (br), 2955 (m), 1707 (s), 1649 (s), 1450 (m), 1365 (w), 1296 (w), 1250 (m), 1161 
(w), 1090 (w), 1049 (w), 741 (m), 698 (m).
1H-NMR (500 MHz, CDCI3, 298K) 8.65-8.41 (m, br), 7.71-7.01 (m, br), 6.79-6.13 (m, br), 5.54- 
2.80 (m, br), 2.23 (m, br), 1.80-1.57 (m, br), 1.50-1.11 (m, br), 0.95-0.80 (m, br).
13C-NMR (125 MHz, CDCI3, 298K) 6 171.4, 170.6, 170.3, 155.7, 155.4, 155.0, 154.9, 143.7,
143.0, 141.2, 136.3, 136.0, 134.1, 125.4-124.8 (Ar), 119.8, 80.6, 78.6, 68.6, 67.6, 58.6, 53.4,
50.0, 47.3, 46.7, 45.1, 43.8, 37.1, 30.5, 29.6, 28.0, 24.8, 24.5, 23.7, 23.1, 22.8, 22.3, 18.9, 18.5,
14.2.
FAB (+) HRMS: Calcd. for CssHeyNyNaOn: (M+Na)+: m/e 1024.47960; Found: m/e 1024.48548.
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Tetrapeptide 166
NZ
NFmoc
Me,
,Me MeCN, rt, 15 min 
(99%) MeMe
MeMe
NHNHBocNHNHBoc
166165
To tetrapeptide 165 (2.45 g, 2.55 mmol) in dry MeCN (21 mL) under N2 was added 
Et2NH (9.3 mL, 89 mmol) and the reaction mixture was stirred at rt for 25 min and concentrated 
in vacuo. The crude oil was purified by Si02 flash chromatography (gradient elution 4:1 to 0:1 
petrol:EtOAc) to afford tetrapeptide 166 as a white foam (1.90 g, 99%).
[a]D + 5.71° (c 0.59, CH2CI2).
IR (neat) 3292 (br), 2930 (m), 1699 (m), 1645 (s), 1452 (m), 1404 (w), 1367 (w), 1261 (m), 1159 
(m), 754 (w), 700 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 8.66 (br), 7.35-7.19 (m, br), 6.77 (br), 5.37 (m, br), 5.27 (m, 
br), 5.18 (d, J = 12.3 Hz), 5.07 (d, J = 12.3 Hz), 5.11-4.95 (m, br), 4.55 (d, J = 8.2 Hz), 4.20 (br), 
3.89 (d, J = 9.8 Hz), 3.77 (br), 3.42 (br), 3.08 (s, 3 H, NCH3), 2.97 (br), 2.21-1.58 (m, br), 1.49 
(d, J = 6.9 Hz), 1.39 (s, 9 H), 1.22 (s), 0.94 (d, J = 7.4 Hz), 0.93 (d, J = 6.5 Hz), 0.85 (m, br).
13C-NMR (125 MHz, CDCI3, 298K) 6 172.5, 171.6, 170.1, 155.8, 155.5, 136.7, 136.4, 129.0,
128.9, 128.7, 128.4, 128.0, 127.9, 80.8, 80.1, 77.2, 67.2, 59.1, 57.4, 56.6, 54.5, 52.7, 47.6, 
44.6, 37.0, 31.7, 30.7, 30.1, 28.1, 26.9, 24.9, 24.5, 23.3, 23.0, 22.4, 13.5.
FAB (+) HRMS: Calcd. for C^HsyNyNaOg: (M+Na)+: m/e 802.41153; Found: m/e 802.41531.
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Depsipeptide 167
NHTroc
Me
MeMeNH
HO NHMe
MeMe, BocNH
Me. OBn
O "
NHNHBoc
(71 %, 2 steps)
To a stirred solution of acid 157 (480 mg, 0.78 mmol) in dry C6H6 (2.4 mL) at rt under N2 
was added (COCI)2 (2.4 mL, 27.3 mmol). The reaction mixture was stirred at rt under N2 for
2.5 h and then concentrated in vacuo. The resulting oil was co-evaporated from benzene (3 x 
10 mL). To the residue was added a solution of tetrapeptide 166 (610 mg, 0.78 mmol) in dry 
C6H6 (7.2 mL) at rt under N2. AgCN (167 mg, 1.25 mmol) was then added in one portion. The 
reaction vessel was fitted with a reflux condenser and immersed for 10 min in an oil bath pre­
heated to 80 °C. The reaction mixture was then cooled, diluted with EtOAC (10 mL) and filtered 
through Celite®, the Celite® was then washed with EtOAc. The filtrate was concentrated in 
vacuo and the product purified by S i02 flash chromatography (gradient elution 4:1 to 1:1 
petrol:EtOAc) to afford depsipeptide 167 as a white foam (764 mg, 71%).
[a]D- 57.1° (c 0.41, CH2CI2).
IR (neat) 3306 (br), 2876 (w), 2930 (m), 1716 (s), 1643 (s), 1698 (m), 1508 (m), 1452 (m), 1390 
(m), 1367 (w), 1240 (m), 1161 (s), 1045 (w), 735(w), 698 (w).
1H NMR (500 MHz, CDCI3, 298K) 5 8.82 (br), 8.54 (br), 8.00 (br), 7.67 (br), 7.49-7.11 (m, br), 
6.74 (br), 5.86 (br), 5.59 (br), 5.60 (m, br), 4.47 (m, br), 4.32 (m, br), 4.12 (m, br), 3.73 (m, br), 
3.49 (m, br), 3.31 (m, br), 3.07 (m, br), 2.93 (m, br), 2.80 (m, br), 2.60-2.45 (m, br), 2.26 (m, br),
2.10-1.75 (m, br), 1.49-1.25 (m, br), 1.21 (d, J = 6.2 Hz), 0.95-0.81 (m, br).
13C-NMR (125 MHz, CDCI3, 298K) 5 174.0, 172.4, 171.3, 170.6, 170.4, 169.7, 156.0, 155.5,
155.1, 154.0, 153.3, 137.6, 135.7, 133.5, 129.2, 128.3, 128.6, 128.2, 127.5, 127.4, 126.0,
132
125.7, 95.3, 81.5, 81.1, 79.8, 79.1, 78.5, 74.4, 70.7, 70.3, 68.6, 68.0, 58.4, 58.1, 57.8, 52.8,
52.4, 51.4, 50.8, 50.6, 48.2, 47.6, 47.1, 45.5, 37.0, 28.6, 28.2, 28.0, 24.8, 24.3, 22.9, 22.7, 22.4,
19.8, 19.6, 17.9, 17.1, 16.3, 16.1, 15.9, 13.9.
FAB (+) HRMS: Calcd. for CegClaHgoNgNaO^: (M+Na)+: m/e 1396.54176; Found: m/e 
1396.54502.
Cyclodepsipeptide 168
NHTroc
(j)Bn
oX *Me °X^ Me
N BocNH :
Mev > 7 ^ 0  O Bn
7 1
\  NHNHBoc
167
Me
(1) CF3C 0 2 H, CH2CI2i 0 °C, 2 h 
(2) NBS, THF/H2 0, rt, 2 h
(3) NEM and deprotected 167 added 
over 6  h to HATU very diluted in 
CH2 CI2 at 0°C, stir at rt for 72 h,
(70%, 3 steps) Me
NZ NHTroc
To depsipeptide 167 (1.19 g, 0.865 mmol) in dry CH2CI2 (13.4 mL) at 0 °C under N2 was 
added in one portion CF3C 02H (13.4 mL, 0.17 mol). The reaction mixture was stirred for 2 h at 
0 °C, concentrated in vacuo and co-evaporated from toluene ( 2x10  mL) to remove the excess 
CF3C 02H. To the residue in THF (9.7 mL) and H20  (9.7 mL) was added NBS (0.31 g, 1.7 mmol) 
portionwise over 10 min. The reaction mixture was stirred at rt for 2 h, diluted with EtOAc 
(50mL) and washed with brine (50 mL). The organic layer was dried (MgS04), filtered and 
concentrated in vacuo affording a white foam. To a suspension of HATU (3.28 g, 8.65 mmol) in 
dry CH2CI2 (1 L) at 0 °C and under N2 was added dropwise over 5 h, a solution of the above 
crude product and A/-ethylmorpholine (1.48 mL, 11.6 mmol) in dry CH2CI2 (1 L). The reaction 
mixture was stirred at rt for 60 h. The reaction mixture was concentrated in vacuo and the yellow 
residue dissolved in EtOAc (300 mL), washed with 1 M aq. HCI (2 x 70 mL), 5% aq. NaHC03 (2 
x 70 mL) and brine (70 mL). The organic layer was dried (MgS04), filtered and concentrated in 
vacuo. The product was purified by Si02 flash chromatography (gradient elution 4:1 to 2:1 
petrol:EtOAc) to afford cyclodepsipeptide 168 as a white foam (698 mg, 70% over 3 steps).
[a]D + 3.90° (c 0.59, CH2CI2).
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IR (neat) 3290 (br), 2876 (w), 1739 (s), 1676 (s), 1641 (s), 1508 (m), 1452 (w), 1391 (m), 1234 
(m), 1196 (w), 1153 (w), 1090 (w), 1040 (w), 999 (w), 746 (m), 700 (m).
1H-NMR (500 MHz, CDCI3l 298K) 6 7.44-7.17 (m, br), 5.86-5.39 (m, br), 5.24-4.49 (m, br), 4.21-
4.01 (m, br), 3.91 (m, br), 3.84 (m, br), 3.78 (m, br), 3.42 (m, br), 3.44 (m, br), 3.26, 3.21 (m, br), 
2.94 (m, br), 2.83 (m, br), 2.07-1.65 (m, br), 1.56 (m, br), 1.50-1.40 (m, br), 1.23 (br), 1.17 (d, J 
= 6.4 Hz), 1.15 (d, J = 6.4 Hz), 0.98-0.73 (m, br).
13C-NMR (125 MHz, CDCI3, 298K) 5 173.1, 172.3, 171.2, 170.1, 169.5, 168.7, 165.7, 157.8,
155.8, 153.9, 153.1, 137.8, 135.3, 134.0, 129.5, 128.9, 128.5, 128.2, 127.9, 127.5, 95.1, 79.5,
74.9, 70.7, 69.0, 60.4, 59.0, 58.7, 57.2, 55.9, 55.6, 53.5, 53.0, 51.1, 49.6, 48.2, 47.8, 46.9, 45.7,
37.7, 37.4, 30.3, 29.7, 29.6, 28.4, 28.0, 27.7, 26.4, 24.9, 24.7, 23.2, 22.9, 22.7, 22.2, 19.5, 17.1,
15.8, 15.5, 14.9, 13.8.
FAB (+) HRMS: Calcd. for C55CI3H7oN7Na013: (M+Na)+: m/e 1164.39946; Found: m/e 
1164.39772.
Cyclodepsipeptide 169
NZ NHTroc NZ NHZOBnOBn Me
Me
Me
MeMeMe (1) Zn dust 
AcOH/H20  (10:1)
,Me
(2) ZCI, aq NaHC03  
CH2CI2 
(56%, 2 steps)
Me Me
NH Me.Me.
OBnOBn Me"Me'
168 169
To cyclodepsipeptide 168 (337 mg, 0.296 mmol) in a solution of 10 :1 AcOH:H20  ( 7.7 
mL) at rt was added Zn dust (387 mg, 5.90 mmol). The reaction mixture was left to stir at rt for 1 
h and was filtered through Celite®. The Celite® pad was washed with THF (50 mL) and the 
filtrate was concentrated in vacuo and the residue co-evaporated from toluene ( 2 x 6  mL). To 
the resulting residue was added dropwise and simultaneously, over 10 min, a solution of Z-CI 
(0.13 mL, 0.888 mmol) in CH2CI2 (1.55 mL) and 10% aq. NaHC03 (1.55 mL). The reaction 
mixture was diluted with EtOAc (20 mL), washed with brine (10 mL), dried over MgS04, filtered
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and concentrated in vacuo. The product was purified by Si02 flash chromatography (gradient 
elution 4:1 to 2:1 petrol:EtOAc) to afford 169 as a white foam (184 mg, 56% over 2 steps).
IR (neat) 3302 (m), 2959 (m), 1728 (s), 1676 (s), 1634 (s), 1506 (m), 1452 (w), 1394 (m), 1257 
(m), 1236 (m), 1194 (w), 1151 (w), 1035 (w), 1001 (w), 741 (m), 700 (m).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.45-7.09 (m, br), 6.73 (m, br), 5.76-5.49 (m, br), 5.42 (m,
br), 5.27-5.81 (m, br), 4.70 (m, br), 4.63-4.47 (m, br), 4.15 (m, br), 4.07 (m, br), 3.91 (m, br),
3.78 (m, br), 3.69 (m, br), 3.43 (m, br), 3.25 (m, br), 3.23 (m, br), 2.94 (m, br), 2.81 (m, br), 2.01-
1.40 (m, br), 1.23 (s), 1.16 (m), 0.96-0.70 (m, br).
13C-NMR (125 MHz, CDCI3, 298K) 5 173.0, 171.1, 170.4, 170.1, 169.8, 169.5, 168.7, 165.8,
157.8, 155.4, 154.8, 137.8, 136.2, 135.8, 135.4, 134.0, 129.6, 128.9, 128.6, 128.5, 128.3,
128.2, 128.1, 128.0, 127.8, 127.5, 127.4, 79.1, 77.9, 75.3, 74.6, 77.2, 70.8, 70.5, 68.9, 68.7,
67.0, 59.0, 57.1, 55.6, 52.8, 52.4, 51.1, 50.8, 49.3, 48.2, 47.8, 46.8, 45.7, 45.1, 37.6, 37.3, 30.3,
29.8, 28.4, 27.9, 26.4, 25.1, 24.9, 24.6, 23.2, 23.0, 22.7, 22.1, 19.6, 17.2, 15.6, 15.0, 13.6.
FAB (+) HRMS: Calcd. for CeoHysNyNaOia: (M+Na)+: m/e 1124.53203; Found: m/e 1124.52750.
Cyclodepsipeptide 13
ci-jMZ NHZBn Me
Me
Me
MeH2 , 10% Pd/C MeOH, HCI
Me, Me,
(100%)
Me MeNH NHMe Me
OBn OH
c r
Me Me
169
To cyclodepsipeptide 169 (0.210 g, 0.19 mmol), in dry methanolic HCI (0.01 M, 19 mL, 
0.19 mmol) was added 10% wet Pd/C (0.14 g) and the system purged with H2. The reaction 
mixture was left to stir vigorously at room temperature for 24 h, diluted with MeOH (20 mL) and 
filtered through Celite®. The Celite® was washed well with MeOH (100 mL) and the filtrate 
concentrated in vacuo to yield 13 as a yellow solid (0.14 g, 94%).
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1H-NMR (500 MHz, CDCI3, 298K) 5 6.17 (m), 6.06 (br), 5.80, 5.64, 5.58, 5.49 (m, br), 5.08 (s), 
5.03 (br), 4.72 (m, br), 4.65 (s, br), 4.59 (m, br), 4.56-4.47 (m, br), 4.43 (m, br), 4.34 (m, br),
4.10-3.38 (m, br), 3.22 (m, br),3.13 (m, br),3.02 (m, br), 2.97 (m, br), 2.93 (s, 3 H, NCH3), 2.31- 
1.44 (m, br), 1.36 (d), 1.33 (m, br), 1.21 (d), 1.17 (m, br), 1.07 (m, br), 0.95 (s, br).
13C-NMR (125 MHz, CDCI3, 298K) 5 174.9, 174.4, 173.1, 172.9, 172.3, 171.7, 171.4, 171.2,
170.9, 170.1, 169.8, 168.4, 168.1, 156.7, 79.4, 79.0, 75.4, 70.6, 70.1, 69.4, 68.7, 67.8, 66.5,
63.2, 62.1, 61.6, 61.3, 58.8, 58.3, 56.9, 56.5, 55.1, 54.5, 54.1, 53.2, 52.5, 51.8, 50.4, 49.8, 46.3,
38.3, 31.5, 31.0, 30.8, 29.6, 29.4, 28.4, 27.9, 26.5, 26.0, 25.9, 25.8, 25.7, 23.4, 23.3, 23.1, 22.9,
22.4, 22.1, 21.5, 21.1, 20.4, 20.2, 20.1, 19.8, 19.4, 18.2, 16.1, 15.1, 14.9, 14.5.
The NMR analysis showed that the salt is not pure.
Oxazolidinone 179
DBAD, D M PU  
(58%) Boc
To a stirred solution of diisopropylamine (0.93 mL, 6.65 mmol) in THF (5.7 mL) at -78 °C 
was added dropwise n-BuLi (2.5 M in hexanes, 2.7 mL, 6.65 mol). The reaction mixture was 
stirred at -78 °C for 35 min. A solution of the bromide 17838 (2.7 g, 6.04 mmol) in THF (6 mL) 
was added dropwise to the mixture. The mixture was stirred at -78 °C for 75 min and a solution 
of DBAD (1.67 g, 7.26 mmol) in CH2CI2 (7 mL) was added. After 1h 40 min at -78 °C, DMPU 
(11.7 mL, 96.8 mmol) was added dropwise and the mixture was maintained at -78 °C for 5 min, 
then allowed to warm to rt and stirred at rt for 50 min. The mixture was added to a flask 
containing Et02 (170 mL) and sat. aq. KH2P04 (100 mL). The organic layer was washed with 
water (100 mL), brine (100 mL), dried (MgS04) and filtered. The solvent was then removed in 
vacuo and the crude residue was purified by Si02 flash chromatography (graduent elution 8:1 to
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5:1 petrol:EtOAc) and recrystallised with petrol and ether to afford compound 179 as a white 
solid (2.10 g, 58%).
[a]D + 50.7 (c 0.49, CH2CI2).
1H-NMR (400 MHz, DMSO, 353K) 5 7.26 (m, Ar), 5.73 (m br, 1 H, H5), 4.56 (d, J = 11.9 Hz, 
1 H, OCH^Ar), 4.51 (br, 1 H, CHNH), 4.47 (d, J = 11.9 Hz, 1 H, OCHzAr), 4.22 (br, 1 H, H2),
4.14 (m, 2 H, CH^O), 3.72 (m, br, 1 H, H3), 3.14 (m br, 1 H, H2), 3.09 (m, br, 1 H, ChLAr), 2.92 
(m, br, 1 H, ChhAr), 2.13 (ddd, J = 3.3, 6.9, 14.1 Hz 1 H, H4), 1.97 (m, br, 1 H, H4), 1.46 (s, 
CH3), 1.48 (s, CH3).
13C-NMR (125 MHz, C6H6, 353K) 5 168.8, 167.6 (br), 153.3 (0=C(OfBu)), 152.5, 138.1, 135.2,
128.8, 128.0, 127.5, 126.9, 126.3, 80.6, 78.9, 69.2, 69.1, 66.3, 54.8, 52.5 (br), 36.3, 29.6, 27.4 
(C(CH3)3), 27.5 (C(CH3)3).
OQ
The spectral data for this molecule corresponded with that in literature.
Ester 180
NaOMe
CH2CI2
BocN BocN
To a solution of 179 (11.8 g, 19.8 mmol) in CH2CI2 (120 mL) was added a solution of 
NaOMe (0.4 M, 55 mL, 21.8 mmol) at - 30 °C. The reaction mixture was stirred at -30 °C for 15 
min and then was neutralised to pH 6 with 10% aq. KH2P04. The mixture was then extracted 
with CH2CI2 (3 x 100 mL). The combined organic layers were dried (MgS04) and filtered. The 
solvent was then removed in vacuo and the crude residue was purified by Si02 flash 
chromatography with 4:1 petrol:EtOAc as eluent to afford the title compound 180 as a yellow oil 
(8.40 g, 94 %).
[a]D - 8.45° (c 0.72, CH2CI2).
137
IR (neat) 2978 (m), 2932 (w), 1763 (m), 1732 (s), 1697 (s). 1450 (w), 1416 (s), 1392 (s), 1365 
(s), 1342 (m), 1296 (m), 1250 (m), 1171 (s), 1132 (m), 1094 (s), 858 (w), 752 (w), 735 (w).
1H-NMR (400 MHz, DMSO, 353K) 5 7.28 (m, Ar), 4.78 (dd, J = 2.8, 6.9 Hz, 1 H, 
BocNCHCOOMe), 4.52 (d, J=  11.6 Hz, 1 H, OCJiAr), 4.43 (d, J=  11.6 Hz, 1 H, OChhAr), 4.22 
(d br, J = 13.0 Hz, ChhNBoc), 3.68 (m, br, 1 H, CHOBn), 3.48 (s, 3 H, OCH3), 3.0 (m, 1 H, 
CH2NB0C), 2.32 (d, br, J = 2.3 Hz, 1 H, CH-CH^CH), 1.95 (ddd, J = 2.9, 6.9, 14.1 Hz 1 H, 
CH-Chb-CH), 1.43 (s, 9 H, C(CH3)3), 1.42 (s, 9 H, C(CH3)3).
13C-NMR (125 MHz, C6H6, 333K) 6 169.4 (Me0C=0), 153.2 (C=0), 138.1, 127.4, 126.6, 80.6 ,
78.8 (C(CH3)3), 78.6 (C(CH3)3), 68.9 (OCH2Ar), 68.6 (CHOBn), 52.1 (br, CHNBoc), 50.8 (OCH3),
44.6 (br, CH2NBoc), 28.9 (CH-CH2-CH), 27.5 (C(CH3)3), 27.4 (C(CH3)3).
FAB (+) HRMS: Calcd. for C23H38N20 4: (M+H)+: m/e 451.24441; Found: m/e 451.24565.
Ester 181
(1)TFA,CH 2 CI2  
..OBn (2) NaHC03, ZCI 
I' CH2 CI2 MeO'MeO'
(94%, 2 steps)
Boc
180 181
To a solution of 180 (8.40 g, 18.6 mmol) in CH2CI2 (50 mL) was added TFA (13.8 mL, 
186 mmol). The reaction mixture was stirred at rt for 2 h and evaporated in vacuo. The oil was 
co-evaporated from CH2CI2 and used directly for the next step.
To a solution of crude TFA salt (18.6 mmol) in CH2CI2 (122 mL) was added at 0°C, 10% 
aq. NaHC03 (18.6 mL). Then a solution of ZCI in CH2CI2 (1 M, 18.6 mL, 18.6 mmol) was added 
dropwise via pipette over 15 min. After stirring 20 min at rt, the layers were separated and the 
aqueous layer extracted with EtOAc (3 x 100 mL). The combined organic layers were dried 
(MgS04) and filtered. The solvent was then removed in vacuo and the crude residue was 
purified by Si02 flash chromatography with 2:1 petrol:EtOAc as eluent to afford compound 181 
as a yellow oil (6.8 g, 94 % over 2 steps).
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[a]D + 20.2° (c 0.28, CH2CI2).
IR (neat) 3283 (w), 3032 (w), 2951 (m), 2870 (m), 1742 (s), 1705 (s), 1605 (w), 1497 (w), 1448 
(m), 1410 (m), 1350 (m), 1269 (m), 1111 (m), 1169 (s), 1092 (m), 1028 (w), 744 (m), 700 (m).
1H-NMR (500 MHz, C6H6, 333K) 6 7.31 (d, J=  7.3 Hz , Ar), 7.31 (m, Ar), 5.18 (d, J=  12.3 Hz, 1 
H, COOChbAr), 5.09 (d, J = 12.3 Hz, 1 H, COOCHsAr), 4.12 (d, J = 12.3 Hz, 1 H, OCh^Ar), 4.06 
(d, J=  12.3 Hz, 1 H, OCh^Ar), 3.73 (m, br, 1 H, HNCHCOOH), 3.38 (s, 3 H, OCH3), 3.10 (m, br, 
2 H, CF^NZ), 3.14 (m, 1 H, CHOBn), 2.49 (d, br, J = 18.0 Hz, 1 H, CH-Chh-CH), 2.09 (ddd, J =
2.2, 4.6, 18.8 Hz 1 H, CH-CI^-CH).
13C-NMR (125 MHz, C6H6, 333K) 6 165.0 (MeOC=0), 154.5 (C=0), 138.3 (Ar), 136.7 (Ar),
128.7-127.6 (Ar), 70.2 (OCH2Ar), 68.3 (CHOBn), 65.4 (COOCH2Ar), 51.7 (OCH3), 51.6 
(HNCHCOOH), 44.5 (CH2NZ), 38.4 (CH-CH2-CH).
FAB (+) HRMS: Calcd. for C2iH24N2Na05: (M+Na)+: m/e 407.15828; Found: m/e 407.15878.
The spectral data for this molecule corresponded with that in literature.38
Acid 182
LiOH-H20  
O'0B n THF:H2Q (2:1)
MeO' HO'
(98%)
181 182
To a mixture of ester 181 (3.75 g, 9.7 mmol) in THF/H20  (2:1, 74 mL:37 mL) at 0 °C 
was added LiOH-H20  (0.409 g, 9.7 mmol). The resulting mixture was stirred 15 min at 0 °C. 
10% aq. HCI was added until pH 2 was attained and the mixture was extracted with EtOAc (3 x 
80 mL). The combined organic layers were washed with brine, dried (MgS04) and filtered. The 
solvent was then removed in vacuo and the resulting oil (3.54 g) was sufficiently pure for use in
139
the next step and was not purified any further. Therefore, the yield of the formation of 182 was 
assumed to be ca. 98%.
IR (neat) 3210 (br), 3032 (w), 2920 (br), 1703 (s), 1497 (w), 1452 (w), 1410 (m), 1354 (w), 1257 
(m), 1178 (m), 1122 (m), 1092 (m), 1153 (w), 742 (m), 700 (m).
1H-NMR (400 MHz, C6H6, 333K) 6 7.22-7.03 (m, 10 H, Ar), 6.76 (br, 2 H, NH, OH), 5.05 (d, J =
12.5 Hz, 1 H, COOCHsAr), 5.00 (d, J = 12.5 Hz, 1 H, COOCFbAr), 4.37 (d, J = 12.1 Hz, 1 H, 
O C h h A r ) ,  4.20 (d, J = 12.1 Hz, 1 H, OCh^Ar), 3.44 (dd, J = 13.1, 6.2 Hz, 1 H, HNCHCOOH), 
3.23 (t, J=  5.7 Hz, 2 H, CFbNZ), 3.14 (m, 1 H, CHOBn), 2.17 (m, 1 H, CH-CFb-CH), 1.67 (m, 1 
H, CH-CFb-CH).
13C-NMR (125 MHz, C6H6, 333K) 6 172.7 (C=0), 157.1 (C=0), 138.4 (Ar), 136.6 (Ar), 128.7-
127.6 (Ar), 70.5 (OCH2Ar), 70.3 (CHOBn), 68.3 (COOCH2Ar), 55.7 (HNCHCOOH), 48.8 
(CH2NZ), 30.8 (CH-CH2-CH).
FAB (+) HRMS: Calcd. for C20H22N2NaO5: (M+H)+: m/e 371.16069; Found: m/e 371.16179.
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Compound 183
NH 2NHBoc, d c c  
HOBt, THF BocHNHN
To acid 182 (9.7 mmol) in dry THF (55 mL), was added at 0 °C under N2, HOBt (1.42 g,
10.5 mmol), DCC (2.17 g, 10.5 mmol) and BocNHNH2 (1.39 g, 10.5 mmol). The reaction mixture 
was stirred at 0 °C for 30 min and at rt overnight. The suspension was then filtered through a 
pad of Celite®, the filtrate was washed with 1 M aq. HCI (50 mL), 5% aq. NaHC03 (50 mL) and 
brine (50 mL). The organic layer was dried on MgS04 and concentrated in vacuo, the crude 
residue was purified by S i02 flash chromatography (gradient elution 2:1 to 1:2 petrol:EtOAc) to 
give 183 as a white foam (4.3 g, 93%).
[a]D - 40.8° (c 0.51, CH2CI2).
IR (neat) 3277 (br), 2977 (w), 2930 (w), 1695 (s), 1499 (w), 1454 (w), 1367 (w), 1344 (m), 1163 
(s), 1124 (m), 1091 (w), 1026 (w), 737 (w), 698 (w).
1H-NMR (400 MHz, C6H6, 333K) 5 9.47 (s, 1 H, CONH) 7.25-7.06 (m, 10 H, Ar), 6.76 (br, 2 H, 
NH, OH), 5.11 (d, J = 12.5 Hz, 1 H, COOCjiAr), 5.07 (d, J = 12.5 Hz, 1 H, COOCFbAr), 4.42 
(d, J = 12.1 Hz, 1 H, OCFbAr), 4.27 (d, J = 12.1 Hz, 1 H, OCHzAr), 3.56 (dd, J = 13.2, 6.0 Hz, 1 
H, CFbNZ), 3.43 (t, J = 5.7 Hz, 1 H, HNCHCOOH), 3.32 (dd, J = 13.2, 1.6 Hz, 1 H, C H ^Z  ), 
3.28 (m, 1 H, CHOBn), 2.30 (m, 1 H, CH-CFb-CH), 1.79 (m, 1 H, CH-CFb-CH), 1.36 (s, 9 H, 
C(CH3)3).
13C-NMR (125 MHz, C6H6, 333K) 5 170.5 (C=0), 156.7 (C=0), 155.8 (C=0), 139.3 (Ar), 137.1 
(Ar), 128.7-127.5 (Ar), 80.6 (C(CH3), 70.4 (OCH2Ar), 70.2 (CHOBn), 67.9 (COOCH2Ar), 56.0 
(HNCHCOOH), 49.0 (CH2NZ), 30.3 (CH-CH2-CH), 28.3 (C(CH3)).
FAB (+) HRMS: Calcd. for C25H33N40 6: (M+H)+: m/e 485.24000; Found: m/e 485.23909.
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Dipeptide 156
(1) (COCI)2, c h 2c i2 
(2) AgCN, PhMe, 70°C
MeN ^Fmoc 
N
Fm txx .Me  
N
Me
OH BocHNHN
Me
NHNHBoc
184 183 "N
Z
OBn 156
(81 %, 2  steps)
To acid 184 (2.0 g, 6.34 mmol, dried from C6H6) at rt under N2 was added dry CH2CI2 
(15 mL) followed by (COCI)2 (11.06 mL, 127 mmol). The mixture was stirred at rt for 2 h, 
concentrated in vacuo and dried from C6H6. To the residue was added a solution of the amine 
183 (2.9 g, 6.02 mmol, dried from C6H6) in C6H6 (20 mL) at rt under N2. Then AgCN (1.27 g, 
9.51 mmol) was added and the reaction mixture was heated at reflux for 40 min. The reaction 
mixture was cooled to rt and EtOAc was added (30 mL). The suspension was then filtered 
through a pad of Celite®, the solvent concentrated in vacuo, and the crude residue was purified 
by Si02 flash chromatography (gradient elution 3:1 to 1:1 petrol:EtOAc) to give 156 as a white 
foam (3.95 g, 81%, 2 steps).
[a]o + 3.97° (c 0.57, CH2CI2).
IR (neat) 3284 (br), 2977 (w), 1703 (s), 1450 (m), 1403 (m), 1365 (w), 1310 (w), 1241 (m), 1159 
(m), 1120 (w), 1153 (w), 741 (m), 698 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 9.98 (m, br), 7.75-7.65 (m, br), 7.42-7.04 (m, br), 6.12 (m, 
br), 5.34-4.68 (m, br), 4.50 (d, J = 12.3 Hz), 4.33 (d, J = 12.3 Hz), 4.44-4.08 (m, br), 4.57 (m, br),
3.37 (m, br), 3.16 (d), 2.93 (br), 2.84-2.50 (m, br), 2.32 (br), 1.87 (br), 1.72 (br), 1.45 (s) 1.41 (s),
1.30 (m, br), 0.86 (m, br).
13C-NMR (125 MHz, CDCI3, 298K) 6 174.0, 168.8, 157.8, 155.8, 154.5, 143.7, 141.1, 137.8,
134.8, 128.6, 128.5, 128.3, 128.2, 127.9, 127.6, 127.4, 127.1, 127.0, 125.5, 124.9, 124.4,
124.2, 119.8, 80.8, 69.7, 69.0, 67.7, 67.5, 66.4 52.1, 51.6, 50.9, 50.0, 47.0, 29.6, 29.1, 28.0,
27.2, 27.0, 14.9, 14.1.
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FAB (+) HRMS: Calcd. for C44H49N5Na09: (M+Na)+: m/e 814.34278; Found: m/e 814.34649.
Tetrapeptide 185
(1) Et2NH, MeCN 
(2) Collidine, -20°C  
then BOPCI
NFmoc
Me
Me'
NFmoc
ZN NHNHBoc Me
Me'
64
Z N ' NHNHBocOH
(67%, 2 steps)
OBn
156
To dipeptide 156 (2.0 g, 2.52 mmol) in dry MeCN (20 mL) was added at rt under N2l 
Et2NH (9.2 mL, 88.4 mmol). The reaction mixture was stirred at rt under N2 for 30 min and 
concentrated in vacuo. The crude residue was co-evaporated from benzene. Dipeptide 64 (1.6
g, 2.41 mmol) in dry CH2CI2 (4.2 mL) at rt under N2 was cooled at -10 °C and dry collidine (0.62 
mL, 5.55 mmol) followed by BOP-CI (0.737 g, 3.03 mmol) were added. The reaction mixture 
was stirred at -10 °C for 20 min and a solution of the deprotected amine in dry CH2CI2 (5.0 mL) 
was added at -10 °C. The reactants were allowed to stir at -10 °C for 20 min and at 0 °C for 2.5
h. The reaction mixture was diluted with EtOAc (80 mL), washed with 0.5 M aq. HCI (2 x 40 mL), 
5% aq. NaHC03 (2 x 40 mL) and brine (40 mL). The organic layer was dried over MgS04, 
filtered and concentrated in vacuo. The product was purified by Si02 flash chromatography 
(gradient elution 3:1 to 1:2 petrol:EtOAc) to afford tetrapeptide 185 as a white foam (2.07 g, 
67%, 2 steps).
[a]D - 25.8° (c 0.69, CH2CI2).
IR (neat) 3290 (br), 2974 (m), 1716 (S), 1666 (s), 1499 (m), 1456 (m), 1392 (m), 1242 (s), 1161 
(s), 1124 (w), 1078 (w), 999 (w), 735 (m), 700 (m).
1H-NMR (500 MHz, CDCI3, 298K) 5 9.84 (br), 9.62 (br), 7.76-7.10 (m, br), 6.73 (m, br), 5.60-
4.70 (m, br), 4.58-3.86 (m, br), 3.70-2.59 (m, br), 2.28 (m, br), 2.12 (m, br), 2.02 (m, br), 1.88- 
1.68 (m, br), 1.42 (s), 1.39-1.32 (m, br), 1.24 (m, br).
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13C-NMR (125 MHz, CDCI3i 298K) 5 172.3, 169.8, 168.7, 164.0, 158.7, 155.7, 154.5, 154.1,
143.7, 143.1, 141.2, 137.9,136.4, 135.9, 135.2, 134.7, 128.4, 128.2, 127.7, 127.4, 127.2, 127.0,
125.0, 119.9, 80.9, 78.5, 70.5, 69.7, 68.5, 67.4, 57.5, 57.0, 56.0, 52.8, 52.1, 49.7, 46.7, 45.2,
43.9, 35.0, 32.1, 29.8, 28.0, 26.9, 24.0, 23.7, 18.8, 18.4, 15.6, 13.9.
FAB (+) HRMS: Calcd. for CeyH^NaNaOu: (M+Na)+: m/e 1237.52219; Found: m/e 1237.52395.
Tetrapeptide 186
NFmoc NH
Me Me
Et2NH. MeCN
rt, 15 min 
(97%)
Me' Me’
ZN NHNHBoc ZN NHNHBoc
OBn OBn
185 186
To tetrapeptide 185 (1.90 g, 1.56 mmol) in dry MeCN (15 mL) under N2 was added 
Et2NH (5.7 mL, 54.7 mmol) and the reaction mixture was stirred at rt for 25 min and 
concentrated in vacuo. The crude residue was purified by Si02 flash chromatography (gradient 
elution 4:1 to 0:1 petrol:EtOAc) to afford tetrapeptide 186 as a white foam (1.5 g, 97%).
[a]D - 35.3° (c 0.43, CH2CI2).
IR (neat) 3284 (br), 2935 (w), 1701 (s), 1653 (s), 1452 (m), 1406 (m), 1364 (w), 1310 (w), 1259 
(m), 1161 (m), 1122 (w), 1083 (w), 744 (m), 700 (m).
1H-NMR (500 MHz, CDCI3, 298K) 5 9.80 (br), 9.61 (br), 8.58 (br), 7.36-7.15 (m, br), 6.18 (br),
6.0 (br), 6.73 (m, br), 5.45-4.85 (m, br), 4.50-3.80 (m, br), 3.70-2.59 (m, br), 2.30-1.67 (m, br), 
1.52-1.20 (m, br).
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13C-NMR (125 MHz, CDCI3) 298K) 6 174.0, 173.2, 172.6, 169.7, 169.2, 168.8, 158.7, 155.7,
155.0, 154.6, 137.9, 137.6, 136.5, 136.2, 135.2, 134.2, 133.5, 129.4, 129.0, 128.6, 128.4,
128.2, 127.9, 127.4, 127.2, 80.9, 78.7, 69.7, 67.2, 56.5, 52.5, 51.2, 46.8, 45.0, 31.6, 30.0, 29.5,
28.0, 26.8, 23.0, 15.8, 14.5, 13.9.
FAB (+) HRMS: Calcd. for C52H64N8Na012: (M+Na)+: m/e 1015.45412; Found: m/e 1015.46087.
Depsipeptide 131
(1 )(C 0 C I)2 
(2) AgCN,C6H(
NZ NHTroc 
if = Me
Bn<
NH
HO NZMe
Me
MeMe ,0  BocHN
Me OBnMe -MeBocHN 186 ZN NHNHBocOBn
Me'157
OBnZN NHNHBoc
187
OBn 
(81 %, 2 steps)
To acid 157 (303 mg, 0.49 mmol) in dry C6H6 (1.5 mL) at rt under N2 was added (COCI)2 
(1.5 mL, 17.2 mmol). The reaction mixture was stirred at rt under N2 for 2.5 h and concentrated 
in vacuo. The resulting oil was co-evaporated from benzene. To the residue was added a 
solution of tetrapeptide 186 (600 mg, 0.49 mmol) in dry C6H6 (4.6 mL) at rt under N2. AgCN (106 
mg, 0.79 mmol) was then added in one portion. The reaction vessel was fitted with a reflux 
condenser and immersed for 10 min in an oil bath pre-heated to 80°C. The reaction mixture was 
then cooled, diluted with EtOAC and filtered through Celite®, the Celite® was then washed with 
EtOAc. The filtrate was concentrated in vacuo and the product purified by Si02 flash 
chromatography (gradient elution 4:1 to 1:3 petrol:EtOAc) to afford depsipeptide 187 in the form 
of two isomers 187a (339 mg, 43%) and 187b (375 mg, 48%).
[a]D - 42.5° (c 0.59, CH2CI2)
[a]D -12.3° (c 0.60, CH2CI2)
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IR (neat) 3288 (br), 2974 (m), 1716 (S), 1666 (s), 1499 (m), 1456 (m), 1392 (m), 1242 (s), 1161
(s), 1124 (w), 1078 (w), 999 (w), 735 (m), 700 (m).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.43-7.15 (m, br), 5.69 (m, br), 5.43-4.91 (m, br), 4.76-4.07 
(m, br), 3.64 (m, br), 3.54 (m, br), 3.20-3.03 (m, br), 3.02 (s), 2.95-2.70 (m, br), 2.03 (m, br), 
1.65 (d, br, J = 6.9 Hz), 1.40 (s), 1.39 (s), 1.34 (s), 1.25-1.12 (m, br), 0.88 (m).
13C-NMR (125 MHz, CDCI3, 298K) 5 171.9, 171.0, 170.0, 168.6, 157.9, 156.3, 156.0, 155.7,
155.2, 154.6, 154.0, 153.3, 138.0, 137.7, 135.8, 134.4, 128.4, 128.3, 127.5, 127.3, 81.2, 79.9,
78.8, 74.7, 70.6, 69.8, 68.8, 68.4, 58.2, 52.4, 51.1, 50.1, 48.4, 47.2, 45.6, 30.5, 28.7, 28.1, 24.5,
19.7, 17.3, 16.7, 16.5, 16.2, 15.9, 15.7, 13.9.
The two compounds obtained were analysed separately by Mass Spectroscopy
FAB (+) HRMS: Calcd. for CyyClsHgyN^NaC^o: (M+Na)+: m/e 1609.58436; Found: m/e
1609.59520.
FAB (+) HRMS: Calcd. for CyyClaHgyN^NaOzo: (M+Na)+: m/e 1609.58436; Found: m/e 
1609.59929.
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Cyclodepsipeptide 436
NZ NHTroc NZ NHTroc
YVCeMe-, / N
1  c ,M e
(1 )C F 3 C 02H ,C H 2 Cl2, 0°C, 2 h  
(2) NBS, THF/H2 0 , rt, 2 h
OBn
OBn
187 436
To depsipeptide 187 (1.45 g, 0.912 mmol) in dry CH2CI2 (14.1 mL) at 0 °C under N2 was 
added in one portion CF3C 02H (14.1 mL, 182 mmol). The reaction mixture was stirred for 2 h at 
0 °C, concentrated in vacuo, co-evaporated from toluene (2 x 10 mL) to remove the excess 
CF3C 02H. T o the residue in THF (10.2 mL) and H20  (10.2 mL) was added NBS (0.32 g, 1.82 
mmol) portionwise over 10 min. The reaction mixture was stirred at rt for 2 h, diluted with EtOAc 
(50mL) and washed with brine (50 mL). The organic layer was dried over MgS04, filtered and 
concentrated in vacuo to give a white foam. To a suspension of HATU (3.47 g, 9.12 mmol) in 
dry CH2CI2 (1 L) at 0°C and under N2 was added dropwise over 5 h, a solution of the above 
crude product and A/-ethylmorpholine (1.56 mL, 12.3 mmol) in dry CH2CI2 (1 L). The reaction 
mixture was stirred at rt for 60 h. The reaction mixture was concentrated in vacuo and the yellow 
residue dissolved in EtOAc (500 mL), washed with 1M aq. HCI (2 x 150 mL), 5% aq. NaHC03 (2 
x 150 mL) and brine (150 mL). The organic layer was dried over MgS04, filtered and 
concentrated in vacuo. The crude residue was purified by Si02 flash chromatography (gradient 
elution 4:1 to 1:2 petrol:EtOAc) but no product could be isolated.
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9. Toward the Synthesis of (+)-Allopumiliotoxin 339A
Aldehyde 342
TsCI, DMAP PCC
NEt3, C H 2CI2 c h 2c i2
1 ,4-butanediol 344 345 342
To a 250-mL round-bottomed flask were added 1,4-butanediol (20 g, 0.222 mol, 7.7 eq), 
NEt3 (4.2 mL, 0.0303 mol, 1.05 eq), DMAP (128 mg, 0.04 eq) and recrystallised TsCI (5.50 g, 
0.0288 mol, 1 eq). The reaction mixture was stirred at rt for 1.5 h before being added to a 
separating funnel containing CH2CI2 (160 mL) and HCI (8 mL of 37% HCI and 112 mL of H20). 
The aqueous layer was extracted with CH2CI2 (100mL), combined organic layers were washed 
with water, dried (MgS04), and concentrated in vacuo. To the crude oil in CH2CI2 (600 mL) was 
added PCC (6.21 g, 0.0288 mol, 1 eq). The reaction mixture was stirred at rt for 2.5 h and 
concentrated in vacuo. The obtained slurry was very rapidly purified by S i02 flash 
chromatography (gradient elution 6:1 to 3:1 petrol:EtOAc); the unstable aldehyde 342 was 
obtained as a yellow oil. Aldehyde 342, which was not characterised any further, was used 
immediately for the next step as described below.86
Alkene 341
OEt TsO-O OEtC H 2CI2 
(21 %, 3 steps) Me342 341
To aldehyde 342 in CH2CI2 (30 mL) was added carbethoxyethylidene 
triphenylphosphorane (10.44 g, 0.0288 mol, 1 eq). The reaction mixture was stirred at rt for 20 h 
and concentrated in vacuo. The crude residue was purified by Si02 flash chromatography 
(gradient elution 10:1 to 6:1 petrol:EtOAc) to afford alkene 341 as a yellow oil (1.95 g, 21 % 
over 3 steps).
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IR (neat film) 2982 (m), 1707 (s), 1649 (m), 1599 (m), 1447 (m), 1364 (s), 1267 (s), 1176 (s), 
1134 (m), 1097 (m), 1007 (w), 932 (m), 816 (m), 744 (m) 663 (s) 577 (m), 555 (s).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.71 (ddd, J = 8.4, 3.7, 2.0 Hz, 2 H, Ph ), 7.28 (d, J = 8.5 
Hz, 2 H, Ph ), 6.54 (tq, J = 7.5, 1.3 Hz 1 H, HC=C), 4.10 (q, J = 7.2 Hz, 2 H, OChh), 3.97 (t, J =
6.2 Hz, 2 H, H3), 2.38 (s, 3 H, CH3-Ar), 2.14 (dd, J = 14.2, 7.4 Hz, 2 H, H1), 1.73 (m, 2 H, H2),
1.71 (s, 3 H, CH=CCH3), 1.21 (s, 3 H, OCH2CH3).
13C-NMR (125 MHz, CDCI3, 298K) 6 167.6 (C=0), 144.7 (C Ar), 139.3 (CH=C), 132.5 (C Ar),
129.7 (CH Ar), 129.0 (C(CH3)), 127.7 (CH Ar), 69.5 (C3), 60.3 (OCH2CH3), 27.6 (C1), 24.3 (C2),
21.4 (CH3-Ar), 14.1 (C=C(CH3)), 12.2 (OCH2CH3).
FAB (+) HRMS: Calcd. for Ci6H22Na05S : (M+Na)+: mle 349.10856; Found: m/e 349.10794. 
Alkene 348
DIBAL-H
346
4-bromobutyronitrile
Et20 , 0°C to rt
347
Ph* W
Me OEt----------------- i
CH2CI2 
(61 %, 2 steps)
OEt
348
To a three-necked, round-bottomed flask, equipped with an addition funnel and 
containing 4-bromobutyronitrile 346 (20 g, 13.51 mL, 0.135 mol) and ether (135 mL) was added 
dropwise over 0.5 h at 0 °C a solution of DIBAL-H (1 M in hexane, 175 mL, 0.175 mol). The 
mixture was stirred at 0 °C for 2 h and at rt for 0.5 h, and then was slowly added to a precooled 
(0 °C) 10% aq. H2S04 (250 mL). The resulting solution was stirred for 1 h and extracted with 
Et20  (2 x 250 mL). The combined organic layers were washed with water and brine, dried 
(MgS04), and concentrated in vacuo (water bath at 28 °C, aldehyde 347 is volatile). To the 
crude oil in CH2CI2 (135 mL) was added carbethoxyethylidene triphenylphosphorane (48.9 g, 
0.135 mol, 1 eq). The reaction mixture was stirred at rt for 20 h, concentrated in vacuo and the 
crude residue was purified by Si02 flash chromatography (gradient elution 30:1 to 10:1 
petrol:EtOAc) affording the title compound 348 as a yellow oil (19.29 g, 61 % over 2 steps).88
IR (neat film) 3402 (w), 2978 (m), 1713 (s), 1651 (m), 1443 (m), 1365 (w), 1280 (br), 1111 (m).
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1H-NMR (500 MHz, CDCI3, 298K) 5 6.68 (tq. J = 7.4, 1.3 Hz, 1 H, HC=C), 4.17 (q, J = 7.2 Hz, 
2 H, CHjO), 3.40 (t, J = 6.5 Hz, 2 H, H3), 2.33 (ddd, J = 14.7, 7.5, 0.6 Hz, 2 H, H1), 1.99 (m, 
2 H, H2), 1.84 (s, 3 H, CH=CCH3), 1.30 (t, J = 7.2 Hz, 3 H, CH3CH20).
13C-NMR (125 MHz, CDCI3, 298K) 6 168.0 (C=0), 139.6 (HC=C), 129.3 (CH=C), 60.5 (CH20),
33.0 (C3), 31.4 (C2), 27.0 (C1), 14.3 (CH3CH20) 12.5 (CH=CCH3).
FAB (+) HRMS: Calcd. for C9BrH15Na02: (M+Na)+: m/e 257.01531; Found: m/e 257.01563.
Alcohol 357
(DHQ)2PHAL (5 mol %) 
K2 0 s0 2 (0 H )4  (4 mol %) 
BnOCONH2 (3.1 eq) biz + BnOCONHOEt 'OEtNaOH (3 eq) 
f-BuOCI (3 eq) 
MeCN /H 20  (1:1)
Me Me OH
345 357
To benzylcarbamate (940 mg, 6.2 mmol) in MeCN (5 mL) at rt was added a freshly 
prepared solution of NaOH (0.244 g of NaOH in 10 mL of water) followed by a freshly prepared 
solution of terf-butylhypochlorite (0.66 mL, 6.10 mmol). Then a solution of the ligand 
(DHQD)2PHAL (77 mg, 0.059 mmol) in MeCN (5 mL) was added followed by olefin 347 (500 
mg, 2.00 mmol) and the osmium catalyst. (29 mg, 0.079 mmol). The reaction mixture was 
stirred at rt for 24 h and did not go to competion according to TLC analysis. It was then 
quenched with saturated sodium sulfite (10 mL). The two phases were separated and the 
aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic extracts were 
washed with brine (20 mL), dried (MgS04) and concentrated. Purification by chromatography 
(gradient elution petrol:EtOAc 30:1 to 20:1) provided 357 contaminated by benzylcarbamate 
(100 mg). The mixture which was not characterised any further was used directly for the next 
step as described below.
150
Alcohol 362
n o 2HZ
NaHC03, 2,4-DNPF
CH2 CI2, H20, EtOH 
rt, overnight
q H OEt EtOH, rt, 
overnight
OH OEt361367 362
To a mixture of alcohol 357 and benzylcarbamate (100 mg) in EtOH (10 mL) under N2 
was added Pd(OH)2 (20% wet, 10 mg). The flask was purged and the N2 balloon was replaced 
by a H2 balloon. The mixture was stirred rigorously for 20 h. The suspension was filtered through 
a pad of Celite® and the solvent concentrated in vacuo. To the crude residue in CH2CI2 (1 mL), 
H20  (1 mL), and EtOH (2 mL) was added NaHC03 (250 mg, 3 mmol) and dinitrofluorobenzene 
(0.38 mL, 3 mmol). The reaction mixture was stirred at rt overnight and extracted with EtOAc. 
The combined organic layers were dried (MgS04) and filtered. The solvent was then removed in 
vacuo and the crude residue was purified by Si02 flash chromatography (gradient elution 20:1 to 
5:1 petrol:EtOAc) affording 362 as a yellow oil (55 mg).
1H-NMR (500 MHz, CDCI3, 298K) 5 8.69 (d, J = 2.7 Hz, 1 H, Ar), 8.10 (dd, J = 9.5, 2.7 Hz, 1 H, 
Ar), 7.22 (d, J = 9.5 Hz, 1 H, Ar), 4.60 (t, J = 7.2 Hz, 1 H, CH-N), 3.92 (dd, J = 14.3, 7.2 Hz, 1 H, 
CH2-O), 3.82 (dd, J = 14.3, 7.2 Hz, 2 H, CHj-O), 3.58 (td, J = 10.4, 6.4 Hz, 1 H, H3), 2.73 (m, 1 
H, H3), 2.20 (m, 2 H, H1), 2.05 (m, 1 H, H2), 1.71 (m, 1 H, H2), 1.39 (s, 3 H,CCH3), 1.13 (t, 3 H, 
CH3CH20).
13C-NMR (125 MHz, CDCI3, 298K) 5 174.8 (C=0), 147.4 (Ar), 137.1 (A r), 136.9 (Ar), 126.8 (Ar),
123.7 (Ar), 117.8 (Ar), 68.1 (CHN), 64.1 (CH2-0), 62.3 (C3), 25.5 (C1), 25.1 (C2), 21.9
(C(CH3)), 13.7 (CH3CH20).
FAB (+) HRMS: Calcd. for C15H19NaN30 7: (M+Na)+: m/e 376.11206; Found: m/e 376.11254.
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Tetrahydrofuran 366
(DHQ)2PHAL (10 mol %)
0  K2 0 s0 2 (0 H) 4 ( 8  mol %) / - " 0  O /■"■ NZ O
B r 'v ^ . X  BnOCONH2 (3.1 eq) 2 <^ V ^ O E t  ------------------------- -- ^ OEt
Me NaOH (3 eq) 1 
Me f-BuOCI (3 eq) Me OH Me OH
346 MeCN / H20  (3:2) 366 357
To benzylcarbamate (1.99 g, 13.2 mmol) in MeCN (17 mL) at rt was added a freshly 
prepared solution of NaOH (0.50 g of NaOH in 20 mL of water) followed by freshly prepared 
terf-butylhypochlorite (1.43 g, 13.0 mmol). Then a solution of the ligand (DHQD)2PHAL (0.33 g, 
0.425 mmol) in MeCN (17 mL) was added followed by olefin 345 (1 g, 4.25 mmol) and the 
osmium catalyst (0.125 g, 0.340 mmol). The reaction mixture was stirred at rt for 20 h and 
quenched with saturated sodium sulfite. The two phases were separated and the aqueous 
phase was extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with 
brine (20 mL), dried (MgS04) and concentrated in vacuo. Extensive purification by S i02 flash 
chromatography (gradient elution 30:1 to 10:1 petrol:EtOAc) followed by preparative 
chromatography provided the nearly pure dihydroxylated product 366 in order to carry out 
analysis.
Data for 366: IR (neat film) 3510 (m), 2982 (s), 2878 (m), 1736 (s), 1454 (w), 1373 (w), 1259 
(m), 1203 (m), 1136 (m), 1072 (m), 1024 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 4.17 (qd, J = 10.7, 7.0 Hz, 2 H, ChbO), 4.02 (t, J = 7.0 Hz 1 
H, CH-O), 3.77 (m, 1 H, H3), 3.69 (m, 1 H, H3), 3.14 (br, 1 H, OH), 1.83 (m, 4 H, H1, H2), 1.22 
(s, 3 H, CCH3) 1.21 (t, J=  7.0 Hz, 3 H, CH3CH20).
13C-NMR (125 MHz, CDCI3, 298K) 6 175.6 ((OEt)-C=0), 82.9 (CH-O), 75.6 (CH3COH), 69.2 
(C3), 61.6 (CH20), 26.0 (C1), 25.1 (C2), 21.4 (HO-CCH3), 13.9 (CH3CH20).
FAB (+) HRMS: Calcd. for C9H170 4: (M+H)+: mie 189.11268; Found: mle 189.11286.
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Improved procedure for Sharpless Asymmetric Aminohydroxylation93 
Alcohol 357
•
(DHQ)2PHAL (6 mol %)
n  K20 s0 2(0 H )4 (5mol %) r-Nz. O
B r \ ^ J I  BnOCONH2 (3.1 eq) \
I NaOH (3 eq) 
Me NBuOCI (3 eq)
Me OH
345 M e C N /H 20  (3:2) 357
To benzylcarbamate (11.15 g, 73.8 mmol) in MeCN (90 mL) at rt was added a freshly 
prepared solution of NaOH (2.9 g of NaOH in 112 mL of water, 72 mmol) followed by freshly 
prepared te/f-butylhypochlorite91 (7.87 g, 72 mmol). Then a solution of the ligand (DHQ)2PHAL 
(1.11 g, 1.4 mmol) in MeCN (90 mL) was added (It is important that the ligand be completely 
dissolved in MeCN) and the reaction mixture was cooled to 0 °C. Then olefin 345 was added 
(5.6 g, 23.8 mmol) followed by the osmium catalyst that was added by portion over 20 min 
(0.439 g, 1.19 mmol). The reaction mixture was stirred at 0 °C for 30 min and at rt for 2 h and 
quenched with saturated sodium sulfite (150 mL). The two phases were separated and the 
aqueous phase was extracted with EtOAc (3 x 100 mL). The combined organic phases were 
washed with brine (150 mL), dried (MgS04) and concentrated in vacuo. Purification by Si02 
flash chromatography (gradient elution 30:1 to 20:1 petrol:EtOAc) provided alcohol 357 
contaminated by some excess benzylcarbamate. Intermediate 357 was not characterised any 
further and was used immediately for the next step described below.
Alcohol 375
NBoc O
2
OEt
Me OH 
357
Me OH 
375
To a mixture of the alcohol 357 contaminated by some benzylcarbamate (7.8 g) in EtOH 
(100 mL) under N2 was added Pd/C (10% wet, 2.0 g) and Boc20  (7.3 g, 35.7 mmol). The flask 
was purged and the N2 balloon was replaced by a H2 balloon. The mixture was stirred rigorously 
overnight. The suspension was filtered through a pad of Celite® and the solvent concentrated in 
vacuo. The resulting oil was purified by Si02 flash chromatography (gradient elution 20:1 to 10:1 
petrol:EtOAc) affording the title compound 375 as a colorless oil (1.05 g, 15 % over 2 steps).94
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[a]D- 16.8° (c 0.34, CH2CI2).
IR (neat film) 3512 (m), 3342 (w), 2978 (s), 1730 (s), 1697 (s), 1454 (w), 1392 (s), 1257 (m), 
1171 (s), 1119 (m), 1078 (w), 1024 (w).
1H-NMR (500 MHz, CDCI3, 298K) 6 4.54 (br, 1 H, OH), 4.19 (m, 1 H, Ch^O), 4.14 (m, 1H, 
N-CH), 4.09 (m, 1 H, ChhO), 3.50 (br, 1 H, H3), 3.20 (m, 1 H, H3), 1.86 (m, 3 H, H2, H1), 1.67 
(m, 1 H, H2), 1.39 (s, 9 H, C(CH3)3), 1.27 (s, 3 H, CCH3) 1.20 (t, J=  7.0 Hz, 3 H, CH3CH20).
13C-NMR (125 MHz, CDCI3, 298K) 5 175.1 (COOEt), 156.3 (0=C-0(C(CH3)3), 80.0 (C(CH3)3),
77.2 (CH3COH), 63.3 (CHNH), 61.7 (CH20), 48.0 (C3), 28.3 (C(CH3)3), 26.8 (C1), 24.4 (C2),
20.6 (HO-CCH3), 14.0 (CH3CH20).
FAB (+) HRMS: Calcd. for C44H49N5Na0 9: (M+Na)+: mle 310.16303; Found: mle 310.16196. 
Mixture of 376 and 377
NBoc
Me OH
OEt
NaH, BnBr
n-(Bu)4 NI, CH2CI2  
0°C, 3 h
. X
■CH
1 H Me 
376
C 0 2Et
, I
>CH
H MeC° 2Bn 
377
To a solution of 375 (100 mg, 0.311 mmol) in THF (1.5 mL) at 0 °C under N2 was added 
NaH (60% suspension in oil, 12.5 mg, 0.311 mmol). After 10 min at 0 °C, r?-(Bu4)NI (11.5 mg, 
0.031 mmol) was added followed by BnBr (0.040 mL, 0.311 mmol). The reaction was warmed to 
rt and stirred for 3 h. It was then slowly quenched with water (3 mL) and extracted with EtOAc 
(3x10 mL). The resulting oil was purified by Si02 flash chromatography (gradient elution 10:1 
to 2:1 petrol:EtOAc) affording an inseparable mixture of 376 and 377 (55 mg) in proportion 2:1.
1H-NMR (500 MHz, CDCI3, 298K) 376 5 7.37-7.31 (m, 5 H, Ar), 5.24 (d, J = 12.4 Hz, 1 H, 
PhCHzO ), 5.21 (d, J=  12.4 Hz, 1 H, PhCHzO), 3.96 (m, 1 H, CH-N), 3.63 (m, 1 H, H3), 3.18 (m, 
1 H, H3), 2.07 (m, 1 H, H2), 2.07 (m, 2 H, H2, H1), 1.58 (s, 3 H, CCH3), 1.50 (m, 1 H, H1); 377 5 
4.25 (qd, J = 7.1 Hz, 2 H, OCHzCHa), 3.96 (m, 1 H, CH-N), 3.63 (m, 1 H, H3), 3.18 (m, 1 H, H3),
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2.07 (m, 1 H, H2), 2.07 (m, 2 H, H2, H1), 1.58 (s, 3 H, CCH3), 1.50 (m, 1 H, H1), 1.30 (t, J =
12.4 Hz, 3 H, CH3CH20).
13C-NMR (125 MHz, CDCI3, 298K) 5 172.1, 171.8 (C=0), 160.2, 160.1 (C=0), 134.9, 128.7,
126.6, 128.1 (Ar), 80.2, 67.8 (PhCH20), 66.2, 66.1 (CHN), 62.4 (0-CH2CH3), 46.0 (C3), 26.1 
(C1), 24.9 (C2), 19.2 (C(CH3)), 14.0 (CH3CH20).
Alcohol 384
385
Pd2(dba)3CHa3 
Et3B, PMBOH 
(S.g-L,
CH2CI2 , rt, 1 2 h 
6 8 %, 82%ee ^ J ) - p p h 2  Ph2 p - n f  }
384
386
Ligand (’S.SJ-L.)
To a 2 L round bottomed flask containing (dba)3Pd2.CHCI3 (0.749 g, 0.723 mmol), chiral 
ligand (S.S)-!^ 386 (1.5 g, 2.17 mmol) and PMB-OH (9.05 mL, 72.3 mmol) was added dry 
CH2CI2 (720 mL) at rt under N2. The resulting dark purple mixture was stirred at rt until it turned 
a deep orange color (roughly 15 min). Triethylborane (1 M solution in THF, 0.723 mL, 0.723 
mmol) was added followed by 2-methyl-2-vinyloxirane 385 (8.04 mL, 72.3 mmol). The reaction 
mixture was stirred for 20 h. The solvent was removed in vacuo and the crude product was 
purified by Si02 flash chromatography (gradient elution 30:1 to 10:1 petrol:EtOAc) affording 
alcohol 384 as a yellow oil (11.00 g, 68 %, 82% ee).97
[a]D + 18.1° (c 0.21, CH2CI2).
IR (neat film) 3440 (br), 2933 (br), 1726 (s), 1612 (m), 1514 (s), 1460 (w), 1412 (w), 1379 (w), 
1248 (s), 1174 (w), 1115 (m), 1038 (m), 929 (w), 822 (m), 733 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.23 (d, J = 8.6 Hz, 2 H, Ar), 6.86 (d, J = 8.6 Hz, 2 H, Ar), 
5.90 (dd, J=  17.6, 10.9 Hz, 1 H, CH=CH2), 5.32 (dd, J=  17.5, 1.1 Hz, 1 H, CH=C\^), 5.42 (dd, 
J = 11.0, 1.1 Hz, 1 H, CH=CH2), 4.32 (s, 2 H, O-Chh-Ar), 3.78 (s, 3 H, OCH3), 3.52 (dd, J = 
11.1, 5.0 Hz, 1 H, CHs-OH), 3.45 (dd, J =  11.1, 6.4 Hz, 1 H, Chh-OH), 2.10 (t, J = 6.4 Hz, 1 H, 
OH), 1.36 (s, 3H, CH3).
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13C-NMR (125 MHz, CDCI3i 298K) 5 159.0 (Ar), 139.5 (CH=CH2), 131.0 (Ar), 129.0 (Ar), 117.1 
(CH=CH2), 113.3 (Ar), 78.3 (MeCOPMB), 69.5 (CH2-OH), 65.8 (0-CH2-Ar), 55.2 (OCH3), 18.6 
(CH3).
FAB (+) HRMS: Calcd. for C i3H18Na03: (M+Na)+: mle 245.11536; Found: 245.11588.
Ester 391
(RM+)-MTPA  
DCC. DMAP o r oAxphMe OPMB MeO b F 3
384 391
To alcohol 384 (50 mg, 0.227 mmol) and (R)-(+)-MTPA (53 mg, 0.227 mmol) was 
added at rt under N2, CH2CI2 (0.8 mL) followed by DCC (47 mg, 0.227 mmol) and DMAP 
(2.8 mg, 0.023 mmol). The reaction mixture was stirred at rt overnight but did not go to 
completion according to TLC analysis. The solvent was removed in vacuo and the crude 
product was purified by Si02 flash chromatography (10:1 petrol:EtOAc) to isolate ester 391 
(55 mg, 56%), the faster moving product of the TLC as yellow oil. 19F NMR of the mixture 
showed a 100:10 mixture of diastereoisomers (82% ee).
[a]D + 33.1° (c 0.56, CH2CI2).
IR (neat film) 2947 (m), 2849 (w), 1753 (s), 1612 (w), 1512 (m), 1454 (w), 1379 (w), 1250 (s), 
1175 (s), 1119(m), 1032 (s), 822 (w), 719 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.53 (d, J = 8.0 Hz, 2 H, Ar), 7.36 (m, 1 H, Ar), 7.29 (m, 2 
H, Ar), 7.18 (d, J = 8.7 Hz, 2 H, Ar(PMB)), 6.83 (d, J = 8.7 Hz, 2 H, Ar(PMB)), 5.84 (dd, J = 17.4,
11.4 Hz, 1 H, CH=CH2), 5.32 (dd, J = 11.4, 0.9, 1 H, C H ^hb), 5.29 (dd, J=  17.4, 0.9 Hz, 1 H, 
CH=CH2), 4.39 (d, J=  11.2 Hz, 1 H, CHj-OCO), 4.32 (s, 2 H, OCh^Ar), 4.25 (d, J=  11.2 Hz, 1 
H, CH2-OC=0 ), 3.78 (s, 3 H, ArCH3), 3.52 (s, 3 H, 3FCCOCH3), 1.38 (s, 3 H, CH3).
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13C-NMR (125 MHz, CDCIa, 298K) 6 166.3 (C=0), 158.9 (Ar), 138.9 (CH=CH2) , 132.2 (Ar),
130.9 (Ar), 129.5 (Ar), 128.7 (Ar), 128.3 (Ar), 127.5 (Ar), 117.7 (CH=CH2), 113.7 (Ar), 84.6 (q, 
CF3), 76.4 (MeCOPMB), 70.8 (CH2-0C=0), 65.8 (0-CH2-Ar), 55.4 (OCH3), 55.3 (OCH3), 19.7 
(CH3).
FAB (+) HRMS: Calcd. for C23H25F3Na0 5: (M+Na)+: m/e 451.15517; Found: 461.15438.
Aldehyde 392
Swern
Oxidation Me OPMBMe OPMB
384 392
To a stirred solution of DMSO (19.9 mL, 280 mmol) in dry CH2CI2 (287 mL) at -78° C 
under N2 was added (COCI)2 (12.2 mL, 140 mmol) dropwise over 5 min. The reaction mixture 
was stirred at -78 °C under N2 for 20 min and a solution of alcohol 384 (10.38 g, 46.7 mmol) in 
dry CH2CI2 (97 mL) was added via canula over 15 min. The reaction mixture was stirred at - 
78 °C for 30 min and freshly distilled NEt3 (98.3 mL, 700 mmol) was added dropwise, the 
mixture was allowed to warm to rt over 20 min and was then quenched with brine (150 mL) and 
extracted with CH2CI2 (3 x 100 mL). The combined organic extracts were dried (MgS04), filtered 
and concentrated in vacuo to afford the crude aldehyde 392 which was used without further 
purification.
An analytical sample was purified by Si02 flash chromatography (gradient elution 20:1 to 10:1 
petrol:EtOAc) affording the title compound 392 as a yellow oil.
1H-NMR (500 MHz, CDCI3, 298K) 5 9.49 (s, 1 H, CHO), 7.28 (d, J = 8.7 Hz, 2 H, Ar), 6.87 (d, J 
= 8.7 Hz, 2 H, Ar), 5.81 (dd, J = 17.6, 10.8 Hz, 1 H, CH=CH2), 5.46 (dd, J = 17.6, 0.9 Hz, 1 H, 
CH=CH2), 5.42 (dd, J = 10.8, 0.9 Hz, 1 H, CH=CFb), 4.46 (d, J = 10.8 Hz, 1 H, CFh-O), 4.40 (d, 
J=  10.8 Hz, 1 H, CHj-O), 3.79 (s, 3 H, OCH3), 1.45 (s, 3 H,CH3).
13C-NMR (125 MHz, CDCI3, 298K) 6 200.7 (CHO), 159.3 (Ar), 135.5 (CH=CH2), 130.2 (Ar),
129.3 (Ar), 119.1 (CH=CH2), 113.9 (Ar), 83.4 (MeCOPMB), 65.8 (CH2-0), 55.3 (OCH3), 18.7 
(CH3).
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FAB (+) HRMS: Calcd. for C13H16Na03: (M+Na)+: mle 243.09971; Found: m/e 243.09876.
Acid 393
NaCI02, NaH2P 04 
/-BuOH, H20
2-methyl-2-butene 
rt, 2h
OH 
Me' OPMB
392 393
To the crude aldehyde 392 (46.7 mmol) in f-BuOH (140 mL) and 2-methyl-2-butene, 
were added simultaneously over 15 min at rt a solution of NaCI02 (12.7 g, 140 mmol) and a 
solution of NaH2P04 (16.79 g, 140 mmol) in water (140 mL). The reaction mixture was stirred at 
rt for 2 h, then diluted with sat. aq. NH4CI (100 mL) and extracted with EtOAc (3 x 100 mL). The 
combined organic extracts were dried (MgS04), filtered and concentrated in vacuo to afford the 
crude carboxylic acid 393 which was used without further purification. An analytical sample was 
purified by Si02 flash chromatography (gradient elution 5:1 to 1:2 petrol:EtOAc) affording the 
title compound 393 as a colorless oil.
[a]D + 11.0° (c 0.63, CH2CI2).
IR (neat film) 3180 (br), 2995 (m), 2943 (m), 1718 (s), 1612 (m), 1514 (s), 1458 (w), 1381 (w),
1248 (s), 1120 (m), 1034 (m), 933 (w), 822 (m).
1H-NMR (500 MHz, CDCI3, 298K) 5 9.96 (s, broad, 1 H, COOH), 7.28 (d, J = 8.7 Hz, 2 H, Ar), 
6.87 (d, J = 8.7 Hz, 2 H, Ar), 6.01 (dd, J = 17.4, 10.7 Hz, 1 H, CH=CH2), 5.49 (dd, J = 17.6, 0.9 
Hz, 1 H, CH=CH2), 5.39 (dd, J = 10.8, 0.9 Hz, 1 H, C H ^hh), 4.47 (d, J=  10.4 Hz, 1 H, CHj-O), 
4.43 (d, J = 10.4 Hz, 1 H, CH2-O), 3.79 (s, 3 H, OCH3), 1.64 (s, 3 H,CH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 176.2 (COOH), 159.3 (Ar), 136.9 (CH=CH2), 129.7 (Ar),
129.4 (Ar), 118.3 (CH=CH2), 113.9 (Ar), 80.4 (MeCOPMB), 66.5 (CH2-0), 55.3 (OCH3), 21.9 
(CH3).
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FAB (+) HRMS: Calcd. for C13H16Na04: (M+Na)+: m/e 237.11268; Found: m/e 237.11215.
Ester 394
o Mel, K2C 0 3 DMF, rt
(80%, 3 steps) OMe
Me OPMB Me OPMB 
394393
To a solution of the crude acid 393 (47.6 mmol) in dry DMF (155 mL) at rt under N2 was 
added K2C03 (32.2 g, 233 mmol) followed by Mel (291 mL, 467 mmol) over 10 min. The 
reaction mixture was stirred at rt for 3 h then quenched by addition of water (100 mL) and 
extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with water (3 x 
100 mL), dried (MgS04) and concentrated in vacuo. Purification by Si02 flash column 
chromatography (gradient elution 30:1 to 20:1 petrol:EtOAc) afforded ester 394 as a yellow oil 
(9.39 g, 80%, 3 steps).
[a]D + 9.54° (c 1.05, CH2CI2).
IR (neat film) 2995 (m), 2851 (m), 2908 (w), 2874 (w), 2837 (w), 1740 (s), 1612 (m), 1514 (s), 
1460 (m), 1381 (w), 1300 (w), 1250 (s), 1201 (w), 1176 (w), 1117 (s), 1034 (m), 935 (w), 824 
(m).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.30 (d, J = 8.7 Hz, 2 H, Ar), 6.85 (d, J = 8.7 Hz, 2 H, Ar),
6.06 (dd, J=  17.4, 10.7 Hz, 1 H, CH=CH2), 5.41 (dd, J=  17.5, 0.9 Hz, 1 H, CH ^Fh), 5.29 (dd, 
J = 10.8, 0.9 Hz, 1 H, CH=CH2), 4.45 (d, J = 10.6 Hz, 1 H, CFk-O), 4.41 (d, J = 10.6 Hz, 1 H, 
CHj-O), 3.77 (s, 3 H, OCH3), 3.76 (s, 3 H, OCH3), 1.58 (s, 3 H,CH3).
13C-NMR (125 MHz, CDCI3, 298K) 6 173.3 (COOCH3), 159.0 (Ar), 138.2 (CH=CH2) , 130.6 (Ar), 
129.1 (Ar), 116.5 (CH=CH2), 113.6 (Ar), 80.5 (MeCOPMB), 66.6 (CH2-0), 55.2 (OCH3), 52.2 
(OCH3), 23.3 (CH3).
FAB (+) HRMS: Calcd. for C14H190 4: (M+H)+: m/e 251.12833; Found: m/e 251.12869.
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Aldehyde 395
i) O3 , CH2CI2 
MeOH
OMe O 'OMe
Me OPMB 
394
ii) Me2S 
(92%)
Me OPMB
395
A mixture of alkene 395 (1.0 g, 4.0 mmol) in CH2CI2 (25mL) and MeOH (1.25 mL) at 
-78 °C was purged with 0 2 for 30 s and 0 3 was bubbled into the flask until the mixture turned 
blue. Residual ozone was flushed out with nitrogen and Me2S (2.22 mL, 40 mmol) was added at 
-78 °C. The reaction mixture was warmed to rt, stirred for 30 min and concentrated in vacuo. 
Purification by Si02 flash column chromatography (gradient elution 7:1 to 2:1 petrol:EtOAc) 
afforded aldehyde 395 as a yellow oil (0.94 g, 92%).
[a]D - 3.16 0 (c 0.28, CH2CI2).
IR (neat film) 3447 (br), 2955 (m), 2841 (w), 1736 (s), 1688 (w), 1606 (m), 1514 (s), 1458 (m), 
1254 (s), 1157 (m, br), 1032 (m), 827 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 9.64 (s, 1 H, CHO), 7.32 (d, J = 8.7 Hz, 2 H, Ar), 6.87 (d, J 
= 8.7 Hz, 2 H, Ar), 4.54 (d,J = 10.4 Hz, 1 H, CHj-O), 4.50 (d, J = 10.4 Hz, 1 H, CH2-O), 3.79 (s, 
3 H, COOCH3), 3.78 (s, 3 H, OCH3), 1.58 (s, 3 H,CH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 197.3 (CHO), 169.6 (COOCH3), 159.5 (Ar), 129.6 (Ar),
129.3 (Ar), 113.9 (Ar), 84.8 (MeCOPMB), 67.8 (CH2-0), 55.3 (OCH3), 52.8 (COOCH3), 18.3 
(CH3).
Cl HRMS: Calcd. for C5H160 5 m/e : 252.09977; Found: 252.09953.
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Sulfinimine 383
396 'p 
f-Bu + NH-
OMe OMeCuS04, THF 
5 days (97%)Me OPMB Me OPMB
395 383
To a solution of aldehyde 395 (1.87 g, 7.4 mmol) in dry CH2CI2 (15 mL) at rt under N2 
was added anhydrous CuS04 (0.90 g, 7.4 mmol) followed by solid (R)-terf-butanesulfinamide 
(0.87 g, 7.4 mmol). The reaction mixture was stirred at rt for 5 days, then filtered through Celite® 
and concentrated in vacuo. The resulting oil (2.56 g) was used in the next step and was not 
purified any further. Therefore, the yield of the formation of sulfinimine 383 was assumed to be 
ca. 97%.100
[a]D - 43.0° (c 0.52, CH2CI2).
IR (neat film) 2955 (m), 1745 (s), 1618 (m), 1514 (s), 1456 (m), 1369 (w), 1250 (s), 1257 (br), 
1032 (w), 827 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 8.17 (s, 1 H, N=CH), 7.28 (d, J = 8.8 Hz, 2 H, Ar), 6.84 (d, J 
= 8.8 Hz, 2 H, Ar), 4.52 (d, J = 10.4 Hz, 1 H, CJi-O), 4.50 (d, J = 10.4 Hz, 1 H, CHj-O), 3.76 (s, 
3 H, OCH3), 3.75 (s, 3 H, OCH3), 1.67 (s, 3 H, CH3), 1.18 (s, 9 H, C(CH3)3).
13C-NMR (125 MHz, CDCI3, 298K) 5 170.8 (COOCH3), 167.1 (N=CH), 159.3 (Ar), 129.6 (Ar),
129.3 (Ar), 113.7 (Ar), 82.4 (MeCOPMB), 67.6 (CH2-0), 57.7 (C(CH3)3), 55.2 (OCH3), 52.5 
(OCH3), 22.4 (C(CH3)3), 21.2 (CH3).
FAB (+) HRMS: Calcd. for C17H25NNa0 5S: (M+Na)+: m/e 378.13511; Found: mle 378.13362.
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Alkene 382
-
9 0 AIIBr, In ?I ^ U THF. 55°C f-Bu"? VNHt r~0 Me (85%)/Me OPMB
Me
OMe
OPMB
383 382
To sulfinimine 383 (200 mg, 562 mmol) in dry THF (1.9 mL) at rt under N2 was added 
Indium (84 mg, 731 mmol) followed by allylbromide (0.098 mL, 731 mmol) after 10 min. The 
reaction vessel was fitted with a reflux condenser and immersed for 40 min in an oil bath pre­
heated to 55 °C. The reaction mixture was then cooled to rt, quenched with water (5 mL) and 
extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried (MgS04) and 
concentrated in vacuo. Purification by Si02 flash column chromatography (gradient elution 5:1 
to 1:1 petrol:EtOAc) afforded alkene 382 as the major product of a mixture of 2 isomers in 
proportion 80/20 (189 mg, 85 %).103
IR (neat film) 3331 (w), 2951 (s), 1742 (s), 1612 (w), 1514 (m), 1462 (m), 1387 (w), 1250 (s), 
1178 (w), 1119 (m), 1072 (s), 1037 (m), 912 (w), 820 (w).
1H-NMR (500 MHz, CDCI3, 298K) Major isomer fS) 6 7.30 (d, J = 8.6 Hz, 2 H, Ar), 6.85 (d, J =
8.6 Hz, 2 H, Ar), 5.71 (m, 1 H, HC=CH2), 4.97 (m, 2 H, H C ^ th ), 4.60 (d, J = 10.3 Hz, 1 H, 
CHa-O), 4.41 (d, J = 10.3 Hz, 1 H, CHa-O), 3.89 (d, J = 8.5 Hz, 1 H, NH), 3.77 (s, 3 H, OCH3), 
3.74 (s, 3 H, COOCH3), 3.53 (dt, J = 9.1, 3.5 Hz, 1 H, CH-NH), 2.29 (m, 1 H, Ch^CH), 2.15 (m, 
1 H, CH^CH), 1.68 (s, 3 H, CH3C), 1.16 (s, 9 H, C(CH3)3); Minor isomer (R) 6 7.27 (d, J = 8.6 
Hz, 2 H, Ar), 6.84 (d, J = 8.6 Hz, 2 H, Ar), 5.94 (m, 1 H, IHC=CH2), 5.09 (m, 2 H, H C ^ tb ), 4.59 
(d, J = 10.3 Hz, 1 H, CHa-O), 4.42 (d, J = 10.3 Hz, 1 H, CHa-O), 3.81 (d, J = 8.6 Hz, 1 H, NH), 
3.77 (s, 3 H, OCH3), 3.68 (s, 3 H, COOCH3), 3.58 (m 1 H, CH-NH), 2.56 (m, 1 H, ChhCH), 2.40 
(m, 1 H, ChbCH), 1.50 (s, 3 H, CH3C), 1.12 (s, 9 H, C(CH3)3).
13C-NMR (125 MHz, CDCI3, 298K) Major isomer (S) 6 173.8 (COOCH3), 159.1 (Ar), 135.4 
(HC=CH2), 130.5 (Ar), 129.2 (Ar), 117.3 (HC=CH2), 113.6 (Ar), 82.1 (MeCOPMB), 66.5 (CH2- 
O), 63.5 (CH-NH), 56.8 (C(CH3)3), 55.2 (OCH3), 52.1 (COOCH3), 37.1 (CH3C), 22.9 (C(CH3)3),
20.0 (CH3) Minor isomer (R) 5 173.3 (COOCH3), 159.0 (Ar), 134.8 (HC=CH2), 130.6 (Ar), 128.9
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(Ar), 118.0 (HC=CH2), 113.6 (Ar), 82.9 (MeCOPMB), 66.3 (CH2-0), 63.0 (CH-NH), 56.2 
(C(CH3)3), 55.2 (OCH3), 51.8 (COOCH3), 35.8 (CH3C), 22.6 (C(CH3)3), 19.1 (CH3).
FAB (+) HRMS: Calcd. for C20H31NNaO5S: (M+Na)+: m/e 420.18205; Found: m/e 420.18129.
Alcohol 403
Me OPMB
f-Bu
i)B Hr THF 
THF, 2h
ii) H2 0 2 ,Et0H 
Buffer 7, 1 h 
(40%, 2 steps)
HO
Me OPMB
382 403
To alkene 382 (180 mg, 0.453 mmol) in dry THF (2.26 mL) was added a BH3-THF 
solution (1 M in THF, 0.22 mL, 0.226 mmol) at rt under N2 . The resulting solution was stirred at 
rt for 1.5 h and EtOH (0.9 mL), a pH 7 buffer solution (0.9 mL) and H20 2 (30% in water, 0.9 mL) 
were added. (The pH 7 buffer was made by dissolving 2 g of NaOH pellet in 1 L of water and by 
adding 6.8 g of KH2P04) The mixture was stirred for 1.5 h at rt, quenched slowly at 0 °C with 
sat. aq. Na2S20 3 (5 mL) and extracted with EtOAc ( 3x 10  mL). The combined organic extracts 
were dried (MgS04) and concentrated in vacuo. Purification by S i02 flash column 
chromatography (gradient elution 5:1 to 1:3 petrol:EtOAc) afforded alcohol 403 as a white foam 
(88 mg, 40 %, 2 steps).
[a]D + 8.5° (c 1.01, CH2CI2).
IR (neat film) 3333 (br), 2947 (s), 2908 (s), 2874 (s), 2837 (s), 1740 (s), 1612 (m), 1514 (s), 
1460 (w), 1381 (w), 1300 (w), 1259 (s), 1202 (w), 1177 (w), 1117 (m), 1034 (m), 933 (w), 823.5 
(w).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.27 (d, J = 8.7 Hz, 2 H, Ar), 6.84 (d, J = 8.7 Hz, 2 H, Ar), 
4.57 (d, J = 10.3 Hz, 1 H, CH2-O), 4.40 (d, J = 10.3 Hz, 1 H, CFh-O), 3.89 (d, J = 8.5 Hz, 1 H, 
NH), 3.76 (s, 3 H, OCH3), 3.74 (s, 3 H, COOCH3), 3.54 (m, 2 H, H3), 3.42 (td, J=  10.9, 2.6 Hz, 
1 H, CH-NH), 1.88 (s br, 1 H, OH), 1.69 (m, 1 H, H1), 1.65 (s, 3 H, CH3), 1.63 (m, 1 H, H2), 1.44 
(m, 2 H, H1, H2), 1.18 (s, 9 H, C(CH3)3).
163
13C-NMR (125 MHz, CDCI3, 298K) 6 173.7 (COOCH3), 159.2 (Ar), 130.4 (Ar), 129.3 (Ar), 113.7 
(Ar), 82.5 (MeCOPMB), 69.4 (C3), 66.6 (CH2-0), 62.8 (CH-NH), 56.8 (C(CH3)3), 55.2
(COOCH3), 52.2 (OCH3), 37.3 (CH3-C), 28.5 (C2), 26.0 (C1), 22.9 (C(CH3)3), 19.8 (CH3).
FAB (+) HRMS: Calcd. for C2oH3iNna0 6S: (M+Na)+: mle 438.19262; Found: mle 438.23181.
Mesylate 404
f-Bu *  NHt-Bu + NH
MsOHO OMeOMe C H 2CI2, rt 
7 min (99%) Me OPMBMe OPMB
404403
To a solution of alcohol 403 (460 mg, 1.11 mmol) in dry CH2CI2 (3.7 mL) was added 
dropwise CH3S02CI (0.17 mL, 0.22 mmol) and NEt3 (0.77 mL, 5.55 mL). The reaction mixture 
was stirred at rt for 7 min, quenched with water (10 mL) and extracted with CH2CI2 (3x10 mL). 
The combined organic extracts were dried (MgS04) and concentrated in vacuo. Purification by 
Si02 flash column chromatography (gradient elution 3:1 to 1:2 petrol:EtOAc) afforded the title 
compound 404 as a colorless oil (540 mg, 99%).
[a]D - 27.3° (c 0.67, CH2CI2).
IR (neat film) 2963 (s), 1741 (m), 1612 (w), 1514 (w), 1454 (w), 1356 (m), 1259 (s), 1173 (m), 
1101 (s), 1026 (s), 930 (w), 800 (s).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.27 (d, J = 8.7 Hz, 2 H, Ar), 6.84 (d, J = 8.7 Hz, 2 H, Ar), 
4.59 (d, J = 10.3 Hz, 1 H, CH2-O), 4.40 (d, J = 10.3 Hz, 1 H, Chh-O), 4.13 (td, J = 6.07, 0.9 Hz, 
2 H, H3), 3.86 (d, J = 8.4 Hz, 1 H, NH), 3.77 (s, 3 H, OCH3), 3.76 (s, 3 H, OCH3), 3.43 (td, J = 
9.3, 2.9 Hz, 1 H, CH-NH), 2.93 (s, 3 H, CH3-S), 1.92 (m, 1 H, H2), 1.66 (s, 3 H,CH3), 1.63 (m, 2 
H, H2, H1), 1.45 (m, 1 H, H1), 1.17 (s, 9 H, C(CH3)3).
164
13C-NMR (125 MHz, CDCI3i 298K) 6 173.9 (COOCH3), 159.1 (Ar), 130.5 (Ar), 129.3 (Ar), 113.7 
(Ar), 82.5 (MeCOPMB), 66.5 (CH2-0), 63.2 (CH-NH), 62.1 (C3) 56.7 (C(CH3)3), 55.2
(COOCH3), 52.1 (OCH3), 29.5 (C1), 28.6 (C2), 22.9 (C(CH3)3), 19.7 (CH3).
FAB (+) HRMS: Calcd. for C21H35NNa0 8S: (M+H)+: m/e 494.18822; Found: m/e 494.18907.
Ester 405
imidazole 
NaH, THF
t-Bu^¥ NH
2MsO
OMe OMe0oC to rt 
1 h (70%)Me OPMB Me OPMB
405404
To mesylate 404 (367 mg, 0.743 mmol) in THF (2.5 mL) at 0 °C under N2 was added 
imidazole (5 mg, 0.074 mmol) followed by NaH (60% dispersion in oil, 60 mg, 1.490 mmol). The 
reaction mixture was stirred at 0 °C for 15 min and at rt for a further 1 h. The reaction mixture 
was quenched with MeOH (0.3 mL) and water (2 mL) and extracted with Et20  ( 3 x 5  mL). The 
combined organic extracts were dried (MgS04) and concentrated in vacuo. Purification by Si02 
flash column chromatography (gradient elution 3:1 to 1:1 petrol:EtOAc) afforded the title 
compound 405 as a yellow oil (227 mg, 70%).
[a]D + 38.6° (c 0.74, CH2CI2).
IR (neat film) 3442 (s), 2953 (s), 1738 (s), 1612 (w), 1514 (m), 1456 (m), 1383 (w), 1250 (s),
1173 (w), 1120 (m), 1078 (w), 1034 (w), 822 (w).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.30 (d, J = 8.5 Hz, 2 H, Ar), 6.81 (d, J = 8.6 Hz, 2 H, Ar),
4.36 (s, 2 H, CH2-O), 4.03 (dd, J = 8.0, 2.7 Hz, 1 H, CH-N), 3.74 (s, 3 H, OCH3), 3.71 (s, 3 H, 
OCH3), 3.28 (m, 1 H, H3), 3.16 (m, 1 H, H3), 2.01 (m, 1 H, H2), 1.76 (m, 2 H, H2, H1), 1.68 (m, 
1 H, H1), 1.56 (s, 3 H, CH3C), 1.15 (s, 9 H, C(CH3)3).
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13C-NMR (125 MHz, CDCIa, 298K) 6 173.9 (COOCH3), 158.8 (Ar), 130.7 (Ar), 128.9 (Ar), 113.5 
(Ar), 83.4 (MeCOPMB), 66.3 (CH2-0), 64.7 (CH-NH), 58.4 (C(CH3)3), 55.1 (COOCH3), 52.0 
(OCH3), 50.2 (C3), 29.5 (C2), 28.6 (C1), 23.2 (C(CH3)3), 18.5 (CH3).
FAB (+) HRMS: Calcd. for C17H25NNa0 5S: (M+Na)+: m/e 368.18954; Found: m/e 368.19047.
Alcohol 406
-
f-BuN / °  /-Buv / °
<; s
To ester 406 (255 mg, 0.641 mmol) in THF (2.2 mL) at -78 °C under N2 was added 
dropwise a solution of DIBAL-H (1.5 M in toluene, 0.94 mL, 1.28 mmol).104 The reaction mixture 
was stirred at -78 °C for 10 min and at rt for 1 h. A saturated aqueous solution of Rochelle’s salt 
(5 mL) was added followed by Et20  (10 mL). The mixture was stirred at rt for 1 h and extracted 
with Et20  ( 3x10  mL). The combined organic extracts were dried (MgS04) and concentrated in 
vacuo. Purification by S i02 flash column chromatography (gradient elution 4:1 to 1:1 
petrohEtOAc) afforded alcohol 406 as a white foam (212 mg, 89%).
[o ] d + 46.7° (c 0.51, CH2CI2).
IR (neat film) 3391 (br), 2957 (s), 2874 (m), 2874 (s), 1612 (w), 1514 (s), 1462 (m), 1371 (w), 
1300 (w), 1246 (s), 1173 (w), 1121 (w), 1070 (s), 1040 (s), 822 (w).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.25 (d, J = 8.7 Hz, 2 H, Ar), 6.82 (d, J = 8.7 Hz, 2 H, Ar), 
4.53 (d, J = 10.8 Hz, 1 H, CHj-OAr), 4.49 (d, J=10.8 Hz, 1 H, CH^O), 4.19 (dd, J = 8.4, 5.7 Hz, 
1 H, CH-N), 3.80 (dd, J=  12.8 Hz, 1 H, ChbOH), 3.75 (s, 3 H, OCH3), 3.66 (dd, J=  12.8, 9.0 Hz, 
1 H, ChbOH), 3.11 (m, 1 H, H3), 3.04 (m, 1 H, H3), 1.95 (m, 2 H, H1), 1.83 (m, 1 H, H2), 1.70 
(m, 1 H, H2), 1.15 (s, 9 H, C(CH3)3), 1.06 (s, 3 H, CH3).
DIBAL-H, THF
A 0H  
Me OPMBMe OPMB
405 406
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13C-NMR (125 MHz, CDCI3i 298K) 6 158.7 (Ar), 131.5 (Ar), 128.8 (Ar), 113.5 (Ar), 80.2
(MeCOPMB), 64.5 (CH2-OH), 64.1 (CH2-OAr), 60.1 (CHN), 58.7 (C(CH3)3), 55.2 (OCH3), 51.2 
(C3), 26.5 (C1), 25.7 (C2), 22.9 (C(CH3)3), 16.7 (CH3).
FAB (+) HRMS: Calcd. for C19H31NNa04S: (M+Na)+: mle 393.19496; Found: mle 393.19392. 
Aldehyde 381
TEMPO, BAIB
CH2 CI2  (50%)A 0H  
Me OPMB Me OPMB
To a solution of alcohol 406 (0.10 g, 0.271 mmol) in dry CH2CI2 (2.7 mL) at rt under N2 
was added TEMPO (6.8 mg, 0.044 mmol) followed by [bis(acetoxy)iodo]benzene (141 mg, 
0.439 mmol). The reaction mixture was stirred at rt for 5 h, quenched with sat. aq. Na2S20 3 (5 
mL) and extracted with CH2CI2 (3x10 mL). The combined organic extracts were dried (MgS04), 
filtered and concentrated in vacuo. The crude product was purified by Si02 flash 
chromatography (gradient elution: 5:1 to 1:1 petrol:EtOAc) to afford aldehyde 381 as a colorless 
oil (50 mg, 50%).104
[a]D + 39.4° (c 0.45, CH2CI2).
IR (neat film) 2956 (s), 1730 (s), 1612 (w), 1514 (s), 1462 (m), 1385 (w), 1362 (w), 1302 (w), 
1248 (s), 1175 (w), 1127 (w), 1088 (s), 1034 (s), 822 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 9.68 (s, 1 H, CHO), 7.24 (d, J = 8.7 Hz, 2 H, Ar), 6.84 (d, J 
= 8.7 Hz, 2 H, Ar), 4.46 (d, J=  10.8 Hz, 1 H, CFh-O), 4.28 (d, J = 10.8 Hz, 1H, CHj-O), 4.06 (t, J 
= 6.7 Hz, 1 H, CH-N), 3.78 (s, 3 H, OCH3), 3.19 (m, 1 H, H3), 3.11 (m, 1 H, H3), 1.89 (m, 2 H, 
H1), 1.72 (m, 2 H, H2), 1.37 (s, 3 H, CH3), 1.13 (s, 9 H, C(CH3)3).
167
13C-NMR (125 MHz, CDCI3i 298K) 5 204.1 (C=0), 159.2 (Ar), 130.2 (Ar), 129.2 (Ar), 113.7 (Ar),
84.5 (MeCOPMB), 66.1 (CH2-0), 62.2 (CH-NH), 58.5 (C(CH3)3), 55.2 (OCH3), 51.3 (C3), 29.7 
(C1), 27.1 (C2), 24.9 (C(CH3)3), 14.1 (CH3).
FAB (+) HRMS: Calcd. for C19H3oN04S: (M+H)+: m/e 368.18954; Found: mle 368.19047.
Ester 421
ft Me i) NaN0 2, H2 S0 4 jf V®
M  ») MeOH. AcCI M e O ' " T o
HO 1 OH -------------------------------------   A / -
NH2  iii) 2,2-dimethoxypropane / M e
. , PPTS, CH2CI2  MeL-threonine i i  421
(L)-Threonine (110 g, 0.92 mol) was suspended in water (250 mL) at -5 °C and was 
treated simultaneously while stirring with a solution of NaN02 (69 g, 1 mol) in water (100 mL) 
and concentrated H2S04 (27.9 mL, 0.5 mol) in water (75 mL). The two solutions were added at 
such a rate that the temperature remained between 0 °C and 5 °C. The solution was then stirred 
at rt for 20 h. The water was evaporated in vacuo and the remaining mixture treated with EtOH 
(150 mL). The salts were then filtered and the solution evaporated to dryness. The crude 
mixture was dissolved in MeOH (150 mL) and acetyl chloride (128 mL, 1.4 mol) was added very 
slowly at 0 °C under N2. The reaction mixture was then refluxed for 6 h. Evaporation of the 
solvent gave the crude dihydroxy ester which was dissolved in CH2CI2 (150 mL) and treated 
with 2,2-dimethoxypropane (226 mL, 1.84 mol) and PPTS (23 g, 0.092 mol). The reaction 
mixture was stirred at rt for 20 h, quenched with aq. sat. NaHC03 and extracted with CH2CI2 (3 x 
150 mL). The combined organic extracts were dried (MgS04), filtered and concentrated in 
vacuo. Distillation (70-75 °C, 1 mmHg) afforded methyl ester 421 (70 g, 43%) as a colorless 
oil.108
[a]D -17.1° (c 1, CHCI3).
1H-NMR (500 MHz, CDCI3, 298K) 5 4.01 (dq, J = 8.0, 6.0 Hz, 1 H, CH-CH3), 3.87 (d, J = 8.0 Hz, 
1 H, CH-C=0), 3.60 (s, 3 H, 0-CH3), 1.37 (s, 3 H, CH3), 1.35 (s, 3 H, CH3)
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13C-NMR (125 MHz, CDCI3i 298K) 6 170.8 (C=0), 110.5 (C(CH3)2), 80.3 (CH-C=0), 75.0 (CH- 
CH3), 52.3 (0-CH3), 27.1 (C(CH3)2), 25.6 (C(CH3)2), 18.4 (CH-CH3).
The spectral data for this molecule corresponded with that in the literature.
Dibromide 422
i) DIBAL-H, ether, -78°C
ii) Soxhlet, CH2CI2, reflux
M eO  o
...421 Me
P  iii) Zn, CBr4, PPh3, CH2Cl2 
^M p  (41%, 2 steps)
422  Me
Br “ " / 'M e
To a solution of the ester 421 (15 g, 83.1 mmol) in dry ether (90 mL) at -78 °C was 
added dropwise over 30 min via addition funnel, a solution of DIBAL-H in hexanes (1 M, 100 
mL, 100 mmol). The reaction mixture was stirred at -78 °C for 45 min and quenched with a 
saturated aqueous solution of Rochelle’s salt (100 mL). The mixture was poured into a conical 
flask containing Et20  (200 mL), stirred at rt for 1 h and extracted with Et20  (3 x 250 mL). The 
combined organic extracts were dried (MgS04), filtered and concentrated in vacuo to afford a 
mixture of the aldehyde and its hydrate. The crude oil was dissolved in CH2CI2 (120 mL) and the 
mixture was heated at reflux for 20 h in a Soxhlet apparatus containing activated 4 A powdered 
molecular sieves. The reaction mixture was directly added to a suspension which has been 
prepared as follows. To a suspension of CBr4 (55.0 g, 166 mmol) and Zn (10.85 g, 166 mmol) at 
0 °C in CH2CI2 (320 mL) was added PPh3 by portions ove 20 min (43.50 g, 166 mmol). After 24 
h at rt, the crude aldehyde in CH2CI2 was added via canula over 10 min at 0 °C. The reaction 
mixture was stirred at 0 °C for 2 h and then poured onto petrol (200 mL) and filtered through 
Celite®. The filtrate was concentrated in vacuo, the residue was filtered through Celite® and the 
Celite®was washed with petroleum ether (5 x 100 mL). The procedure was repeated until no 
dibromoolefin was detected by TLC. The crude oil was purified by Si02 flash chromatography 
(20:1 petrol:EtOAc) to afford the desired unstable product 422 as a colorless oil (10.3 g, 41% 
over 2 steps).109
[a]D - 3.1° (c 1, CHCI3).
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IR (neat film) 3460 (br, w), 2984 (s), 2934 (m), 2874 (m), 1622 (m), 1452 (m), 1377 (s), 1242 (s), 
1173 (s), 1092 (s), 1038 (s), 926 (m), 862 (s), 810 (m), 783 (s).
1H-NMR (500 MHz, CDCI3, 298K) 6 6.42 (d, J = 7.9 Hz, 1 H, Br2C=CH), 4.21 (t, J = 8.3 Hz, 1 H, 
OCHC=), 3.86 (m, 1 H, OCHCH3), 1.80 (br, OH), 1.43 (s, 3 H, CCH3), 1.37 (s, 3 H, CCH3), 1.32 
(d, J = 6.2 Hz, 3 H, CHCH3).
13C-NMR (125 MHz, CDCI3, 298K) 6 135.4 (Br2C=CH), 109.3.0 (C(CH3)2), 93.8 (Br2C=), 82.1 
(OCHC=), 75.8 (OCHCH3), 27.2 (CCH3), 26.7 (CCH3), 17.0 (CHCH3).
The spectral data for this molecule corresponded to those reported in the literature.
Alcohol 423
To a solution of the dibromo olefin 422 (5.4 g, 18.1 mmol) in dry THF (80 mL) at -78 °C under N2 
was added dropwise over 5 min a solution of n-BuLi (2.5 M in hexanes, 16 mL, 39.9 mmol). The 
reaction mixture was stirred at -78 °C for 1 h and then allowed to warm to rt where it was stirred 
for a further 1.5 h before being cooled to -78 °C. Solid paraformaldehyde (1.0 g, 36.2 mmol) 
was added in one portion and the reaction was held at -78 °C for 30 min before being warmed 
to rt where it was stirred for 1 h. Brine (100 mL) was added to the reaction mixture which was 
then extracted with Et20  (3 x 100 mL). The combined organic extracts were dried (MgS04), 
filtered and concentrated in vacuo. The crude product was quickly purified by Si02 flash 
chromatography (gradient elution: 10:1 to 3:1 petrol:EtOAc) to afford the propargylic alcohol 423 
as a non stable colorless oil (2.83 g, 92%). The structure of alcohol 423 was confirmed by its 
500 MHz 1H-NMR spectrum in CDCI3 and was used directly without further characterisation.
ii) HCHO (solid)
Me
170
1H-NMR (500 MHz, CDCI3, 298K) 6 4.29 (s br, 2 H, CH2OH), 4.15 (dt, J = 8.2, 1.6 Hz, 1 H, 
OCHCEC), 4.06 (ddd, J = 11.9, 8.2, 6.0 Hz, 1 H, OCHCH3), 1.80 (br, OH), 1.42 (s, 3 H, CCH3),
I.39 (s, 3 H, CCH3), 1.32 (d, J = 6.0 Hz, 3 H, CHCH3) .
Bromide 420
CBr4> PPh3
0     .0
THF 0 - 7C
4 2 3  M e M e (63% )________________ 4 2 0  Me Me
To the propargylic alcohol 423 (4.1g, 24 mmol) and PPh3 (12.6 g, 48 mmol) in dry THF 
(120 mL) at 0 °C was added by portions over 30 min, CBr4 (16 g, 48 mmol). The resulting brown 
mixture was stirred at 0 °C for 20 min and petrol (100 mL) and ether (100 mL) were added. 
Triphenylphosphine oxide was removed by filtration through Celite® and the filtered pad washed 
with petrol (3 x 150 mL). The procedure was repeated until no bromide was detected by TLC. 
The filtrate and washings were concentrated in vacuo. The crude oil was quickly purified by 
Si02 flash chromatography (gradient elution 40:1 to 20:1 petrol:EtOAc) to afford 420 as an 
unstable yellow oil (3.5 g, 63%).
The structure of 420 was confirmed by its 500 MHz 1H-NMR spectrum in CDCI3 and was used 
directly without further characterisation.
1H-NMR (500 MHz, CDCI3) 298K) 6 4.15 (dt, J = 8.2, 1.9 Hz, 1 H, OCHCEC), 4.05 (ddd, J =
II.9 , 8.2, 6.0 Hz, 1 H, OCHCH3), 4.29 (d, J=  1.8 Hz, 2 H, Ch^Br), 1.42 (s, 3 H, CCH3), 1.40 (s,
3 H, CCH3), 1.30 (d, J = 6.0 Hz, 3 H, CHCH3).
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Alkyne 337
KHMDS, THF 
l^ lg -TS'C to 0°C
Ph
424
To a solution of 424 (0.91 g, 3.90 mmol) in THF (8 mL) at -78 °C under N2 was added 
dropwise over 10 min a solution of KHMDS (0.5 M in PhMe, 9.36 mL, 4.68 mmol). The reaction 
mixture was stirred at -78 °C for 1 h. A solution of bromide 420 (0. 91 g, 3.90 mmol) in THF (10 
mL) was added dropwise over 10 min via canula. The reaction mixture was stirred at -78 °C for 
40 min and at 0 °C for 2 h. The mixture was then quenched with sat. aq. NH4CI (10 mL) and 
extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried (MgS04), filtered 
and concentrated in vacuo. The crude product was purified by Si02 flash chromatography; 
gradient elution: 20:1 to 6:1 petrol:EtOAc to recover the unreacted starting material 424 (0.2 g, 
22%) and 5:1 to 4:1 to afford alkyne 337 in the form of a colorless oil (0.685 g, 45%).
[a]D + 30.2° (c 0.45, CH2CI2).
IR (neat film) 2982 (w), 2922 (m), 2852 (w) 1780 (s),1699 (m), 1454 (w), 1385 (m), 1242 (m), 
1213 (m), 1171 (w), 1094 (m), 1028 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.35-7.26 (m, 5 H, Ar), 4.66 (m, 1 H, CH-N), 4.17 (dd, J = 
16.7, 9.0 Hz, 1 H, CH^O), 4.14 (dd, J = 9.0, 3.2 Hz, 1 H, ChhO), 4.09 (dt, J = 8.1, 1.9 Hz, 1 H, 
CEC-CH-O), 3.99 (qd, J=  8.1, 6.0 Hz, 1 H, CH3-CH-0), 3.91 (m, 1H, CH2-CH-CH3), 3.27 (dd, J 
= 13.4, 3.3 Hz, 1 H, CJ^Ar), 2.74 (dd, J = 13.4, 9.5 Hz, 1 H, CFbAr), 2.61 (ddd, J = 16.9, 6.9, 2.0 
Hz, 1H, CH-CFh-CE), 2.53 (ddd, J =  16.9, 6.9, 2.0 Hz, 1 H, CH-CHs-CE), 1.35 (s, 3 H, CCH3), 
1.34 (s, 3 H, CCH3), 1.28 (d, J = 6.0 Hz, 3 H, CH3CHO), 1.19 (d, J = 6.9 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 6 174.9 (CHC=0), 152.9 (0-C=0), 135.1(C, Ar), 129.3 (CH, 
Ar), 128.9 (CH, Ar), 127.3 (C, Ar), 109.2 (C(CH3)2), 84.1 (CH2-CEC), 77.9 (CEC-CHO), 77.5
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(CH3-CH-0), 72.1 (CEC-CH-O), 66.1 (CH20), 55.2 (CH-N), 37.9 (CH2Ar), 37.2 (CH2CHCH3), 
27.1 (C(CH3)2), 26.3 (C(CH3)2), 16.8 (CH3CHO), 16.5 (CH3CH).
FAB (+) HRMS: Calcd. for C22H27NNa05: (M+Na)+: m/e 408.17868; Found: m/e 408.178770.
Stannane 425
Ph3SnH (0.418 g, 1.19 mmol) was weighed in a glove bag and added to a round- 
bottomed flask containing alkyne 337 (0.230 g, 0.596 mmol). The flask was immediately purged 
with N2 and dry PhMe (0.6 mL) was added. Et3B (1 M solutions in hexanes, 0.21 mL, 0.21 
mmol) was then added dropwise. Air was injected into the reaction vessel to initiate the 
reaction. The reactants were stirred at rt overnight. H20  (10 mL) was added and the mixture 
was extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried (MgS04), 
filtered and concentrated in vacuo. The crude residue was purified by Si02 flash 
chromatography (gradient elution: 100:1 to 25:1 petrol:EtOAc) without separation of the 
individual vinylstannanes 425 and 426 from each other. 500 MHz NMR analysis of this 
unseparated mixture in CDCI3 indicated that vinylstannanes 425 and 426 were present in 10:1 
ratio. The mixture was obtained in the form of a colorless oil (0.33 g, 75%).105 The structure of 
the minor isomer 426 is only assigned tentatively.
[a]D + 15.1° (c 0.33, CH2CI2).
IR (neat film) 3061 (w), 2980 (m), 2928 (m), 2862 (w), 1780 (s), 1699 (m), 1614 (w), 1429 (m), 
1383 (s), 1213 (s), 1097 (m), 1024 (m), 972 (w), 918 (w), 731 (m), 700.1 (m), 509 (w), 451 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 7.64-7.13 (m, 20 H, Ar), 6.60 (dd, J = 6.62, 8.20 Hz ( 3J 
117Sn-1H = 149 Hz), 1 H, HC=CSn), 4.54 (m, 1 H, CH-N), 4.10 (dd, J=  9.0 Hz, 1 H, CFhO), 4.07
PhMe, rt 
(72%)
337 425 426
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(ddd, J = 9.0, 3.1 Hz, 1 H, CH2O), 3.75 (m, CH3-CH-0), 3.62 (m, CH3-CH-C=0), 3.12 (dd, J = 
13.4, 3.3 Hz, 1 H, C h h A r), 2.74 (d d , J = 13.4, 9.5 Hz, 1 H, CHzAr), 2.61 (m, 1 H, C ^ C H ^ , 2.17 
(m, 1 H, CH2CH=), 1.25 (s, 3 H, CCH3), 1.20 (d, J = 6.1 Hz, 3 H, CH3CH-O), 0.79 (d, J = 6.9 Hz, 
3 H, CH3CHC=0), 0.66 (s, 3 H, CCH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 176.0 (CHC=0), 152.9 (0-C=0), 144.3 (HC=CSn), 140.1,
139.7 (CSn), 137.1 129.5, 129.3, 129.1, 128.9, 128.8, 128.5, 128.3, 127.3, 107.9 (C(CH3)2),
89.3 (CHN), 65.9 (CH2-0), 55.3 (CH-N), 38.0 (CH2Ar), 37.6 (CH3CHC=0), 37.4 (CH2CH=) 27.2 
(C(CH3)2), 25.9 (C(CH3)2, 16.7 (CH3CHO), 16.4 (CH3CHC=0).
FAB (+) HRMS: Calcd. for C4oH43NNa0 5Sn: (M+Na)+: mle 760.20608; Found: m/e 760.20449.
Iodide 427
Me
Me
PhPh Me
0  °C, (80%)Me
Me
425 427
To a stirred solution of vinyl triphenylstannane 425 (250 mg, 0.338 mmol) in dry CH2CI2 (4 mL)at 
0 °C under N2 was added solid l2 (103 mg, 0.406 mmol) in one portion. The mixture was stirred 
at rt for 1 h. The solvent was removed in vacuo and the residue purified by Si02 flash 
chromatography (gradient elution: 20:1 to 6:1 petrol:EtOAc) to give vinyl iodide 427 as a pale 
yellow oil (140 mg, 80%).107
[a]D + 41.8° (c 0.16, CH2CI2).
IR (neat film) 2982 (m), 2930 (m), 2851 (w) 1780 (s), 1724 (m), 1699 (m), 1454 (w), 1383 (m), 
1350 (w), 1242 (s), 1211 (m), 1175 (w), 1099 (m), 1036 (m), 974 (w), 858 (w), 731 (m), 702 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 7.34-7.17 (m, 5 H, Ar), 6.14 (t, J = 6.8 Hz, 1 H, HC=CI),
4.66 (m, 1 H, CH-N), 4.18 (dd, J=  16.5, 9.1 Hz, 1 H, Ch^O), 4.15 (dd, J = 9.1, 3.1 Hz, 1 H,
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ChhO), 4.0 (qd, J = 8.0, 6.0 Hz, 1 H, CH3-CH-0), 3.90 (m, 1 H, CH3-CH-C=0) 3.59 (d, J = 8.0 
Hz, 1 H, IC-CH-O), 3.27 (dd, J = 13.4, 3.1 Hz, 1 H, ChbAr), 2.77 (dd, J = 13.4, 9.9 Hz, 1 H, 
ChbAr), 2.63 (m, 1 H, CH-CH2-CH=C), 2.54 (m, 1 H, CH-CFL-CHC), 1.48 (s, 3 H, C(CH3)2), 
1.41 (s, 3 H, C(CH3)2), 1.28 (d, J = 6.1 Hz, 3 H, CH3CHO), 1.19 (d, J = 6.8 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 6 175.8 (CHC=0), 153.1 (0-C=0), 136.4 (HC=CI), 135.2 
(Ar), 129.4 (Ar), 129.0 (Ar), 127.4 (Ar), 109.1 (C(CH3)2), 109.0 (HC=CI), 87.8 (IC-CH-O), 77.6 
(CH3-CH-0), 66.1 (CH20), 55.4 (CH-N), 39.6 (CH-CH2-CH=C), 38.1 (CH2Ar), 36.8 (CH3-CH- 
CH2), 27.7 (C(CH3)2), 27.1 (C(CH3)2, 16.8 (CH3CHO), 16.4 (CH3CH).
FAB (+) HRMS: Calcd. for C22H28INNa05: (M+Na)+: mle 536.09044; Found: mle 536.09098.
Alkene 419
Me
Me4Sn, Cul, Ph3As 
(MeCN)2 PdCI2Me PhPh Me MeDMF, NEt3, 140 'C  
(72%) Me
419427
To a solution of vinyl iodide 427 (57 mg, 0.11 mmol) in dry DMF (1.1 ml_) and freshly 
distilled Et3N (1.1 mL, 7.89 mmol) at rt under N2 was added Me4Sn (0.05 ml_, 0.36 mmol), Cul (2 
mg, 0.011 mmol), and Ph3As (3.3 mg, 0.011 mmol) followed by (MeCN)2PdCI2 (2.8 mg, 0.011 
mmol). The reactants were heated at 130 °C for 2 h, cooled to rt, and H20  (5 mL) was added. 
After extraction with Et20  ( 3x5  mL), the combined organic extracts were dried (MgS04), filtered 
and concentrated in vacuo. The crude product was purified by Si02 flash chromatography 
(gradient elution: 100:1 to 6:1 petrol:EtOAc) to afford alkene 419 in the form of a colorless oil 
(32 mg, 72%).107
[a]D + 4.4° (c 0.20, CH2CI2).
IR (neat film) 2980 (m), 2926 (m), 2876 (w) 1780 (s), 1724 (m), 1452 (w), 1383 (m), 1242 (s), 
1097 (m), 1036 (w), 974 (w), 729 (m).
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1H-NMR (500 MHz, CDCI3, 298K) 5 7.35-7.15 (m, 5 H, Ar), 5.53 (t, J = 7.2 Hz, 1 H, HC=CCH3),
4.66 (m, 1 H, CH-N), 4.15 (dd, J=  16.5, 9.1 Hz, 1 H, CH2O), 4.15 (dd, J = 9.1, 3.1 Hz, 1 H, 
CHzO), 3.83 (m, 3 H, CH3-CH-0, CH3-CH-CH2, IC-CH-O), 3.26 (dd, J=  13.4, 3.4 Hz, 1 H, 
ChbAr), 2.69 (dd, J = 13.4, 9.9 Hz, 1 H, Cj^Ar), 2.50 (m, 1 H, CH-CH2-CH=), 2.27 (m, 1 H, CH- 
CH2-CH=), 1.67 (s, 3 H, =C(CH3)), 1.38 (s, 3 H, C(CH3)2), 1.37 (s, 3 H, C(CH3)2), 1.20 (d, J =
5.6 Hz, 3 H, CH3CHO), 1.15 (d, J = 6.8 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 5 176.6 (CHC=0), 153.1 (0-C=0), 135.3 (Ar), 127.3 (Ar),
126.3 (HC=CCH3), 108.0 (C(CH3)2), 109.0 (HC=CI), 88.4 (CH3C-CH-0), 74.4 (CH3-CH-0), 66.0 
(CH20), 55.4 (CH-N), 38.0 (CH2Ar), 37.4 (CH2CHCH3), 31.9 (CH-CH2-CH=), 27.5 (C(CH3)2),
26.9 (C(CH3)2, 17.0 (CH3CHO), 16.4 (C=CCH3).
FAB (+) HRMS: Calcd. for C23H31NNa05: (M+Na)+: m/e 424.20998; Found: m/e 424.21073.
Alkyne 429
(1) nBuLi in Hex, THF
Me' 420 MeMe
in HMPA
428 429
(84%) Me
Me
To a solution of compound 428111 (1.16 g, 4.29 mmol) in THF (21 mL) at -78 °C under 
N2 was added dropwise over 10 min a solution of n-BuLi (2.5 M in Hexanes, 1.7 mL, 4.29 
mmol). The reaction mixture was stirred at -78 °C for 1 h and a solution of bromide 420 (1.0 g,
4.3 mmol) in HMPA (2.24 mL, 12.9 mmol) was added dropwise via canula over 10 min. The 
reaction mixture was stirred at -78 °C for 4 h, quenched with water (20 mL) and extracted with 
Et20  (3 x 20 mL). The combined organic extracts were dried (MgS04), filtered and concentrated 
in vacuo. The crude product was purified by Si02 flash chromatography (gradient elution: 50:1 
to 20:1 petrol:EtOAc) to afford alkyne 429 in the form of a white foam (1.53 g, 84%).
[a]D + 52.2° ( c1,CH2CI2).
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IR (neat film) 2980 (s), 2887 (m), 1697 (s), 1456 (w), 1381 (m), 1331 (s), 1267 (m), 1236 (s), 
1169 (m), 1128 (m), 1093 (w), 1061 (w), 1030 (m), 976 (w), 860 (w), 769 (w), 540 (m).
1H-NMR (500 MHz, CDCI3, 298K) 6 4.03 (dt, J=  8.3, 1.8 Hz, 1 H, CEC-CH-O), 3.96 (qd, J = 8.1,
5.9 Hz, 1 H, CH3-CH-O), 3.85 (dd, J = 7.5, 5.0 Hz, 1 H, CH-N), 3.44 (q, J=  13.8 Hz , 2H, 0 2S- 
CH2), 3.25 (m, 1 H, CH-CH3), 2.55 (ddd, J=  16.6, 6.4, 1.8 Hz, 1 H, CH-Ch^-CE), 2.49 (ddd, J =
16.6, 6.4, 1.8 Hz, 1 H, CH-Ch^-CE), 2.04 (m, 2 H, CH2-CHN), 1.85 (m, 3 H, CHz-CH-Chh, 
CHC(CH3)2), 1-38 (s, 3 H, 0 2C(CH3)2), 1.36 (m, 2 H, CCH2-CH2) 1.35 (s, 3 H, 0 2C(CH3)2 , 1.27 
(d, J = 6.0 Hz, 3 H, CH3CHO), 1.19 (d, J = 6.6 Hz, 3 H, CH3CH), 1.14 (s, 3 H, HCC(CH3)2), 0.94 
(s, 3 H, HCC(CH3)2).
13C-NMR (125 MHz, CDCI3, 298K) 6 174.0 (C=0), 109.1 (C(CH3)2), 83.6 (CH2-CEC), 78.1 
(CEC-CHO), 77.5 (CH3-CH-O), 72.0 (CEC-CH-O), 65.2 (CH-N), 53.1 (CH2-S), 48.3 (CCH3 (Xc)),
47.7 (C-CH2S), 44.6 (CHC(CH3)2), 39.0 (CH-CH3), 38.4 (CH2-CHN), 32.8 (CH2), 27.1 
(02C(CH3)2), 26.4 (CH2-CH2), 26.4 (HC(CH3)2), 24.3 (CH-CH2-CEC), 20.9 (HC(CH3)2), 19.8 
(02C(CH3)2), 16.6 (CH3CHO), 16.0 (CH3CH).
FAB (+) HRMS: Calcd. for C22H33NNa0 5S: (M+Na)+: m/e 446.19770; Found: m/e 446.19707. 
Alkyne 430
Ti(OEt)4. EtOH
Me 130°C, 3 days 
(100%)
To a solution of alkyne 429 (760 mg, 1.8 mmol) in absolute EtOH (36 mL) was added 
Ti(OEt)4 (3.77 mL, 18 mmol) in one portion. The resulting heterogeneous mixture was heated at 
reflux for 3 days. After being cooled to 0°C, the mixture was quenched with 1M aqueous HCI 
(15 mL) and extracted with Et20  (3 x 200 mL). The combined organic extracts were washed 
with sat. aq. NaHC03 (50 mL), dried (MgS04), filtered and concentrated in vacuo to give a
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mixture of ethyl ester 430 and recovered sultam 436. The crude residue was purified by Si02 
flash chromatography (20:1 petrol:EtOAc) to afford ethyl ester 430 as a colorless oil (455 mg, 
100%) and (5:1 petrol:EtOAc) to recover the auxiliary 373 (370 mg, 96%).112
[a]D - 2.18° (c1.01,CH2CI2).
IR (neat film) 2984 (s), 2933 (m), 1736 (s), 1456 (w), 1431 (m), 1377 (m), 1234 (m), 1175 (s), 
1099 (m), 1028 (s), 858 (w).
1H-NMR (500 MHz, CDCI3) 298K) 6 4.08 (q, J = 7.1 Hz, 2 H, CH2-O), 4.07 (dt, J = 8.1, 1.9 Hz, 1 
H, CEC-CH-O), 3.97 (qd, J = 8.1, 6.1 Hz, 1 H, CH3-CH-O), 2.58 (m, 1 H, CH-CH3), 2.45 (ddd, J 
= 16.7, 5.9, 1.9 Hz, 1 H, CI^-CH), 2.36 (ddd, J = 16.7, 7.6, 1.9 Hz, 1H, CH2-CH), 1.39 (s, 3 H, 
CCH3), 1.36 (s, 3 H, C CH3), 1.27 (d, J = 6.0 Hz, 3 H, CH3-CH-0), 1.22 (t, J = 7.1 Hz, 3 H, 
CH3CH20), 1.21 (d, J = 7.0 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 5 174.7 (C=0), 109.2 (C(CH3)2), 84.5 (CEC), 77.6 (CH3-CH- 
O), 72.1 (CEC-CH-O), 60.5 (CH2-0), 38.7 (CH-CH3), 27.1 (CCH3), 26.3 (CCH3), 22.9 (CH2-CH),
16.8 (CH3CH), 16.3 (CH3-CH-0), 14.2 (CH3CH20).
FAB (+) HRMS: Calcd. for C14H22Na04: (M+Na)+: m/e 277.14157; Found: mle 277.14189.
Stannane 431
Me Ph3SnH Ph3Sn MeX ^
CD
Et3 B, Air
/ M e
EtO O Tol
(92%) EtO O
430 Me 431 Me
Ph3SnH (1.77 g, 5.03 mmol) was weighed in a glove bag and added to a round- 
bottomed flask containing alkyne 430 (0.640 g, 2.52 mmol). The flask was immediately purged 
with N2 and dry PhMe (2.52 mL) was added. Et3B (1 M solutions in hexanes, 0.76 mL, 0.756 
mmol) was then added dropwise. Air was injected into the reaction vessel to initiate the 
reaction. The reactants were stirred at rt overnight. H20  (30 mL) was added and the mixture
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was extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried (MgS04), 
filtered and concentrated in vacuo. The crude product was purified by Si02 flash 
chromatography (gradient elution: 100:1 to 25:1 petrol:EtOAc) to afford the vinylstannane 431 
as a single isomer in the form of a colorless oil (1.40 g, 92%).105
[a]D- 19.1° (c 0.42, CH2CI2).
IR (neat film) 3059 (w), 2980 (s), 2931 (m), 2866 (w), 1732 (s), 1454 (w), 1431 (m), 1375 (s), 
1229 (m), 1180 (s), 1095 (m), 1026 (m), 858 (w), 731 (s), 700 (s).
1H-NMR (500 MHz, CDCI3l 298K) 5 7.56 (m, 6 H, Ar), 7.32 (m, 9 H, Ar), 6.55 (ddd, J = 8.4, 6.4,
1.2 Hz ( 3J 11?Sn-1H = 150 Hz), 1 H, HC=CSn), 3.16 (dd, J = 8.4, 1.1 Hz, 1 H, SnC-CH-O), 4.01 
(q, J = 7.2, 1.7 Hz, 2 H, CHj-O), 3.73 (qd, J = 8.4, 1.7 Hz, 1 H, CH3-CH-0), 2.32 (m, 1 H, CHb- 
CH), 2.13 (m, 2 H, CHs-CH, CH-CH3), 1.25 (s, 3 H, CCH3), 1.19 (d, J=  6.0 Hz, 3 H, CH3-CH-0), 
1.16 (t, J=  7.1 Hz, 3 H, CH3CH20), 0.72 (d, J = 6.9 Hz, 3 H, CH3CH), 0.66 (s, 3 H, CCH3).
13C-NMR (125 MHz, CDCI3, 298K) 5 175.4 (C=0), 144.7 (HC=CSn), 139.6 (HC=CSn), 137.0 
(Ar), 128.9 (Ar), 128.7 (Ar), 108.0 (C(CH3)2), 89.3 (SnC-CH-O), 77.1 (CH3-CH-0), 60.2 (CH20),
39.8 (CH-CH3), 37.4 (CH2CH=), 27.2 (CCH3), 25.9 (CCH3), 16.6 (CH3CH), 16.5 (CH3CHO),
14.2 (CH3CH20).
FAB (+) HRMS: Calcd. for C32H38Na04Sn: (M+Na)+: m/e 629.16896; Found: m/e 629.16654.
Iodide 432
Me
Me
Me0 °C (77%)
EtOMeEtO'
Me 432431
To a stirred solution of vinyl triphenylstannane 431 (1.2 g, 2.00 mmol) in dry CH2CI2 (20 
mL) at 0 °C under N2 was added solid l2 (0.604 g, 2.38 mmol) in one portion. The mixture was 
stirred at rt for 1 h. The solvent was removed in vacuo and the residue purified by Si02 flash
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chromatography (gradient elution: 40:1 to 10:1 petrol:EtOAc) to give vinyl iodide 432 as a pale 
yellow oil (0.600 g, 77 %).107
[a]D + 4.8° (c 1.19, CH2CI2).
IR (neat film) 3439 (w), 2995 (s), 2931 (m), 2908 (s), 1732 (s), 1454 (w), 1377 (m), 1234 (m), 
1178 (s), 1101 (m), 1036 (m), 860 (w).
1H-NMR (500 MHz, CDCI3) 298K) 5 6.07 (ddd, J = 7.2, 6.3, 0.9 Hz, 1 H, HC=CI), 4.10 (q, J = 7.2 
Hz, 2 H, CHz-O), 3.97 (qd, J = 8.0, 6.0 Hz, 1 H, CH3-CH-0), 3.55 (d, J = 8.0 Hz, 1 H, IC-CH-O), 
2.56 (m, 1 H, CH-CH3), 2.52 (m, 1 H, CHz-CH), 2.39 (m, CFh-CH), 1.48 (s, 3 H, CCH3), 1.40 (s, 
3 H, CCH3), 1.26 (d, J = 6.0 Hz, 3 H, CH3CHO), 1.22 (t, J=  7.1 Hz, 3 H, CH3CH20), 1.17 (d, J 
= 6.9 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 6 175.4 (C=0), 136.6 (HC=CI), 109.1 (C(CH3)2), 108.6 
(HC=CI), 87.7 (C=IC-CH-0), 76.8 (CH3-CH-0), 60.5 (CH2-0), 39.3 (CH2CH=), 38.5 (CH-CH3),
27.7 (CCH3), 27.0 (CCH3), 16.9 (CH3CH), 16.7 (CH3-CH-0), 14.2 (CH3CH20).
FAB (+) HRMS: Calcd. for C14H23INa04: (M+Na)+: m/e 405.05387; Found: m/e 405.054665.
Alkene 433
Me
Me4Sn, Ph3As 
Cul, (MeCN)2PdCI2 Me/(
Me CH2CI2, ISO'C, 3h 
(80%)Me EtO' Me
MeEtO
433432
To a solution of vinyl iodide 432 (600 mg, 1.53 mmol) in dry DMF (15.3 mL) and freshly 
distilled Et3N (15.3 mL, 109 mmol) at rt under N2 was added Me4Sn (0.70 mL, 5.05 mmol), Cul 
(29 mg, 0.153 mmol), and Ph3As (47 mg, 0.153 mmol) followed by (CH3CN)2PdCI2 (39 mg, 
0.153 mmol). The reactants were heated at 130 °C for 3 h, cooled to rt, and H20  (50 mL) was 
added. After extraction with Et20  (3 x 100 mL), the combined organic extracts were dried 
(MgS04), filtered and concentrated in vacuo. The crude product was purified by Si02 flash
180
chromatography (gradient elution: 100:1 to 20:1 petrol:EtOAc) to afford alkene 433 in the form 
of a colorless oil (330 mg, 80%).107
[a]D- 8.1° (c 0.26, CH2CI2).
IR (neat film) 2980 (s), 2931 (m), 2878 (w), 1734 (s), 1456 (w), 1375 (m), 1240 (m), 1173 (m), 
1097 (m), 1034 (m), 864 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 5.45 (t, J = 6.9 Hz, 1 H, HC=CMe), 4.09 (q, J = 7.2 Hz, 2 H, 
CHz-O), 3.82 (m, 1 H, CH3-CH-0), 3.80 (m, 1 H, C=C-CH-0), 2.45 (m, 1 H, CH-CH3), 2.38 (m, 1 
H, CH2-CH), 2.20 (m, 1 H, Chh-CH), 1.63 (s, 1 H, C=CCH3), 1.39 (s, 6 H, C(CH3)2), 1.22 (t, J = 
7.1Hz, 3 H, CH3CH20), 1.18 (d, J=  5.6 Hz, 3 H, CH3CHO), 1.11 (d, J=  7.0 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 6 176.0 (C=0), 133.1 (MeC=CH), 126.4 (HC=CMe), 108.0 
(C(CH3)2), 88.3 (C=C-CH-0), 74.5 (CH3-CH-0), 60.3 (CH2-0), 39.4 (CH-CH3), 31.7 (CH2CH=), 
27.5 (CCH3), 26.8 (CCH3), 17.0 (CH3CH), 16.4 (CH3CHO), 14.2 (CH3CH20), 11.8 (C=CCH3).
FAB (+) HRMS: Calcd. for C15H26Na04: (M+Na)+: m/e 293.17287; Found: m/e 293.17287.
Alcohol 434
Me MeMe
Dibal-H. THF
(75%)
MeHO'MeEtO' MeMe
433 434
To a solution of alkene 433 (190 mg, 0.703 mmol) in dry THF (2.34 mL) at rt under N2 
was added dropwise over 5 min a solution of DIBAL-H (1.5 M in toluene, 1.16 mL, 1.75 mmol). 
The reaction mixture was stirred for 1 h and a saturated aqueous solution of Rochelle’s salt (10 
mL) and ether (10 mL) were added. The resulting mixture was stirred at rt for 1 h and extracted 
with Et20  (3 x 20 mL). The combined organic extracts were dried (MgS04), filtered and 
concentrated in vacuo. The crude product was purified by Si02 flash chromatography (gradient 
elution: 10:1 to 6:1 petrol:EtOAc) to afford alcohol 434 as a white foam (1.20 g, 75%).
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[a]D + 7.4° (c 0.68, CH2CI2).
IR (neat film) 3433 (br), 2980 (s), 2928 (m), 2878 (m), 1726 (w), 1454 (w), 1377 (m), 1238 (s), 
1175 (m), 1095 (m), 1034 (s), 862 (w).
1H-NMR (500 MHz, CDCI3, 298K) 5 5.50 (qd, J = 6.9 Hz, 1 H, HC=CMe), 3.84 (m, 1 H, CH3-CH- 
O), 3.82 (m, 1 H, =C-CH-0), 3.47 (dd, J = 6.1, 10.6 Hz, 1 H, ChhOH), 3.41 (dd, J = 6.1, 10.6 Hz, 
1 H, ChhOH), 2.16 (m, 1 H, Chh-CH), 1.89 (m, 1 H, CHh-CH), 1.68 (m, 1 H, CH-CH3), 1.62 (s, 1 
H, C=CCH3), 1.39 (s, 6 H, C(CH3)2), 1.18 (d, J = 5.6 Hz, 3 H, CH3CHO), 0.88 (d, J = 6.8 Hz, 3 
H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 5 132.0 (HC=CMe), 128.3 (HC=CMe), 107.9 (C(CH3)2), 88.7 
(C=C-CH-0), 74.3 (CH3-CH-0), 67.7 (CH2-0), 36.1 (CH-CH3), 31.4 (CH2CH=), 27.4 (CCH3),
26.7 (CCH3), 17.0 (CH3CH), 16.4 (CH3CHO), 11.5 (C=CCH3).
FAB (+) HRMS: Calcd. for C13H24Na03: (M+Na)+: m/e 251.16231; Found: mle 251.16182.
Aldehyde 210
Me Me Me Me
TEMPO, BAIB
MeHO Me
Me Me
270434
To a solution of alcohol 434 (0.10 g, 0.271 mmol) in dry CH2CI2 (2.7 mL) under N2 was 
added TEMPO radical (6.8 mg, 0.044 mmol) followed by [bis(acetoxy)iodo]benzene (141 mg, 
0.439 mmol) in one portion. The reaction mixture was stirred at rt for 5 h, quenched with sat. aq. 
Na2S20 3 (5 mL) and extracted with CH2CI2. The combined organic extracts were dried (MgS04), 
filtered and concentrated in vacuo. The crude product was purified by Si02 flash 
chromatography (gradient elution: 5:1 to 1:1 petrol:EtOAc) to afford aldehyde 270 as a colorless 
oil (50 mg, 50%).104
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1H-NMR (500 MHz, CDCI3) 298K) 5 9.64 (d, J=  1.3 Hz, 1 H, CHO), 5.47 (dddd, J = 6.9 Hz, 1 H, 
HC=CMe), 3.83 (m, 1 H, CH3-CH-0), 3.82 (m, 1 H, C=C-CH-0), 2.43 (m, 2 H, Chh-CH), 2.17 
(m, 1 H, CH-CH3), 1.65 (s, 1 H, C=CCH3), 1.40 (s, 6 H, C(CH3)2), 1.19 (d, J = 5.6 Hz, 3 H, 
CH3CHO), 1.08 (d, J = 7.0 Hz, 3 H, CH3CH).
13C-NMR (125 MHz, CDCI3, 298K) 6 204.3 (CHO), 133.6 (MeC=CH), 125.8 (HC=CMe), 108.0 
(C(CH3)2), 88.7 (C=C-CH-0), 74.3 (CH3-CH-0), 46.3 (CH-CH3), 31.4 (CH2CH=C), 27.4 (CCH3),
26.8 (CCH3), 17.0 (CH3CHO), 13.0 (CH3CH), 11.7 (C=CCH3).
FAB (+) HRMS: Calcd. for C13H22Na03: (M+Na)+: m/e 249.14666 ; Found: mle 249.14601.
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01131006: Scan Avg 78-85 (15.50 - 16.90 min) - Back
Base: 176.00 Int: 2.T9332e+006 Sample: VG 70-SE Positive Ion FAB
17fc
Me.
NFmoc
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Sample: ll-AL-106 
Instrument Resolution: 7000 
Theoretical Mass (M+Na) 601.30019 
Measured Mass: (M+Na) 601.29959 
Error: 1.00 ppm
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03290404: Scan 125 (22.87 min) - Back
Base: 154.00 Int: 4.91413e+006 Sample: VG 70-SE Positive Ion FAB
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80% -
Sample: l-AL-65ws (FAB) 
Theoretical Mass: 225.16029 (M+H) 
Measured Mass: 225.16071 (M+H) 
Error = 1.90 ppm
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03170305: Scan Avg 153-154 (35.50 - 35.73 min) - Back 
Base: 176.00 Int: 542989 Sample: VG-70SE Positive Ion FAB
100%
176 Sample: ll-AL-73 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 1024.47960 
Measured Mass: (M+Na) 1024.48548 
Error: 5.74 ppm
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02170105: Scan 23 (5.17 min) - Back
Base: 176.00 Int: 3.74185e+006 Sample: VG-70SE Positive Ion FAB 
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Samle: ll-AL-72 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 802.41153 
Measured Mass: (M+Na) 802.41531 
Error: 4.71 ppm
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01210205: Scan Avg 76-79 (17.53 - 18.23 min) - Back 
Base: 1398.00 Int: 385997 Sample: VG-70SE Positive Ion FAB
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O "
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Instrument Resolution: 7000 
Theroetical Mass: (M+Na) 1396.54176 
Measured Mass: (M+Na) 1396.54502 
Error: 2.33 ppm
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01050405: Scan Avg 209-214 (48.57 - 49.73 min) - Back 
Base: 176.00 Int: 5.79586e+006 T 1   'Sample: VG-70SE Positive Ion FAB
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/  |OBnSample: ll-AL-119
Theoretical Mass: (M+Na) 1164.39946 
Measured Mass: (M+Na) 1164.39772 
Error: 1.49 ppm
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03170305: Scan Avg 102-103 (23.60 - 23.83 min) - Back 
Base: 176.00 Int: 2.13996e+006 C ' ' ~ ‘Sample: VG-70SE Positive Ion FAB 
O B n O  | HZ
100%
Sample: ll-AL-114 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 1124.53203 
Measured Mass: (M+Na) 1124.52750 
Error: 4.00 ppm
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02020804: Scan Avg 164-166 (38.07 - 38.53 min) - Back
Base: 250.00 Int: 2.32882e+00o Sample: VG-SE 70 Positive Ion FAB
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Sample: l-AL-129 (FAB)
Theoretical Mass: 451.24441 (M+H) 
Measured Mass: 451.24565 
Error: 2.7 ppm
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02131006: Scan 103 (20.50 min) - Back
Base: 407.00 Int: 6.26243e+006 Sample: VG 70-SE Positive Ion FAB
40 f
Sample: l-AL-162
Instrument Resolution: 10,000
Theoretical Mass (C21H24N205): 407.15828 (M+Na)
Measured Mass: 407.15878
Error: 1.2ppm
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01050505: Scan 85 (15.53 min) - Back
Base: 154.00 Int: 2.9/87e+006 Sample: VG 70-SE Positive Ion FAB
1 0 0 % -
Sample: l-AL-166 
Instrument Resolution: 6000 
Theoretical Mass: (M+H) 371.16069 
Measured Mass: (M+H) 371.16179 
Error: 2.96 ppm
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01050505: Scan Avg 60-66 (10.95 -12.05 min) - Back
Base: 154.00 Int: 5.43327e+006 Sample: VG /0-SE Positive Ion FAB
10%
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Sample: l-AL-172 
Instrument Resolution: 6000 
Theoretical Mass: (M+H) 485.24000 
Measured Mass: (M+H) 485.23909 
Error: 1.88 ppm
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01131006: Scan 18 (3.50 min) - Back
Base: 176.00 Int: 5.91313e+006 Sample: VG 70-SE Positive Ion FAB
105%
Mev Fmoc176 Sample: ll-AL-38 
Instrument Resolution: 7000 
Theoretical Mass (M+Na) 814.34278 
Measured Mass: (M+Na) 814.34649 
Error: 4.56 ppm
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01131204: Scan Avg 142-143 (32.93 - 33.17 min) - Back
Base: 176.00 Int. 3.52667e+006 Sample: VG-70SE Positive Ion FAB
17(f>
0%
100
Sample: IIAL42 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 1237.52219 
Measured Mass: 1237.52395 
Error: 1.42 ppm
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01131204: Scan 174 (40.40 min) - Back
Base: 176.00 Int: 2.39606e+006 Sample: VG-70SE Positive Ion FAB 
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Sample: ll-AL-48 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 1015.45412 
Measured Mass: (M+Na) 1015.46087 
Error: 6.64 ppm
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01210205: Scan 93 (21.50 min) - Back
Base: 176.00 Int: 3.01202e+006 Sample: VG-70SE Positive Ion FAB
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Sample: ll-AL-110-1 
Instrument Resolution: 7000 
Theroetical Mass: (M+Na) 1609.58436 
Measured Mass: (M+Na) 1609.59520 
Error: 6.73 ppm
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Instrument Resolution: 7000 
Theroetical Mass: (M+Na) 1609.58436 
Measured Mass: (M+Na) 1609.59929 
Error: 9.28 ppm
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03250507: Scan 65 (9.65 min) - Back
Base: 349.00 Int: 2.25384e+006 Sample: VG 70-SE Positive Ion FAB
3 4 6
28
Sample: III-AL-15 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 349.10856 
Measured Mass: (M+Na) 349.10794 
Error: 1.78 ppm
49 67'
1 0 0 . 0
% T
90.0
80.0
70.0
60.0
50.0
40.0 H
30.0
20.0  —
10.0 — I
(2904.6
j) 2929.7 
j 2958.6 
2981.7
TsO OEt
4000.0 3500.0 3000.0 2500.0
  III-AL-15
2 0 0 0 .0
i
! I 
! I !
1598.9
1649.0
1 4 4 1 6 . 1)
i I
123
i i
1006(8
;9 0 . 8
1 744
i i l l  1I : f
! j>56.6 j
34.1 j 8158
931.6
1097.4
! i 706.9
076.7
555.5
1363.6
jl 176.5
663.5
1 i r
1750.0 1500.0 1250.0 1000 .0 750.0 500.0
1/cm
III-AL-68
CDC13 - 298K
O
Me
,____________________ rj
i
9 8 7 6 5 4 3 2 1 0  ppm
III-AL-68
DEPT
CDC13 - 298K
O
Me
III-AL-68
13C
CDC13 - 298K
O
M e
1 9 0  1 8 0  1 7 0  1 6 0  1 5 0 1 4 0  1 3 0  1 2 0
"  , ! "  !Tm » T^-nT-i-i-i-fxr,  ..............J............................., ..........................., ............................., ............................., ...........................-j ..
110 100 90 80 70 60 50 40 30 2 0 10 ppm
L l
T 11........ ” 1—i— r~i— i—r ■ i i— i- “ i— i— i i i i—i—r*
ppm
III-AL-68
COSY
CDC13 - 298K
- 0 . 5
O
Me
- 1 . 5
- 2 . 0
- 2 . 5
- 3 . 0
- 3 . 5
- 4 . 0
- 4 . 5
- 5 . 0
- 5 . 5
- 6 . 0
- 6 . 5
^ ^ { ' - 7 . 0
ppm
I I I - A L - 6 8  
HMBC 
CDC13 -  298K
O
100%
90%
80%
70%
60%
50%-
40%-
30%-
20%
10% -
03101006: Scan 248 (57.67 min) - Back
Base: 235.00 Int: 526362 Sample: VG70-SE Positive Cl-Methane
2 3 k
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Instrument Resolution: 7000 
Theoretical Mass (M+H) 235.03336 
Measured Mass: (M+H) 235.03376 
Error: 1.70 ppm
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03280906: Scan 131 [26.10 min) - Back
Base: 376.00 Int: 169889 Sample: VG 70-SE Positive Ion FAB
Sample: III-AL-63-3 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 376.11206 
Measured Mass: (M+Na) 376.11080 
Error: 3.35 ppm
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01070905: Scan Avg 13-15 (2.83 - 3.30 min)
Base: 89.00 Int: 5.00158e+006 Sample: VG70-SE Positive Cl-Methane 
l 89
Sample: lll-AL-95-3 
Instrument Resolution: 7000 
Theoretical Mass: (M+H) 189.11268 
Measured Mass: (M+H) 189.11286 
Error: 0.95 ppm
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03021006: Scan 12(2.30m in) 
Base: 310.00 Int: 6.5535e+006>535e+006 Sample: VG 70-SE Positive Ion FAB
310
100%
Sample: III-AL-102 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 310.16303 
Measured Mass: (M+Na) 310.16196 
Error: 3.45 ppm
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01131006: Scan Avg 100-104 (19.90 - 20.70 min) - Back
Base: 176.00 Int: 3./6819e+006 Sample: VG 70-SE Positive Ion FAB
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Theoretical Mass (M+Na) 245.11536 /
Measured Mass: (M+Na) 245.11588 
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01160806: Scan Avg 205-215 (40.90 - 42.90 min) - Back
Base: 461.00 Int: 4.70589e+006 Sample: VG 70-SE Positive Ion FAB
105%
90% -
80% -
Sample: lll-AL-163 
Instrument Resolution: 8000 
Theoretical Mass: (M+Na) 461.15517 
Measured Mass: (M+Na) 461.15438 
Error: 1.71 ppm
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01270206: Scan Avg 386-387 (70.72 - 70.90 min) - Back
Base: 176.00 Int: 4.33015e+006 Sample: VG 70-SE Positive Ion FAB
17(p
0 % -
160
Sample: IV-AL-13 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 243.09971 
Measured Mass: (M+Na) 243.09876 
Error: 3.91 ppm
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03151205: Scan Avq 165-172 (30.20 - 31.48 min) - Back 
Base: 154.00 Int: 860049 Sample: VG 70-SE Positive Ion FAB
105%
154
Sample: lll-AL-148 
Instrument Resolution: 7000 
Theoretical Mass: (M+H) 237.11268 
Measured Mass: (M+H) 237.11215 
Error: 2.24 ppm
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01191205: Scan Avg 132-133 (24.15-24.33 min) 
Base: 154.00 Int: 600839 Sample: VG 70-SE Po
RsicR
sitive Ion FAB
105%
154
Sample: III-AL-149 
Instrument Resolution: 7000 
Theoretical Mass: (M+H) 251.12833 
Measured Mass: (M+H) 251.12869 
Error: 1.43 ppm
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01070606: Scan 6(1.30m in)
Base: 121.00 Int: 6.5535e+006 Sample: VG70-SE Positive Cl-lsobutane
12t
Sample: IV-AL-105 
Instrument Resolution: 9000 
Theroetical Mass: 252.09977 
Measured Mass: 252.09953 
Error: 0.95 ppm
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01160806: Scan Avg 390-400 (77.90 - 79.90 min) - Back
Base: 173.00 Int: 3.10403e+006 Sample: VG 70-SE Positive Ion FAB. 
17$
100%-|
Sample: lll-AL-180-2 
Instrument Resolution: 8000 
Theoretical Mass: (M+Na) 378.13511 
Measured Mass: (M+Na) 378.13362 
Error: 3.94 ppm
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01270906: Scan 42 (8.30 min)
Base: 176.00 Int: 5.6423e+006 Sample: VG 70-SE Positive Ion FAB
Sample: lll-AL-176 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 420.18205 
Measured Mass: (M+Na) 420.18129 
Error: 1.81 ppm
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01270206: Scan 369 (67.60 min) - Back
Base: 173.00 Int: 2.89815e+006 Sample: VG 70-SE Positive Ion FAB
1 0 0 %
Sample: IV-AL-21 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 438.19262 
Measured Mass: (M+Na) 438.23181 
Error: 89.40 ppm
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Sample: VG 70-SE Positive Ion FAB
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01130306: Scan Avg 260-266 
Base: 155.00 Int: 3.4272e+00(
15k100%
Sample: IV-AL-25 
Instrument Resolution: 8000 
Theoretical Mass: (M+H) 494.18822 
Measured Mass: (M+H) 494.18907 
Error: 1.72 ppm
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03080306: Scan 249 (45.60 min) - Back
Base: 154.00 Int: 5.31583e+006 Sample: VG 70-SE Positive Ion FAB
0% r
154
Sample: IV-AL-30 
Instrument Resolution: 9000 
Theoretical Mass (M+H): 398.20011 
Measured Mass: (M+H): 398.19931 
Error: 2.01 ppm
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01160806: Scan 424 (84.70 min) - Back
Base: 176.00 Int. 5.75134e+006 Sample: VG 70-SE Positive Ion FAB
0%-
176
150
jSample: IV-AL-36 
Instrument Resolution: 8000 
[Theoretical Mass: (M+Na) 392.18714 
Measured Mass: (M+Na) 392.18674 
Error: 1.02 ppm
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01130306: Scan Avg 332-334 (60.82 - 61.18 min) - Back
Base: 154.00 Int: 6.26878e+006 Sample: VG 70-SE Positive Ion FAB
154
Sample: IV-AL-38 
Instrument Resolution: 8000 
Theoretical Mass: (M+H) 368.18954 
Measured Mass: (M+H) 368.19047 
Error: 2.53 ppm
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04250507: Scan 45 (6.65 min)
Base: 349.00 Int: 53791 Sample: VG 70-SE Positive Ion FAB
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Sample: IV-AL-122 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 760.20608 
Measured Mass: (M+Na) 760.20449 
Error: 2.09 ppm
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02131006: Scan 49 (9.70 min) - Back
Base: 408.00 Int: 5.26814e+006 Sample: VG 70-SE Positive Ion FAB
40&
Sample: IV-AL-70
Instrument Resolution: 10,000
Theoretical Mass (C22H27N05): 408.17868 (M+Na)
Measured Mass: 408.178770
Error: 0.22ppm
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RT: 19.50 AV: 1 SB: 384 0.42-18.08 , 19.70-20.02 NL: 3.41E6
536
Sample: IV-AL-126 
Instrument Resolution: 6250 
Theoretical Mass: (M+Na) 536.09044 
Measured Mass: (M+Na) 536.09098 
Error: 1.01 ppm
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01131006: Scan 147 (29.30 min) - Back 
Base: 176.00 | ~ ~ -----------Int: 2.23748e+006 Sample: VG 70-SE Positive Ion FAB
105%
176 Me MeSample: IV-AL-128 
Instrument Resolution: 7000 
Theoretical Mass (M+Na) 424.20998 
Measured Mass: (M+Na) 424.21073 
Error: 1.77 ppm
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01050906: Scan 89 (17.70 min) - Back
Base: 446.00 Int: 2.00573e+006 Sample: VG 70-SE Positive Ion FAB
44&100%n
Sample: IV-AL-162 
Instrument Resolution: 8000 
Theoretical Mass: (M+Na) 446.19770 
Measured Mass: (M+Na) 446.19707 
Error: 1.14 ppm
90%-
80%-
70%-
60%-
50%-
40%
20%
472173
10% -
323 622541371242 596
150 700650200 600250 500 550300 350 400 450
m/z
105.0 
%T
100.0
95.0
90.0
85.0
80.0
75.0
70.0
65.0
60.0
55.0
50.0
45.0
2887.2
2941.2
2979.8
i  i i— r
4000.0 3500.0
  IV-AL-162
3000.0 2500.0 2 0 0 0 .0
oc
o
V \
/  ' T\
1697.2
1456.2
1380.9
\ I \
1267
1 SI! v
769.5
975.9
860.2
1060.8
1093.6
I  | 1029.9
1128.3 
1168.8
1213.1 
| 1236.3
1330.8
1750.0 1500.0 1250.0 1 0 0 0 .0 750.0
540.0
500.0
1/cm
IV-AL-150
CDC13 - 298K
EtO 'O
4.5 4.0 3.5 3.0 2.5
f
2.0 1.5 1.0 0.5 ppm
IV-AL-150
DEPT
CDC13 - 298K
EtO ' O
y¥m
IV-AL-150
13C
CDC13 - 298K
Me,,
E tO O^
190 180 170 160 150 140 130 120 110 100 2030 10 ppm4050607080
p p m
0.5 
1.0
1.5 
2.0
2.5
3.0
3.5 
4 . 0
4.5
5.0
.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
J u l
T T T
Ju l .A A -A rv^ ppm
20
40
80
-100
-120
- 1 4 0
- 1 6 0
- 1 8 0
5 . 0 4 . 5 4.0 1.03.5 0.53.0 2.5 2.0 1.5 ppm
I V - A L - 1 5 0  
HMQC 
CDC13 -  298K
Ju l JlLJk ^JVA_i ppm
20
40
60
80
-100
-120
- 1 4 0
- 1 6 0
- 1 8 0
I V - A L - 1 5 0  
HMBC 
CDC13 -  298K
| 1 1 1 ' | ' '  i— i— |— i— i— r— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |— i— i— i— i— |
5 . 0  4 . 5  4 . 0  3 . 5  3 . 0  2 . 5  2 . 0  1 . 5  1 . 0  0 . 5  ppm
105%
90%
80%
70%
60%
50%
40%
30%
20%
10%
01290806: Scan Avc 
Base: 173.00 Int: 1.5
173
I 36-37 (7.10-7.30 min) - Back
>3103e+006 Sample: VG 70-SE Positive Ion FAB
0%^
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Sample: IV-AL-150 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 277.14157 
Measured Mass: (M+Na) 277.14189 
Error: 1.15 ppm
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01061006: Scan 12 (2.30 min)
Base: 218.00 Int: 3.51508e+006 Sample: VG 70-SE Positive Ion FAB 
218
Sample: IV-AL-156 
Instrument Resolution: 7000 
(Theoretical Mass: (M+Na) 629.16896 
Measured Mass: (M+Na) 629.16654 
Error: 3.85 ppm
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01290806: Scan Avg 53-54 (10.50 -10.70 min) - Back
Base: 173.00 Int: 6.50748e+006 Sample: VG 70-SE Positive Ion FAB
173
H. ..n.
Sample: IV-AL-160 
Instrument Resolution: 7000 
Theoretical Mass: (M+Na) 405.05387 
Measured Mass: (M+Na) 405.05465 
Error: 1.93 ppm EtO
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01050906: Scan Avg 101-102 (20.10 - 20.30 min) - Back
Base: 293.00 Int: 3.27675e+006 Sample: VG 70-SE Positive Ion FAB
29&
Sample: IV-AL-161 
Instrument Resolution: 8000 
Theoretical Mass: (M+Na) 293.17287 
Measured Mass: (M+Na) 293.17223 
Error: 2.18 ppm
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01080906: Scan Avg 75-78 (14.90 - 15.50 min) - Back 
Base: 173.00 Int: 977730 Sample: VG 70-SE Positive Ion FAB
17b
251
0% ^
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Sample: IV-AL-168-2 
Instrument Resolution: 8000 
Theoretical Mass: (M+Na) 251.16231 
Measured Mass: (M+Na) 251.16182 
Error: 1.95 ppm
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04150906: Scan 19 (3.70 min)
Base: 173.00 Int: 3.29535e+006 Sample: VG 70-SE Positive Ion FAB
178
0%4
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-4411+
Sample: IV-AL-173 
Instrument Resolution: 7000 
Theroetical Mass: (M+Na) 249.14666 
Measured Mass: (M+Na) 249.14601 
Error: 2.61 ppm
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